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Abstract 
Methylation at the cytosine (C) carbon-5 position in DNA is a reversible regulatory 
element of transcription in mammalian cells involved in development and disease. An 
active demethylation pathway through iterative oxidation of 5-methylcytosine (5mC) 
has been identified that leads to abasic sites at which unmodified C are restored via 
the base excision repair (BER) pathway. This process yields 5-hydroxymethylcytosine 
(5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) as partially stable 
intermediates. An increasing amount of data indicate that these 5-modified cytosines 
can also act as epigenetic regulatory elements and are involved in developmental and 
pathological processes. However, the function of epigenetic 5-modified cytosines are 
not fully understood and require sensitive typing and profiling approaches with high 
resolution. 
Engineered transcription activator-like effector (TALE) proteins have been established 
as programmable DNA-binders for the detection of epigenetic 5-modified cytosines. 
However, previous efforts to engineer new TALE selectivities did either not provide full 
selectivity for epigenetic 5-modified cytosines or had low affinity to target DNA. To 
overcome these hurdles, two novel TALE-based strategies based on chemical 
conjugation reactions were developed.  
In the first approach, a size-reduced TALE repeat with universal binding to the four 
canonical nucleobases and four epigenetic 5-modified cytosines was engineered. 
Chemoselective conjugation of 5hmC, 5fC or 5caC to dedicated blocking groups was 
found to abolish TALE binding. This enabled complete decoding of the three oxidized 
5mC derivatives (ox5mCs) at single positions within target DNA. 
In the second approach, the non-canonical amino acid (ncAA) para-
acetylphenylalanine (pAcF) was incorporated into dedicated positions of the universal 
TALE repeat. TALEs bearing pAcF maintained universal binding to cytosine 5-modified 
nucleobases. Furthermore, pAcF-bearing TALE repeats and 5fC-bearing target DNA 
could be crosslinked through oxime condensation via bifunctional hydroxylamine 
linkers. This enabled robust and selective enrichment of 5fC-bearing target DNA from 
genomic DNA (gDNA) backgrounds. 
Taken together, the addition of selective conjugation chemistries to TALE-based 
detection methods expand the toolbox for the selective, programmable analysis of 
epigenetic 5-modified cytosines.  
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Zusammenfassung 
DNA-Methylierung der Carbon-5-Position von Cytosin (C) ist ein reversibles 
regulatorisches Element der Transkription in Säugetierzellen, dass in 
Entwicklungsprozessen und Krankheitsbildern involviert ist. Die aktive Demethylierung 
durch iterative Oxidation von 5-Methylcytosin (5mC) ist eine Möglichkeit C über Basen-
Exzisionsreparatur (BER) von dabei entstehenden abasischen Positionen 
wiederherzustellen. Dabei werden 5-Hydroxymethylcytosin (5hmC), 5-Formylcytosin 
(5fC) und 5-Carboxylcytosin (5caC) gebildet. Daten deuten vermehrt darauf hin, dass 
diese 5-modifizierten Cytosine epigenetische regulatorische Elemente sein können 
und in Entwicklungs- und pathologischen Prozessen involviert sind. Die Funktion von 
5-modifizierten Cytosinen ist jedoch noch nicht vollständig geklärt und erfordert neue 
sensible Detektionsmethoden. 
Transkriptionsaktivator-ähnliche Effektor-Proteine (TALE) wurden als 
programmierbare DNA-Bindeproteine für den Nachweis von epigenetischen 5-
modifizierten Cytosinen etabliert. Diese TALEs boten jedoch entweder nicht die 
vollständige Selektivität für einzelne epigenetische 5-modifizierte Cytosine oder hatten 
eine niedrige Gesamtaffinität. Um diese Hürden zu überwinden, wurden zwei neue 
TALE-basierte Strategien entwickelt, die auf chemischen Konjugationsreaktionen 
beruhen. 
Im ersten Projekt wurden universell bindende TALE-Repeats konstruiert. Daraufhin 
konnte über chemo-selektive Konjugation von 5hmC, 5fC oder 5caC mit dedizierten 
Blockierungsgruppen die TALE-Bindung aufgehoben werden. Dies ermöglichte die 
vollständige Dekodierung der drei oxidierten 5mC-Derivate an einzelnen Positionen 
innerhalb definierter DNA-Sequenzen. 
Im zweiten Projekt wurde die nicht-kanonische Aminosäure (ncAA) para-
Acetylphenylalanin (pAcF) an dedizierten Positionen des universellen TALE-Repeat 
eingebaut. Diese TALE-Repeats mit pAcF banden weiterhin universell an 
epigenetische 5-modifizierte Cytosine. Des Weiteren konnten sie mit DNA-Sequenzen 
mit 5fC durch Oximkondensation über bifunktionelle Hydroxylamin-Linker vernetzt 
werden. Dies ermöglichte eine robuste und selektive Anreicherung von DNA-
Sequenzen mit 5fC aus genomischer DNA (gDNA). 
Diese Strategien erweitern die Toolbox von bisher existierenden TALE-basierten 
Nachweismethoden für die selektive, programmierbare Analyse epigenetischer 5-
modifizierter Cytosine.  
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1. Introduction 
1.1. The Chemical Biology of Epigenetic 5-Modified Cytosines 
1.1.1. Structure and Function of DNA 
Deoxyribonucleic acid (DNA) is known as the blueprint of life.1 DNA encodes the 
essential instructions for development and function of an organism.2 The entirety of 
DNA sequence information of a cell is referred to as the genome.  
DNA is a linear polymer consisting of nucleotide monomers linked via a phosphodiester 
bond (Figure (Fig.) 1a, b).3 Nucleotides in DNA consist of a 2-dexoyribose, a 5’-
phosphate group and one of the four nucleobases cytosine (C), thymine (T), guanine 
(G) and adenine (A) (Fig. 1c).4  
In the DNA, C and G as well as A and T interact via hydrogen bonds and form specific 
base pairs (Fig. 1c).5 This complementary base-pairing is a major stabilizing factor for 
the formation of the antiparallel orientation of double-stranded (ds) DNA (Fig. 1d).  
The DNA sugar-phosphate backbone adopts a helical structure of the dsDNA which is 
mainly stabilized via π-π stacking interactions of the aromatic nucleobases.6 A 
characteristic structural feature of the DNA double helix is the formation of minor and 
major grooves (Fig. 1e).3 Depending on the sequence and environmental conditions 
the conformation of the DNA double helix can vary (Fig. 1f).7 
In Eukaryotes, the dsDNA folds into structures called chromosomes. Here, the DNA is 
wrapped around a DNA-binding protein complex consisting of two copies each of the 
histone proteins H2A, H2B, H3, and H4 to form nucleosomes (Fig. 2).8  
The resulting chromatin 10 nm fiber can be compacted further through interaction with 
DNA-binding proteins into a fiber of approximately 30 nm and further into a 60–130 nm 
chromonema fiber (Fig. 2).3,9 
The structure of DNA molecules is essential for its functionality. They provide the basis 
for a hereditary mechanism as both strands can act as a template for the synthesis of 
new DNA molecules. The synthesis of DNA from another DNA template in a cellular 
environment is called replication. This process is spatially and temporally tightly 
regulated and carried out by a complex machinery.10  
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Figure 1: Deoxyribonucleotides and structure of the DNA double helix.a  
a) Structure of 2’-deoxyribonucleoside n-phosphates (n = mono, di, tri). b) The DNA backbone 
is linked via a 3’-5’ phosphodiester bond. c) Watson-Crick base pairs between pyrimidines 
(C/T) and purines (G/A). d) Watson-Crick model of dsDNA with the two antiparallel forward 
and reverse strands with the sugar-phosphate-backbone on the outside (pink and blue) and 
the base pairs facing (light blue and pink) towards the inside. e) Major and minor groove site 
in the Watson-Crick DNA double helix. f) DNA helix depending on sequence and environmental 
conditions.  
                                            
a Figures in d) and f) reprinted (adapted) with permission from reference (ref.) 3. Copyright 2019 Springer Nature. 
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Figure 2: The organization of DNA into three levels of chromatin structure.b 
 
The flow of genetic information (Fig. 3) is almost the same in all forms of life.3 It is 
based on the expression (transcription) of specific sequence fractions termed genes. 
During gene expression, the DNA is first transcribed to ss ribonucleic acid (RNA), 
which is a polynucleotide with the nucleobases A, G, C and uracil (U) instead of T.3,13 
Usually, the transcription machinery consists of a RNA polymerase for the synthesis of 
the RNA, and additional transcription factors (TFs) for regulation of initiation, 
elongation and termination.14  
Essentially, the transcription machinery assembles near the transcription start sites 
(TSS) of genes at promotors and synthesizes RNA from the DNA template.15 
After transcription, the messenger RNA (mRNA) can be used as template for the 
translation of the mRNA into proteins.  
 
                                            
b reprinted (adapted) with permission from ref.11 and ref.12. Copyright 2019 Okinawa Institute of Science and 
Technology Graduate University and copyright 2019 Springer Nature. 
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Figure 3: The flow of the genetic information. 
 
Proteins are biopolymers consisting of amino acids which are linked via amide bonds 
to a polypeptide chain. Proteins catalyze most biochemical reactions in biological 
processes.9 There are 20 standard proteinogenic amino acids with different α-
substituents and distinct chemical properties (Fig. 4).3 The translation of mRNA into 
proteins follows a non-overlapping, degenerate code where one amino acid is encoded 
by one or multiple sequences of nucleotide triplets (codon) (Fig. 4).3  
Codons are recognized through interaction of a complementary nucleotide triplet 
(anticodon) of the transfer RNAs (tRNA).3 tRNAs are aminoacylated with a specific 
amino acid through ATP activation by high-fidelity aminoacyl-RNA synthetases 
(aaRS).16 The aminoacylation of the tRNA depends on interaction of a cognate 
tRNA/aaRS pair.16  
Translation is catalyzed by ribosomes. These complexes consist of ribosomal RNA 
(rRNA) and specific proteins.17  
The codon AUG serves as the start codon for translation and encodes methionine (Met, 
M). At the beginning of protein synthesis, the synthesis is initiated through the binding 
of the aminoacylated tRNA-Met in the ribosome at the start codon of an open reading 
frame (ORF). 
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Figure 4: Structures, names and three letter and single letter code for the 20 proteinogenic 
amino acids grouped according to chemical properties. The codon diagram displays the 
nucleotide triplet sequences encoding the corresponding amino acids. 
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Then, the next cognate elongating aminoacyl-tRNA can be delivered to the ribosome.18 
There, elongation factors promote the transfer of the amino acid to the growing peptide 
chain and deacylated tRNAs dissociate from the mRNA.19  
The three codons UAA, UAG, and UGA are designated as termination codons, which 
are also referred to as ochre (UAA), amber (UAG) and opal (UGA) stop codons.20 
Throughout the life cycle of organisms, not all genetic information is constitutively 
expressed. Instead, distinct set of genes are required. Spatial and temporal control of 
gene expression can be influenced through epigenetic mechanisms. That is through 
structural modification but without alternating the genetic sequence of chromosomal 
DNA.21 For example, the modification of histone molecules can lead to the formation 
of decondensed euchromatin accessible for the transcription machinery or condensed 
heterochromatin that “silences” gene expression.22 
Another mechanism is the modification of the DNA. The major groove contains a 
nucleobase-specific layer of chemical information. This enables interaction of 
regulatory proteins without dissociating overall Watson-Crick base pairing. Therefore, 
modification of nucleobases in the major groove can affect binding of regulatory DNA-
binding proteins and shape the structure and function of the genome.23  
 
  
 9 
 
1.1.2. Epigenetic DNA Cytosine 5-Modifications 
 
Figure 5: DNMT-mediated methylation of Cytosine with SAM.  
 
Methylation at the carbon-5 position of cytosines is the most abundant epigenetic mark 
in the human genome (Fig. 5). Cytosine 5-methylation is catalyzed by DNA methyl 
transferases (DNMT) through the formation of a covalent DNA-protein intermediate 
with S‐adenosylmethionine (SAM) (Fig. 5).24,25  
Of all cytosines in the human genome, approximately 1-4 % are methylated.26,27 5-
Methylcytosine (5mC) is associated with transcriptional regulation, recruitment of 
transcription factors, and modulation of chromatin structure.28–30 Aberrant methylation 
can also be a hallmark of diseases like cancer or neurological disorders.31,32 
5mC could be an important part of a complex genome-wide crosstalk system.33,34 For 
example, 5mC can recruit histone-modifying proteins through interaction with methyl‐
CpG‐binding domain (MBD) .35 Vice versa, transcriptional activity can modify chromatin 
structure or -associated proteins to recruit writers of cytosine 5-methylation.36  
Between the dinucleotide combinations CpG, CpA, CpT and CpC more than 99 % of 
cytosine 5-methylation can be found in CpG sequences.32,37 Despite its rarity, non-
CpG-methylation can also be a prevalent epigenetic mark of embryonic stem cells and 
aging brain cells.37,38 
Approximately 70 to 80 % of genomic CpGs are methylated.36 Most unmethylated CpG 
sequences are in CpG-rich regions (CpG-islands) of regulatory regions such as 
promotors or first exons.29,39 These regions are involved in transcription and often 
occupied by CXXC domain containing proteins and TFs, which protect the DNA from 
methylation.34 Cytosine 5-methylation in promotor sequences (~10% of CpGs) is 
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usually associated with long-term, stable gene repression, cell differentiation, X‐
chromosome inactivation and genomic imprinting.40  
In contrast, 5mCpGs are predominantly found in repetitive sequences, gene bodies, 
and intergenic regions.39 An example for extensively methylated repetitive regions in 
the human genome are transposons. Transposon-derived sequences can affect 
genome integrity and need to be tightly regulated.29 Thereby, cytosine 5-methylation is 
likely responsible for stable heritable transcriptional repression and silencing in these 
regions.23,29 
Cytosine 5-methylation levels and patterns in other genome sequences are often 
highly variable and can depend on tissue type or developmental stages.29,34 For 
example, 5mC levels in mammalian cells are depleted after fertilization and during 
germ cell development.23 Additionally, transcriptional regulation by 5mC need to be 
dynamic. Therefore, parts of the epigenome are continuously “re-written”. 
Demethylation can occur passively over multiple cycles of DNA replication.41 
Alternatively, 5mCpG-sites can be removed through active demethylation in an 
iterative enzymatic process that yields oxidized 5mC derivatives (ox5mC) (Fig. 6).42 
The oxidation of 5mC is catalyzed by dioxygenases of the Ten-eleven translocation 
(TET) protein family, in both processive and non-processive manner.43,44 In mammals, 
there are three homologs (TET1, TET2 and TET3) with cell/organ-specific 
expression.45 These enzymes oxidize the 5-group of cytosine with α-ketoglutarate (α-
KG) as cofactor at an Fe(II)-center with activated dioxygen (O2) via an Fe(IV)-oxo 
intermediary state.46,47   
During this process 5mC is first oxidized to 5-hydroxymethylcytosine (5hmC), then 
consecutively oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by TET 
proteins.48–51  
5fC and 5caC, but not 5hmC can be actively removed with thymine DNA glycosylase 
(TDG), resulting in abasic sites.50,52 Unmodified cytosines are restored at these sites 
via the base excision repair (BER) pathway.53 Additionally, in mouse embryonic stem 
cells (mESCs) 5fC and possibly 5caC can undergo C–C bond cleavage for the direct 
removal of the 5-substituent.54,55 It could be possible that iterative oxidation is an 
evolutionary solution to the challenging direct removal of the methyl group which is a 
poor leaving group.  
Additionally, ox5mCs have distinct chemical properties which could add another layer 
of accessible chemical information to the DNA.  
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Figure 6: Active demethylation of 5-methylcytosine involves the oxidation and repair of 
5mC. 5hmC: 5-Hydroxylmethylcytosine; 5fC: 5-Formylcytosine; 5caC: 5-Carboxylcytosine; TET: 
Ten-eleven translocation enzyme; TDG: Thymine DNA glycosylase; BER: Base excision repair. 
 
Crystal structure show a rotational dimorphism in the major groove of the 5-
hydroxymethyl group of 5hmC and exhibits with two distinct conformations.56,57 In 
contrast, the formyl group of 5fC is coplanar with the cytosine ring and forming an 
intramolecular hydrogen bond with the exocyclic N4‐amine.58,59 Similarly, the 
carboxylate group of 5caC also can form such an intramolecular hydrogen bond.59,60 
Cytosine 5-modifications do not seem to affect overall DNA conformation significantly, 
but effects on local conformation, flexibility and base pair stability have been 
reported.57,59,61–63 This could facilitate local DNA unwinding and the base-flipping of 
5hmC, 5fC and 5caC by TET and TDG enzymes for example.40  
The contents of ox5mCs in genomic DNA (gDNA) are highly dynamic and cell/tissue 
type dependent but in general levels of 5hmC are 2-3 and 3-4 orders of magnitude 
higher than levels of 5fC and 5caC, respectively.49,64 A reason can be the affinity and 
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activity of TET and TDG. After 5hmC is established in gDNA, it is not readily oxidized 
to 5fC and 5caC.58  
Because of this stability, 5hmC is considered the sixth base in the genome. Elevated 
levels of 5hmC can be found especially in neurons and stem cells, whereas levels are 
depleted in cancer cells.65–68 5hmC is often accumulated at TSS and poised or active 
regulatory regions in the genome marked by histone modifications associated with 
transcriptional repression, activation or enhancement.33,45 Moreover, factors like 
chromatin configuration or protein binding can affect the distribution of 5hmC in the 
genome during cell differentiation and specification.45  
At 5hmC-sites, the polar hydroxyl group can influence interactions with TFs or MBD 
proteins, which indicates a role of 5hmC as cis-element in the regulation of gene 
expression or facilitator of alternative splicing.35,43,45,54 Furthermore, the presence of 
5hmC has been associated with neurodevelopment and oxidative stress response.69–
71 
In contrast, 5fC and 5caC can be rapidly removed due to highly efficient excision by 
TDG.52,72 To a certain extent however, 5fC can be a stable epigenetic mark in 
mammalian genomes.73–75 5fC is enriched in important genetic regions like poised 
enhancers.76–80 Moreover, 5fC has been shown to form DNA-protein crosslinks (DPCs) 
in vitro and in vivo via Schiff-base formation under physiological conditions with 
histones.81–84 This could be a mechanism for nucleosome orientation, increased 
chromatin structure stability and regulation of transcription.85  
Owing to the rarity of 5caC relatively little is understood about its distribution and 
function. Absence or depletion of TDG leads to an accumulation of 5fC and 5caC which 
points towards 5caC as site of active demethylation.72,77,86 5caC accumulates at 
promoters that are demethylated during differentiation of neuronal stem cells and can 
also be detected in specific tissue and cell types including cancer.87–89 Furthermore, 
specific interaction of 5caC with the RNA polymerase II elongation complex, TFs like 
myc-associated factor X (MAX) or CCCTC-binding factor (CTCF) indicate a role in 
transcriptional regulation.90–92 
Taken together, the 5-substituents of 5mC, 5hmC, 5fC and 5caC add an additional 
layer of information to genomic functionality and provide chemical handles with unique 
reactivity and specific hydrogen-bond acceptors and donors. Amongst specific readers 
of 5hmC, 5fC and 5caC are repair proteins, transcriptional and chromatin 
regulators.93,94 Furthermore, the occurrence of 5mC and ox5mCs can provide 
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mechanistic information about progression or treatment of diseases and could be used 
for clinical disease diagnosis and therapy.95  
However, even though many advancements for an improved understanding of 5mC 
and ox5mCs as epigenetic marks have been made, many questions remain. 
Therefore, sensitive detection methods for the analysis of 5mC and ox5mCs are 
required. 
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1.2. Detection and Analysis of Epigenetic Cytosine 5-Modifications 
1.2.1. Overview  
Because cytosine 5-modifications reside in the major groove of the dsDNA and do not 
alter the Watson-Crick base pairing information in a useful manner, conventional 
sequencing techniques cannot be used for the detection of epigenetic cytosine 5-
modifications. Most methods aim at exploiting the characteristic chemical properties of 
the 5-modification and can be grouped into one of three categories (Fig. 7). There are 
analytical platforms, chemical-based and protein-based approaches. To improve 
sensitivity and facilitate analysis of epigenetic cytosine 5-modifications combinational 
strategies can be employed. 
 
 
Figure 7: Methods for the analysis of cytosine 5-modifications. 
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1.2.2. Analytical Platforms and Direct Detection Methods 
A facile method for the overall detection and quantification of methylated cytosines and 
oxidized derivatives is the analysis of single nucleotides with two-dimensional (2D) thin 
layer chromatography (TLC)48–50,65,96,97 and capillary electrophoresis.98–100 However, 
the accuracy of both methods can be limited due to variabilities in matrix or buffer 
compositions.98 
Highly sensitive detection methods of C and 5mC based on electrochemical oxidation 
peak potentials or of C, 5mC and 5hmC with surface-enhanced Raman spectroscopy 
(SERS) have been developed, however the application scope is still quite limited.101–
105 
Standard highly accurate methods include gas chromatography (GC)106 and reverse-
phase (RP) high-performance liquid chromatography (HPLC),107,108 which have been 
combined with mass spectrometry (MS).98,109 Several LC-MS strategies use chemical 
derivatization to increase the information yield of the analyte with polar,110 bulky76 or 
easily chargeable moieties.111–115  
MS-based strategies are considered the “gold standard” for quantitative analysis of 
5mC but usually require highly trained personnel or expensive equipment.98,109,116 
Moreover, MS-based strategies usually requires the degradation of DNA which can 
lead to sample loss.  
Emerging third-generation sequencing technologies for the detection of epigenetic 5-
modified cytosines, like nanopore sequencing117–121 or single molecule real-time 
sequencing (SMRT-Seq)122,123 enable analysis with long reads and base resolution in 
single molecules without any DNA amplification or treatment.124–126  
A drawback of the third-generation sequencing technologies is the relatively high error 
rate.127,128 To improve the detection of epigenetic 5-modified cytosines, chemical 
derivatization strategies have been implemented.129–133 However, accurate typing and 
profiling of epigenetic 5-modified cytosines is still challenging especially in repetitive or 
CG-rich regions.125,128  
  
 16 
 
1.2.3. Chemical-based Detection Methods 
1.2.3.1. Bisulfite-based Methods 
Bisulfite treatment of dsDNA at stable temperature and pH leads to deamination of 
cytosine to uracil (Fig. 8).134–136  
However, under standard reaction conditions up to 96 % of the input DNA are subject 
to degradation due to decomposition of pyrimidines and formation of abasic sites.137  
Methylation of the cytosine 5-position prevents bisulfite conversion (Fig. 8).138 This 
enables a binary readout for the detection of cytosine 5-DNA methylation with 
analytical platforms such as HPLC,139 MS140 or electrochemical arrays141,142.   
Bisulfite conversion can influence enzyme performance or PCR product formation. 
This enables 5mC analysis in assays such as the combined bisulfite restriction analysis 
(COBRA)143 or methylation specific PCR (MSP).144–146  
Additionally, analysis of bisulfite conversion-induced single nucleotide mismatches 
have been used in highly sensitive methylation detection assays with Förster 
resonance energy transfer (FRET)147 and SERS.148,149  
 
 
Figure 8: Bisulfite conversion of C, 5mC and ox5mCs and transition of converted nucleobases 
during PCR. 
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The gold standard for assaying cytosine 5-methylation is bisulfite sequencing (BS-
Seq).150,151 BS-Seq offers analysis with sequence coverage at single base-resolution.  
However, 5hmC reacts with bisulfite to cytosine-5-methylsulfonate (CMS) and cannot 
undergo deamination (Fig. 8).152 In contrast, 5fC and 5caC are deformylated and 
decarboxylated, respectively, and then deaminated.50,153  
Therefore, BS-Seq cannot discriminate between 5mC and 5hmC as well as C, 5fC and 
5caC (Fig. 8; Fig. 9).154 
In oxidative BS-Seq (oxBS-Seq), reaction with potassium perruthenate (KRuO4) can 
be used for oxidation of 5hmC to 5fC.153 This enables discrimination between 5mC and 
5hmC (Fig. 9).  
in TET-assisted-BS-Seq (TAB-Seq) the enzymatic glucosylation155,156 protects 5hmC 
from TET-oxidation while 5mC and 5fC are oxidized to 5caC (Fig. 9).157 This enables 
discrimination between 5mC and 5hmC as well(Fig. 9). 
Reduced bisulfite sequencing (redBS-Seq) enables discrimination of 5fC in the context 
of the other cytosine nucleobases (Fig. 9).78 In this strategy, 5fC is reduced to 5hmC 
with sodium borohydride (NaBH4) and detected in the same manner as 5mC while the 
other bases are not affected. 
Alternatively, a 5fC-selective tagging strategy termed chemical modification-assisted 
bisulfite sequencing (fCAB-Seq) protects the base from the bisulfite-mediated 
deformylation and deamination with aminooxy-functionalized reactants (Fig. 9).77 
Analog, chemical modification-assisted bisulfite sequencing (CAB-Seq) protects 5caC 
decarboxylation and deamination with a primary amine in 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide (EDC)-catalyzed amide bond formation (Fig. 9).158  
In M.SssI methylase-assisted bisulfite sequencing (MAB-Seq)159 unmodified cytosine 
in CpGs are enzymatically methylated and consequently detected in the same manner 
as 5mC (Fig. 9). 5fC can be discriminated from 5caC with NaBH4 reduction prior to 
M.SssI treatment (caMAB-Seq).159 However, MAB-Seq and caMAB-Seq cannot be 
applied to cytosines outside of a CpG context as they are not methylated by M.SssI 
(Fig. 9).159 
Bisulfite-based approaches allow detection and quantification of epigenetic 5-modified 
cytosine nucleobases at single nucleobase resolution in (single cell) reduced-
representation bisulfite sequencing (RRBS160, scRRBS161) or across whole 
genomes.150  
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Figure 9: Analysis of 5hmC, 5fC and 5caC with bisulfite-sequencing (BS-Seq) strategies. 
ox: oxidative; red: reductive; TAB: TET-assisted BS; Enzym.: enzymatic; CAB: chemical-
modification-assisted BS; fCAB: 5fC-specific-CAB; MAB: M.SssI-assisted BS; caMAB: 5caC-
specific-MAB.  
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However, BS-Seq also requires a relatively high amount of template.136 Additionally, 
error-proneness of the reaction due to incomplete conversions or bias in conversion 
steps and PCRs mean that outcomes can be unreliable.162 
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1.2.3.2. Bisulfite-free Chemical Modification-based Detection Methods 
Other methods aim to target the unique chemical handle of the epigenetic cytosine 5-
modifications, preferentially under non-denaturing reaction conditions (Fig. 10). An 
advantage over bisulfite sequencing is that only target nucleobases are derivatized. 
 
 
Figure 10: Exemplary Bisulfite-free strategies for the selective modification of cytosine 5-
modifications. The derivatization of the nucleobases can lead to distinct chemical properties 
(e.g. susceptibility to chemical cleavage, fluorescence, C-to-T transition in PCR) that enable 
identification of the converted nucleobase. Alternatively, chemical handles (e.g. azides) for 
further tagging reactions can be provided with the reagents through functional residues (R) 
for fluorescence or pull-down probes, for example. UDP: Uridine diphosphate; ETMI: 1-ethyl-
2,3,3-trimethyl-3H-indole-5-sulfonate.  
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1.2.3.2.1. 5-Methylctosine 
C and 5mC can be distinguished via derivatization of cytosine nucleobases with O-
allylhydroxylamine as the adduct configurations can affect base pairing.163  
5mC can be selectively oxidized with osmium tetroxide (OsO4) which enables 
interstrand crosslinking or complex formation with bipyridine ligands.164,165 The adduct 
formation can be susceptible to hot piperidine cleavage or can be used to introduce 
reporter probes for the detection of 5mC-sites. Alternatives to OsO4 are vanadium 
pentoxide (V2O5) or sodium periodate (NaIO4) in combination with lithium bromide 
(LiBr).166,167  
Alternatively, oligonucleotide-based strategies for the detection of 5mC including 
interstrand photocrosslinking have been reported.151,168,169 151,170–175 
A common issue of these assays is that they cannot directly distinguish between 5mC 
and the ox5mCs, or that it has not been conclusively tested. 
Information about the symmetry of cytosine 5-methylation at CpGs can be provided by 
methyltransferase M.SssI-mediated labeling of unmodified cytosines with S-
adenosylmethionine analogues bearing an amine or azide groups.176,177 A chemical 
handle for Huisgen cycloaddition with alkyne-bearing probes allows detection of non-
methylated CpGs in gDNA at single base resolution.178    
A novel TET-assisted pyridine borane sequencing (TAPS) can be used for base-level 
resolution detection of 5mC and other cytosine derivatives.179 TAPS induces C-to-T 
transition in PCR through TET-mediated oxidation of 5mC and 5hmC to 5caC and 
subsequent pyridine borane reduction of 5fC and 5caC to dihydroxyuracil (DHU).179 
Enzymatic glucosylation of 5hmC prevents TET-oxidation and reduction with pyridine 
borane. TAPSβ enables differentiation between 5mC and 5hmC.179  
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1.2.3.2.2. 5-Hydroxymethylcytosine 
5hmC can be oxidized to 5fC with reagents such as KRuO4 or Cu(II)/2,2,6,6-
Tetramethylpiperidine-1-oxyl (TEMPO). 5fC can then be labeled with amine, 
hydroxylamine or hydrazine derivatives containing biotin,180 fluorescence,181,182 
ruthenium(II) complex-tagged electrogenerated chemiluminescence (ECL)183 and 
Förster resonance energy transfer (FRET) probes.184 Alternatively, oxidation of 5hmC 
to 5fC with KRuO4 or potassium ruthenate (K2RuO4) and labeling of 5fC with an azido 
derivative of 1,3-indandione or benzothiazole enable single-base resolution analysis. 
Both reagents can participate in a Friedländer intramolecular bicyclic addition reaction, 
which leads to C-to-T transition during PCR amplification due to the loss of the 
exocyclic 4-amino group after adduct formation.185,186  
Selective oxidation of 5hmC to 5fC with KRuO4 has also been used in chemical-
assisted pyridine borane sequencing (CAPS).179 In this method, the oxidation of 5hmC 
to 5fC makes it susceptible for reduction with pyridine borane to DHU which enables 
base-resolution analysis of 5hmC.  
The enzymatic glucosylation with T4 β-glucosyltransferase (T4 BGT) is a direct, 5hmC-
selective tagging strategy,95 which has served as an early method to quantify genomic 
5hmC via scintillation measurements of radiolabeled glucose.187 
Enzymatic glucosylation of 5hmC can protect the base from reduction with pyridine 
borane (cf. chapter 1.4.2.2.1). This enables detection and quantification of 5hmC with 
single base resolution.179 Similarly, glucosylation of 5hmC prevents enzymatic 
deamination of cytosine nucleobases which induces C-to-T transition for sites with C 
or 5mC in APOBEC-coupled epigenetic sequencing (ACE-seq).188 
Boronic acids can make pH-sensitive reversible esters in alkaline solutions with 1,2- or 
1,3-diol groups of carbohydrates.189 Several conjugation strategies of β-glucosyl-5hmC 
(5ghmC) with boric acid-functionalized probes or signal generation via boronic acid 
chemistries have been used to detect 5hmC-sites.190–195 
Oxidation of vicinal hydroxyl groups of the glucosyl moiety to aldehydes after 
glucosylation of 5hmC with NaIO4 provide chemical handles for oxime formation with 
aldehyde reactive probes (ARPs).196 This enables tagging with fluorescent molecules 
to detect 5hmC in the DNA.197 Alternatively biotin-labeled 5ghmC can be enriched for 
downstream analysis.196,198 However, the reaction cannot differentiate between 5hmC- 
and endogenous 5fC-sites.  
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Other multi-step labeling approaches use selective bio-orthogonal labeling of 5hmC 
with an 6-azido-glucose derivative for Huisgen cycloaddition (“click chemistry”).199 This 
enables conjugation with pull-down probes and selective enrichment for downstream 
applications such as genome-wide 5hmC-profiling.130,199–203 Moreover, click chemistry 
enables introduction of reporter molecules for global coverage of 5hmC-sites, or to 
detect complementary 5mCpG/5hmCpG-sites with FRET signals.204–206  
The bacterial DNA methyltransferase M.HhaI can catalyze nucleophilic condensation 
at 5hmC with thiol compounds such as cysteamine.207 The amino-derivatized DNA can 
be subsequently labeled with amine-reactive biotin for example for the recruitment of 
reporter enzymes.208,209  
Additionally, 5hmC can be labeled in a sulfinate based reaction that is similar to the 
formation of CMS during BS-Seq but with a cleavable, biotinylated probe for pull-down 
and downstream analysis of enriched 5hmC-DNA.210,211  
5hmC can be oxidized with peroxotungstate and deaminated to yield a trihydroxylated 
thymine derivative in an one-pot reaction.212 This causes C-to-T transition that enable 
detection of 5hmC with single-base resolution.213 
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1.2.3.2.3. 5-Formylcytosine 
The reduction of 5fC to 5hmC with NaBH4 enables enzymatic glucosylation with an 
azido-glucose moiety and click chemistry analog to 5hmC (c.f. 1.2.3.2.2.).77  
The 5-formyl group of 5fC can be readily functionalized with active nucleophiles like 
hydroxylamines and hydrazines to give rise to oxime or hydrazone conjugates.95 Based 
on these condensation chemistries,74,75 a multitude of direct labelling, enrichment and 
crosslinking approaches have been reported. Strategies for the detection of 5fC-sites 
employ specific pull-down,76,214 fluorogenic,215–217 or oligonucleotide probes.75 
Additionally, labels for supramolecular reversible guest-host complexes218,219 or so-
called “roadblocks”217 for the inhibition of protein activity have been reported.  
Using hydroxylamines or hydrazines has the advantage of convenient, well-
established and comparatively mild acidic reaction conditions for quantitative, rapid 
labeling.215,220 A drawback of ARP with hydroxylamine and hydrazine groups can be 
their cross-reactivity towards abasic sites or 5-formyluridine (5fU).214,220,221 Depending 
on the reaction conditions, labeling of 5fC but not abasic sites have been shown, 
however the reactivity towards 5fU often remains elusive.215,218  
5fU-sites often react more readily with reagents than 5fC.222 To rule out false-positive 
5fC-sites, a possible strategy is selectively reacting 5fU-sites first with dedicated 
moieties that will not interfere with the probe for analysis or enrichment. The probe can 
then be reacted selectively with 5fC-sites.214 
An aldol‐type condensation of 2,3,3‐trimethylindole (TMI) derivatives can be used for 
differentiation between 5fC and 5fU, as the extended conjugated π‐systems of the 
adducts have distinct photophysical characteristics.223 Moreover, labeling of 5fC-sites 
with TMI was found to inhibit or delay DNA polymerase elongation in vitro.223 
Schiff base formation of the carbonyl of 5fC with aliphatic amine is another 5fC-labeling 
reaction.224 Reaction of 5fC and partially of abasic sites can occur under non-
denaturing conditions without the need for a catalyst.215,224 However, the reaction is 
reversible due to hydrolysis.225 In contrast, oxime and hydrazone formation can be also 
reversible but products are generally much more stable than imines due to the negative 
inductive effect of the additional heteroatom.226  
The Friedländer condensation with an azido derivative of 1,3‐indandione (AI) is a highly 
selective 5fC-selective labeling reaction.227 The reaction yields a bicyclic adduct that 
can be used to detect and quantify 5fC in genomic DNA with single base resolution.227 
The azide functional group can also be used for pull-down and enrichment with azido-
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reactive disulfide biotin probes.227 A similar strategy with malonitrile (CLEVER-Seq) 
has been used for 5fC profiling at single base resolution in single cells.80  
Other cyclization reactions of 5fC with 2-(5-chlorobenzo[d]thiazol-2-yl)acetonitrile 
(CBAN) and 3-azido-N-(2-(cyanomethyl)benzo[d]thiazol-6-yl)propanamide (azi-BP) 
also enable base resolution analysis.228,229 Additionally, the cyclization reaction of 
CBAN with 5fC also leads to an extensive fluorescence enhancement of the adduct 
which can be used to quantify global 5fC-levels.228 Azi-BP can participate in copper-
free click-chemistry with dibenzocycloocytne (DBCO) reagents which act as a 
“roadblock” for DNA polymerases.229  
  
 26 
 
1.2.3.2.4. 5-Carboxylcytosine 
To the best knowledge, no bisulfite-free chemical detection method has been reported 
yet for 5caC. 
Liu et al. suggested that EDC-mediated coupling could be used to protect 5caC from 
borane reduction.179 This would enable differentiation between 5fC and 5caC similar 
to 5mC and 5hmC in CAPS.179  
However, conjugation of carboxylic acids to reactive probes can be difficult in aqueous 
solutions and under non-denaturing conditions.230,231 Moreover, chemical-based 
detection strategies for 5caC require very high sensitivity given the low 5caC-levels in 
DNA.49,232   
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1.2.4. Protein-based Approaches 
 
 
Figure 11: Protein-based strategies for the analysis of cytosine modifications. 
 
Detection of cytosine modifications through direct interaction of proteins with DNA 
(Fig. 11) is the main alternative to the chemical derivatization strategy.151 A main 
advantage of this approach is the simple, direct analysis of samples both in vitro and 
in vivo assays. 
A commonly used protein-based approaches for the genome-wide distribution of 5mC 
and ox5mCs in DNA are immunoassays. Immunostaining,48,66,233,234 
immunosensors,102,151 enzyme-linked immunosorbent assay (ELISA)116 or DNA 
immunoprecipitation (DIP)72,235,236 are simple and cost-effective. Antibodies have been 
raised for the highly selective detection of specific epigenetic 5-modified cytosines or 
CMS.72,196,237 However, sequence or modification bias of antibodies as well as cross-
reactivity of IgG antibodies for short tandem repeat (STR) sequences has been 
reported.238–240 Moreover, antibodies lack sequence specificity and detection of 
cytosine 5-modifications can be limited by the density of CpGs.154,241 
Selective cytosine 5-modification-specific enzymatic digestion of DNA enables 
genome-wide mapping of cytosine 5-modifications. Sensitive restriction enzymes for 
5mC or 5hmC have been identified and used for a multitude of high throughput assays 
and electrochemical DNA methylation detection platforms.102,124,151,242 Similarly, 
5ghmC can also regulate enzymatic digestion.243–245 Sensitive endonucleases for 5fC 
or 5caC have not yet been reported to the best knowledge. Instead, 5fC can be 
reduced to 5hmC with NaBH4.246  
A major drawback of restriction endonucleases is the non-programmable specificity of 
recognition sites. Also resolution is limited to restriction sites.150,154 
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MBD proteins have been used for isolation, live-cell imaging and single molecule 
analysis of cytosine 5-methylated DNA.247–252 Similarly, β-d-glucosyl-
hydroxymethyluracil (J)-binding protein 1 (JBP1) can be used to isolate 5hmC-DNA 
after enzymatic glucosylation.253 Both proteins enable quantification and genome wide 
profiling in combination with high throughput sequencing of 5mC or 5hmC.254–258  
No approaches for the profiling of 5fC or 5caC with non-sequence-specific proteins are 
available to the best knowledge. A potential candidate for sequence-non-specific 
5caC-profiling could be a N157D (N = asparagine; D = aspartic acid) mutated variant 
of thymine DNA glycosylase, which has been shown to selectively processes 5caC in 
gDNA.259  
In general, a drawback of these protein-based approaches is no or limited target DNA 
selectivity.  
Zinc finger (ZF) proteins are sequence-specific, modular DNA-binding proteins 
consisting of concatenated units with highly conserved ββα configurations.260 Several 
amino acids localized within the α-helix motif of each unit interact with sequences of 
typically three base pairs (bps) in the major groove of DNA.260 Assembly of ZF domains 
into modular arrays enable “programming” of custom DNA-binding scaffolds with user-
defined sequence-specificity.261 
Additionally, several ZF domains have been shown to recognize epigenetic cytosine 
5-modifications via R (arginine) and E (glutamate) residues.262 In theory, this would 
enable programmable design of DNA-binding domains with sensitivity towards 5mC or 
ox5mCs, but so far no recombinant ZF proteins for the direct detection of 5mC or 
ox5mCs have been reported to the best knowledge. 
Instead, a combination of MBDs and ZF domains has been used.263,264 In this method, 
a functional fluorescent domain can only assemble if MBD binds to 5mC, and the ZFs 
binds in vicinity to the 5mC at a user-defined target DNA sequence.263,264 Alternatively, 
synthetic peptides resembling three ZF domains bearing a phosphotyrosine have been 
used as a proof-of-concept for direct sequence-specific detection of 5mC in the context 
of C and 5hmC in oligonucleotide sequences.265,266  
However, ZF-based methods are limited in sequence-selectivity due to the confined 
recognition mode of ZFs which reportedly suffer from significant off-target effects.267,268  
Alternatively, programmable DNA-binding scaffolds with a single-nucleobase 
recognition mode in the form of transcription activator-like effectors (TALEs) have 
recently emerged as sequence-specific sensors for 5mC and ox5mCs.151,267  
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1.3. Transcription Activator-Like Effectors 
1.3.1. Structure and binding mode of TALE proteins 
TALEs were first discovered in Gram-negative Xanthomonas bacteria and essential 
factors to bacterial virulence, proliferation, and dissemination.269 Natural TALE proteins 
often consist of three parts (Fig. 12a).269  
The N-terminal region (NTR) contains the type III secretion signal.270 The C-terminal 
region (CTR) contains a nuclear localization sequence (NLS) and an acidic activation 
domain (AD).271–273 The central part constitutes the main DNA-binding domain 
(DBD).274 The DBD is a repetitive sequence and referred to as central repeat domain 
(CRD). Repeats of the CRD predominantly have 34 aa, except for the last repeat (LR) 
which is truncated at 20 amino acids.269 TALEs with 2 to 34 repeats exists but the most 
frequent number of repeats in naturally occurring TALEs is 18.269 While at least 7 
repeats are necessary to induce target gene expression,275 the maximum specificity of 
the CRD for a DNA sequence ranges from 15 to 19 repeats.276 
One repeat of the CRD interacts with one nucleobase of the target DNA strand.277 The 
specificity of each repeat is determined by a repeat variable di-residue (RVD) at aa 
position 12 and 13 of each repeat (Fig. 12b, c).275,278 The remaining amino acids in a 
repeat sequence are typically highly conserved (Fig. 12b). The RVD is located in a 
loop region which faces the target nucleobase via the major groove of the DNA duplex 
(Fig. 12c, d).279,280 The loop is flanked by two α-helices. Two repeats are linked via a 
loop region that is located on the outside of the TALE repeat structure. The core of 
single repeats consists of small aliphatic residues (Fig. 12c).280 The small aliphatic 
residues make extensive van der Waals (vdW) contacts and enable close stacking of 
the two helices within each repeat against each other.281 In contrast, the interface 
between repeats contains distinct polar residues that interact with each other.280 
The sequential packing and association of tandem repeats with the DNA double helix 
appears to be facilitated by P27 (P = proline), which interrupts the second helix and is 
followed by a left-handed sequence leading to the right handed α-helix of the next 
repeat.280 Together, the concatenated repeats make a right-handed superhelical 
structure that wraps around the DNA double helix (Fig. 12d).279,280  
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Figure 12: Structure and modular organization of natural TALE proteins.c 
a) Schematic representation of the modular organization of TALE proteins with main regions 
and domains. b) Comparison of natural TALE repeat sequences show the variability at aa 
position 12 to 13 but an overall conserved sequence. c) A TALE repeat structure from PthXo1 
(protein database (pdb): 3UGM) with the RVD highlighted. Important amino acids involved in 
structure formation and DNA binding have been labeled. d) The PthXo1 TALE bound to the 
target DNA sequence (pdb: 3UGM).  
                                            
c Figure in b) reprinted (adapted) with permission from ref.269. Copyright 2019 Annual Reviews.  
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The process behind the formation of the TALE-DNA complex is still not completely 
understood. DNA-binding proteins can identify target sites through one-dimensional 
(1D) diffusion along the DNA helix via sliding and hopping motions.282 A similar motion 
has been observed for TALEs, although with a rotationally decoupled two-state mode 
of target search and binding events in which the TALE follows a direct trajectory along 
the template.283,284  
During target search, TALEs are loosely wrapped around the DNA duplex. This 
conformation minimizes electrostatic interactions between the positively charged 
patches along the inner surface of the CRD and negatively charged DNA backbone, 
and enables the TALE to rapidly hop and slide along the DNA.279,285 In between, 
binding events enable the CRD to test local DNA sequences for compatibility with its 
array. Upon encountering target DNA sequences, TALE proteins undergo a 
conformational compaction.281,286 This aligns RVDs and other residues including aa 
position 4, 30 and 32 of the repeat in the CRD array for energetically favorable TALE-
DNA interactions.283,287,288 
Essential for the transition from the search to the binding state is the recognition of an 
initial nucleobase by a cryptic repeat of the NTR. In most TALEs this occurs through a 
interaction between the indole ring of W232 (W = tryptophan) and the thymine 5-methyl 
group (Fig. 13).280  
 
 
 
Figure 13: Structure of the cryptic repeats -1 and 0 of the PthXo1 TALE NTR and interaction 
of W232 with the initial T of the target DNA. (pdb: 3UGM) 
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Usually, the single T is preceding naturally occurring target DNA and is required for 
TALE activity.275,278 Moreover, repeat number, order, and RVD at position 1 can also 
influence the sensitivity for the initial T.289 Furthermore, the substitution of 
W232R/Q231S (Q = glutamine; S = serine) in the NTR enabled accommodation of an 
initial G.290  
In total, the NTR contains four cryptic repeats (-3,-2,-1,0) which directly precede the 
CRD with repeat at position 0 packing tightly against the first canonical repeat of the 
CRD.285 Similar to the array of the CRD, the repeats of the NTR consists of a loop 
flanked by two α-helices and are arranged in a right-handed superhelical structure.285 
However, crystal structure show that the intervening loops of the cryptic repeats are 
degenerated except for the repeat at position -1 which makes the contact with the initial 
T.280,285  
All four cryptic repeats contain additional positively charged amino acids that contribute 
significantly to the overall basic charge of the protein and enable electrostatic 
interactions to DNA backbone phosphates.285,291 Therefore, the NTR likely acts as 
nucleation site for TALE-DNA binding.285,291 However, the first 152 aa of the natural 
NTR are not required for full activity of TALEs.288,292 
The role of the CTR is uncertain. It has been reported that the removal of the CTR and 
even the removal of the truncated last repeat might affect structural compactness but 
does not affect TALE activity significantly.288,293,294 Accordingly, it has been reported 
that the NTR and N-terminal repeats of the CRD contribute more to TALE–DNA 
recognition than the CTR and C-terminal repeat.288,295–297  
  
 33 
 
1.3.2. The DNA recognition code of TALE repeats 
Several amino acids in a repeat contribute to either stabilizing the repeat structure or 
to DNA binding. Amino acid residues K16 (K = lysine) and Q17 contribute to the 
electrostatic potential and coordinate the backbone phosphate of the forward strand 
DNA through direct or water-mediated hydrogen-bonds.281 These two amino acids 
account for the majority of the total binding energy of TAL proteins to DNA.298  
Additionally, G14 (glycine) and G15 bind to DNA phosphates through water-mediated 
H-bonds.280,281,299  
The four canonical RVDs NI (I = isoleucine), HD (H = histidine), NN and NG have 
different affinity to the four canonical nucleobases (Fig. 14).300 The four canonical 
RVD-nucleobase pairs are HD and C, NG and T, NI and A, NN and G or A.275,278  
In canonical TALE repeat, the 12th position is usually either H or N (Fig. 12b).269 Crystal 
structure show, that the residue faces away from the DNA towards the α-helix of the 
TALE repeat preceding the loop and acts as H-bond donor toward backbone carbonyl 
oxygen of aa position 8 in each repeat.280 This results in a helix break allowing the 
formation and stabilization of the RVD-containing loop from aa position 12 to 
15.280,281,298 
Base discrimination and molecular recognition of the nucleobase is solely provided by 
aa position 13 which can also interacts with the preceding DNA base.280,281  
 
 
Figure 14: Repeat structures in complex with DNA nucleobases. (pdb: 3UGM) 
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Within RVD HD, the side chain of D13 makes vdW interaction with Cytosine whereas 
the carboxylate moiety on D13 forms a stabilizing interaction with the amino group on 
C4 (β) of C.280,281 Models predicting a steric clash of D13 with the methyl group on 
carbon-5 (α) of T and interactions with N7 (γ) of G or A that destabilize the complex.298 
RVD NG makes a vdW interaction between the Cσ of the 5-methylgroup of thymine 
and G13.280,281 G13 does not provide stabilizing interaction with another nucleobase 
and other residues at that position would likely introduce steric clash with the 5-methyl 
group of thymine.281 The RVD NI is the second most common RVD in naturally 
occurring TALEs but is comparatively weak.280,301 In a crystal structure the aliphatic 
side chain of Ile in the RVD NI faces nucleobases without favorable contact.299 I13 
likely clashes sterically with the C4 carbonyl oxygen and the 5-methyl group of T.298 A 
model showed that the aliphatic side chain of I13 can interact with C8 (and N7) of the 
adenine purine ring or carbon-5 of the cytosine pyrimidine ring.298 Between the two 
bases RVD NI seems to prefer adenine on the basis of charge distribution, dipole 
moment and steric discrimination due to the C4 (β) amino group of C.280,298 The RVD 
NN interacts with both purine nucleobases. The side chain of N13 can form a H-bond 
with the pyridine-like nitrogen N7 (γ).280 Interactions with pyrimidine nucleobases are 
not favorable due to steric clashes with groups on C4/C5.298 There are natural 
occurring RVDs that are more selective for G such as RVD NH or NK, however both 
RVDs decrease TALE binding.292,301,302  
In repeats with N* (* = deletion, del) the RVD is replaced by a single asparagine. These 
repeats exhibit a size-reduced loop in which the subsequent amino acid G14 does not 
take the place of the deleted 13th position.269,280 As the loop extends less deeply into 
the major groove, the steric demand is reduced and both pyrimidine nucleobases can 
be accomodated.278  
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1.3.3. Design of TALE repeats and their application 
The arrangement of repeats into a CRD array technically allows to target virtually any 
desired DNA sequence. There are different assembly methods such as Golden Gate 
cloning,303 fast ligation-based automatable solid-phase high-throughput assembly,304 
ligation-independent cloning305 or isothermal assembly306 for “programming” TALEs. 
TALE fusion proteins can be used for genome engineering,307 transcriptional 
regulation,300,308–310 epigenetic writing311 and erasing312 as well as fluorescent 
probes.264,313–315 These applications require high activity and specificity of TALE 
proteins which can be influenced by sequence context, neighboring effects or RVD 
selection.289,295,297,316 For example, RVD NN binds both purine nucleobases but 
contributes to strong TALE-DNA interaction.301 RVD NI is selective for A but displays 
comparatively weak binding.301 Hence, using only the four “canonical” repeats HD, NG, 
NN and NI can limit TALE function. Three studies addressed this issue by testing all 
possible amino acid combinations of the RVD and revealed new selectivity profiles of 
novel RVDs such as RVD RH for G.302,316,317 
5mC and ox5mCs can be found in regulatory regions that are often chosen as targets 
in TALE-based technologies.318 The presence of cytosine 5-modifications can obstruct 
TALE-DNA binding, similar to steric clash between D13 and the 5-methyl group of 
T.298,318–321 In contrast, repeats NG or N* can accommodate 5mC.280,321,322 
Furthermore, in the context of C, 5mC and 5hmC, N* is able to discriminate between 
5mC and 5hmC, while RVD NG shows positive selectivity for 5mC.323,324 However, 
RVD N* shows similar high affinity towards C, 5mC and 5fC and weak affinity to 5hmC 
and 5caC.324,325 
Designing novel size-reduced repeats with a deletion at aa position 13 and variations 
at aa position 12 revealed diverse selectivity profiles for C, 5mC and ox5mCs, which 
are often similar to RVD N*.324,325 Interestingly, repeats with G12 or aa residues 
bearing hydroxyl groups (G*, S*, T* (T = threonine)) exhibited strong binding to all five 
cytosine nucleobases.324,325 A repeat with proline at aa position 12 (P*) was negatively 
selective for 5caC.325  
Notably, the same study showed that double deletions of aa residue 13 and 14 led to 
significantly reduced binding in all cases.325 Variations of aa residue 12 did not restore 
affinity.325 Deletions at aa position 12 and 15 reduced binding even further.326 However, 
a repeat lacking aa position 12 to 15 and with R at aa position 11 showed weak but 
selective recognition of 5caC.326  
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Another study provided a complete assessment of the efficiencies and specificities of 
amino acid combinations in addition to combinations of a deletion at either aa position 
12 or 13 with all amino acids for C, 5mC and 5hmC.327 RVD HA (A = alanine) or NA 
were identified as positive selective for 5mC in the context of C, 5mC and 5hmC.327 
However, no information regarding the other oxidized cytosine derivatives were 
provided, but previous studies had already shown a weak binding and selectivity of 
these RVDs towards other canonical nucleobases.302,316,317,327 
Another strategy focused on mutation of aa position 11 to 14 of the TALE repeat aiming 
at identifying structures with improved methylation-discrimination ability in living 
cells.328 According to this report, RVD NG is insufficient to completely regulate TALE 
binding in a methylation-dependent manner. Instead, the study reported that TALE 
repeat with amino acids ASAA at aa position 11 to 14 (instead of SNGG) shows 
improved methylation-dependent base recognition but weaker affinity.328 
Enhanced 5mC-selectivity of TALEs due to deletion of selected TALE-DNA-phosphate 
interactions has been observed for substitution of aa K16 and Q17 to A.329 This effect 
could be further enhanced through substituting key basic residues of the NTR likely 
responsible for backbone interactions in the DNA-bound state with A.329 However, both 
studies showed that incorporation of two engineered repeats decreased DNA binding 
drastically.328,329 
Despite extensive efforts, no cytosine 5-modification selective TALE repeat with high 
affinity has been found as of writing this thesis.  
It has been shown, that reduction of 5fC to 5hmC enables discrimination of 5fC from 
5mC with the partly selective TALE repeat N*.324 This indicates that chemoselective 
modification of carbon-5 groups can offer a strategy for complete, programmable 
decoding of oxidized 5-methylcytosine nucleobases with non-selective TALE repeats. 
Additionally, engineering strategies for TALE repeats had been limited to the canonical 
amino acids. With the advances regarding genetic code expansion and incorporation 
of artificial amino acid at user-defined positions, utilization of unnatural amino acids 
presents a promising strategy for selective, sensitive detection of ox5mCs as well. 
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1.4. Protein engineering with non-canonical amino acids  
1.4.1. Site-selective non-canonical amino acid incorporation into proteins  
The use of non-canonical amino acids (ncAA) can provide precise chemical properties 
and enable site-selective bio-orthogonal modification of proteins. The bottleneck for 
the applicability can be the incorporation at desired sites. Today, the most commonly 
used method site-selective non-canonical amino acid incorporation into proteins is 
genetically encoding ncAA via amber codon suppression due to its fidelity, efficiency, 
minimal influence on structure and natural environment during translation.330  
Site-specific incorporation of ncAAs can be achieved by exploiting the functionality of 
nonsense suppressor tRNAs in prokaryotic translation systems.331–334 Using an unique 
nonsense codon in the mRNA, the ncAA will be directed to the specific position 
encoding for the targeted amino acid. The amber stop codon UAG is rarely used as 
termination signal and has an overall low frequency in model organisms such as 
Escherichia coli (E. coli) or Saccharomyces cerevisiae (S. cerevisiae).333,335 Moreover, 
growth rates of certain E. coli that are naturally able to suppress amber codons were 
not significantly affected during incorporation of canonical amino acids.336,337  
To ensure high specificity of the incorporation, the aminoacylation of the nonsense 
suppressor tRNA needs to be specific for the ncAA but do not interfere or compete 
with any of the endogenous aaRS/tRNA pairs in the host organism. The orthogonality 
in amber codon suppression can be achieved by natural amber suppression 
aaRS/tRNA pairs from a domain of life different to that of the extract’s origin as the 
recognition of an tRNA by its cognate aaRS is often species specific.338–340 However, 
fully specific and orthogonal aaRS/tRNA pairs often require evolution through 
structure-based mutagenesis and multiple rounds of selection.341–347   
To date, highly efficient amber suppressions with more than 100 structurally diverse 
non-canonical amino acids in vivo have been reported.348 
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1.4.2.  Applications of non-canonical amino acids 
Site-selective non-canonical amino acid incorporation into proteins can be used to 
quantitatively introduce post-translational modifications (PTM) without sequence 
restrictions to study structural and biochemical implications.330,348,349  
ncAA also enable engineering of proteins with new or enhanced catalytic function or 
as highly sensitive probes.330,349,350 These probes can be used to study structural 
properties, conformational changes, interactions or cellular processes of proteins with 
X-ray crystallography,351,352 infrared (IR),353 nuclear magnetic resonance (NMR),354 
electron paramagnetic resonance (EPR),355 and fluorescence spectroscopy or 
microscopy in vitro or prokaryotic or eukaryotic cells.356–358 
Other applications include the spatial and temporal control of protein function and 
reversible activation in vitro or in vivo with photoswitchable ncAA,359,360 or photo-
crosslinking between proteins or between proteins and nucleic acids.361,362  
The use of ncAA in the generation of therapeutic proteins is also an emerging field.363 
But the arguably largest area of applications for genetically encoded chemically 
reactive ncAAs is the selective conjugation of proteins to a variety of molecules, such 
as oligonucleotides, synthetic polymers, and other proteins.364  
A commonly used reactions to modify chemically reactive ncAAs with non-
proteinogenic moieties is oxime formation.365 One advantage is the stable product 
formation under relatively mild acidic reaction conditions.364 A disadvantage is the 
incompatibility with pH-sensitive proteins, live cells and potential cross-reactivity.364  
Keto groups have been introduced into proteins by genetically encoding the amino 
acids para-acetylphenylalanine (pAcF) or meta-acetylphenylalanine (mAcF).365–367 
These amino acids and others have been used as a chemical handle to attach small 
molecules for a variety of applications such as protein conjugation.333,364,368  
Taken together, adding new chemistries via genetically encoding ncAA offers new 
possibilities to engineer protein structures and define protein function beyond the 
canonical amino acids.  
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2. Aim 
The aim of this study is to expand the toolbox for the direct detection of specific 
epigenetic nucleobases in user-defined DNA sequences with two approaches utilizing 
cytosine 5-modification-selective chemical conjugation reactions.  
 
 
Figure 15: Concept of chemoselective blockage of TALE binding for complete decoding of 
oxidized 5mC nucleobases in DNA.  
 
First, a universal TALE repeat is sought as the basis for the accommodation of the four 
canonical and the four epigenetic 5-modified cytosine nucleobases. Next, modification-
specific chemical derivatization strategies for 5hmC, 5fC or 5caC will be tested to 
reintroduce nucleobase-selectivity to the universal TALE repeat. The selective 
exclusion of a modified nucleobase will provide the basis for the sequence-specific 
detection of 5hmC, 5fC and 5caC in DNA (Fig. 15). This approach will be extended to 
the detection of 5hmC, 5fC and 5caC in user-defined target DNA within a complex 
human genomic DNA background. 
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Figure 16: Concept of 5fC-specific crosslinking with TALE proteins bearing a size-reduced 
repeat bearing pAcF through oxime condensation. 
 
Second, 5fC-selective crosslinking with TALE repeats bearing the ncAA pAcF will be 
established to provide a robust strategy to enrich user-defined target DNA with 5fC 
(Fig. 16). First, different amino acid positions in the size-reduced universal repeat will 
be screened for accommodation of pAcF without interfering with TALE-DNA binding. 
Next, a set of bifunctionalized linkers with hydroxylamine moieties will be tested for 
non-denaturating sequence-specific crosslinking. The crosslinking yield will be 
quantified. Selected TALE-linker combinations will then be used for covalent 
enrichment of target DNA with 5fC from complex genomic DNA backgrounds. Finally, 
this advanced TALE-based enrichment strategy will be to quantify 5fC levels of target 
DNA in genomic DNA backgrounds.  
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3. Results and Discussiond 
3.1. Complete, Programmable Decoding of Oxidized 5-
Methylcytosine Nucleobases in DNA by Chemoselective 
Blockage of Universal TALE Repeats 
3.1.1. Design of Universal TALE Repeats 
TALE proteins are programmable DNA-binders than can be used as sensors of 
epigenetic cytosine 5-modifications. However, positive recognition of single cytosine 
5-modifications with full selectivity or high affinity has not been achieved yet with TALE 
proteins. The rational of this work was to engineer universal TALE repeats with equally 
high affinity towards the eight human nucleobases. Then, selectivity towards single 5-
modifcations could be reintroduced by selectively blocking TALE binding via 
chemoselective labeling of cytosine 5-modifications to achieve complete, 
programmable decoding of epigenetic 5-modified cytosine nucleobases.  
The deletion of aa position 13 in the TALE repeat N* reduces steric demand and 
enables accommodation of epigenetic 5-modified nucleobases (c.f. 1.3.3.).320,324 This 
inspired the design of size-reduced loop structures for unhindered accommodation of 
nucleobases in the TALE-DNA complex, including cytosine 5-modifications. Therefore, 
TALE repeats with S or N at aa position 11 were designed by minimalizing the loop of 
the TALE repeat through the deletion (*) of amino acids at positions 12-15 (Fig. 17a, b). 
During the course of this work, two studies from our lab reported uniform 
accommodation of cytosine 5-modifications with size-reduced TALE repeats in which 
the RVD was replaced with single, small amino acids (G, S or T).324,325 
The original and mutated module vectors provided by A. J. Bogdanove and D. F. 
Voytas via Addgene were included in Golden Gate assembly of TALE proteins 
(Fig. SI1a-c). These proteins had size-reduced repeats positioned opposite the C of 
the single CpG dinucleotide (underlined) of either a 26 nucleotide (nt) sequence in the 
human tumor suppressor gene CDKN2A (TCAGCCGAAGGCTCCATGCTGCTCCC, 
human chr9: 21974786-21974811) or a 26 nt sequence of a promotor sequence 
associated with the DNA repair protein BRCA1 
                                            
d The contents of this section have been (partly) published in Gieß et al. (2018) and Gieß et al. (2019).369,370 
Reprinted (adapted) with permission from ref.369 and ref.370 Copyright 2019 American Chemical Society. 
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(TCTTTCCTTTTACGTCATCCGGGGGC, human chr17: 43125551-43125576, 
BRCA1a) (Fig. 17c).  
 
 
Figure 17: The modular organization of TALEs and design of size-reduced TALE repeats. 
a) Schematic illustration of a modular recombinant TALE protein with major domains. The RVD 
of repeats targeting one of the four canonical nucleobases are highlighted in red. GFP: Green 
fluorescent protein. b) Mutagenesis of the loop region (underlined) to generate new size-
reduced TALE repeats. *: Deletion. c) Target DNA of two subsets of TALEs containing a variable 
repeat of b) opposite of the bold, underlined C, which contains one of the five indicated 
cytosine nucleobases. 
 
The recombinant TALEs with N-terminal GFP domain, shortened AvrBs3-type NTR 
and a His6-tag after the CTR were expressed in E.coli from a pET-vector, isolated and 
purified via Ni-Nitrilotriacetic acid (NTA) affinity chromatography (Fig. SI2a, b).303,324 
High yields of TALE proteins with molecular weights (MW) at approximately ~130 kDa 
were isolated with good solubility (Fig. 18a, b). 
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Figure 18: TALE expression and circular dichroism spectroscopy. a) Exemplary sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) image of TALE_wt CDKN2A. 
Lane 1: Protein Ladder. Lane 2: Flow-through after incubation of lysate with Ni-NTA beads. 
Lane 3: Washing with 4x PBS. Lane 4: Washing with buffer supplemented with 20 mM 
Imidazole. Lane 5: Washing with buffer containing 50 mM Imidazole. Lane 6: Purified first 
elution of TALE_wt CDKN2A. b) Exemplary SDS-PAGE analysis of TALE_wt BRCA1. Lane 1: 
Protein Ladder. Lane 2: flow-through after incubation of lysate with Ni-NTA beads. Lane 3: 
Washing with 4x PBS. Lane 4: Washing with buffer supplemented with 20 mM Imidazole. Lane 
5: Washing with buffer containing 50 mM Imidazole. Lane 6: Purified first elution of TALE_wt 
BRCA1. c) Circular Dichroism Spectra of CDKN2A TALEs. 
 
Circular dichroism (CD) spectra of expressed CDKN2A-TALE proteins displayed a 
defined maximum at ~195 nm and two minima at ~210 nm and ~225 nm (Fig. 18c). 
These elements are typically observed for α-helix secondary structures.371 Other 
features that would indicate β-sheet or disordered structures cannot be observed. The 
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comparable CD spectra of the tested TALEs indicate that the folding of TALE proteins 
is not (significantly) affected by the incorporation of size-reduced TALE repeats. 
Therefore, it can be assumed that the overall structure is comparable between all TALE 
proteins. 
Next, an electromobility shift assays (EMSA) with oligonucleotide duplexes containing 
the TALE target sequence was used to analyze TALE-DNA binding.  
 
 
 
Figure 19: EMSA with TALEs and target DNA with C opposite the indicated repeat. a) Binding 
profiles of 150 nM CDKN2A TALEs and b) 150 nM BRCA1a TALEs to their target DNA. 
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Herein, the N-terminal GFP-domain is used for detection of protein bands after native 
polyacrylamide gel electrophoresis (PAGE). A shift down in the gel signals binding to 
DNA. In comparison, the shift of CDKN2A TALE_wt, TALE_SG*GG and SG**G was 
significantly higher to the BRCA1a TALEs indicating a stronger binding of CDKN2A 
TALEs to target DNA with unmodified cytosines at this concentration in EMSA 
(Fig. 19a, b). Furthermore, a similar high fraction of TALE_wt and TALE_SG*GG 
shifted in EMSA. This indicate comparable binding of TALE_wt and TALE_SG*GG with 
unmodified cytosine.  
The strong binding of repeat_SG*GG indicates that this interaction is not affected by 
the single deletion of aa position 13 similar to repeat N*. It is possible that interactions 
could be facilitated due to the absence of the steric demand imposed through residue 
13 and the overall more flexible loop structure due to the N/H12G substitution.  
Amino acid position 14-17 interact with the backbone phosphate of the target DNA. For 
both sets of TALE proteins, the deletion of aa position 14 reduced the binding for 
TALE_SG**G to target DNA (Fig. 19a, b). Strikingly, more than 2 deletions of repeat 
residue 12-15 abolished binding completely (Fig. 19a, b). This shows that repeats with 
residue 11 to 17 consisting of SG***KQ, S****KQ or N****KQ instead of SHDGGKQ 
are insufficient for TALE-DNA interactions, even though the two amino acids which 
account for the majority of the total binding energy of TAL proteins to DNA (K16 and 
Q17)298 are still present in these repeats. 
Next, further binding studies with CDKN2A TALE_wt, TALE SG*GG and TALE SG*GG 
against 5-modified cytosines were conducted (Fig. 20). EMSA data showed the 
expected selectivity profile for TALE-wt. Strong binding was only observable for C but 
not for 5mC or ox5mCs, even at a five-fold excess of DNA to TALE (Fig. 20a, b).  
In contrast, TALE_SG*GG displayed uniform and strong binding to the five 5-modified 
cytosines (Fig. 20a, b). Binding of TALE_SG**G to target DNA was somewhat 
selective for 5mC and 5fC opposite of the variable repeat, but overall lower than for 
TALE_SG*GG (Fig. 20a, b). Both repeat_SG*GG and repeat_SG**G lack loop 
stabilizing aa at position 12 which could cause a more flexible orientation of the loop 
in the major groove of the DNA. The CD spectra indicate that deletions in the loop 
structure of a single repeat would not compromise the overall structure of the TALE, 
but the different binding profiles suggest that deletions influence local flexibility of the 
repeat. Moreover, multiple deletions could tension the structure, restrict conformations 
and also influence the structure of neighboring repeats which could affect overall TALE 
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binding Additionally, the deletion of aa position 13 removes possible steric hindrance 
from a nucleobase-contacting aa side chain for universal accommodation of cytosine 
5-modifications. Presence of G residues could enable vdW interaction between the Cα 
carbons of G residues and 5mC or 5fC. The rotational dimorphism observed for 
5hmC56,57 could be a reason for decreased TALE binding. This could explain why 5mC 
and 5fC are generally bound with better affinity in size reduced repeats.324,325 
 
 
Figure 20: Interaction of CDKN2A TALEs with target DNA bearing C, 5mC, 5hmC, 5fC or 5caC 
opposite the variable repeat. a) Native PAGE images from EMSA for 150 nM TALEs and DNA 
as indicated. b) Quantified TALE binding from EMSA with TALE_wt, TALE_SG*GG and 
TALE_SG**G. 
 
A computational modeling approach (credit to J. Jasper and O. Koch) of TALE 
structures with repeat_wt, repeat_SG*GG and repeat_SG**G projected a similar 
TALE-DNA complex. Furthermore, the repeat_SG*GG and repeat_SG**G form 
cavities with increasing size, which can accommodate even the arguably sterically 
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most demanding 5caC. (Fig. 21, employed modeling approach was not applicable to 
repeats with >2 deletions). This is in good accordance with the experimental data. 
 
 
Figure 21: Models of TALEs bound to targets with C or 5caC opposite of the variable repeat 
position. a) Modelled repeat_SHDGG with C. b) Modelled repeat_SHDGG with 5caC with the 
steric clash of D13 and the 5-carboxyl. c) Modelled repeat_SG*GG with a cavity for 
accommodation of 5caC. d) Modelled repeat_SG**G has a similar cavity for accommodation 
of 5caC but has a somewhat twisted conformation. 
 
TALE-DNA binding at single concentrations cannot accurately define the binding ability 
of the TALE proteins. Therefore, TALE binding curves were determined for 
TALE_SG*GG as the strongest binder and the five cytosine nucleobases (Fig. 22a, b). 
TALE binding was approximately saturated at 80 % for target DNA with C, 5mC or 
ox5mCS, except for TALE binding to target DNA with 5caC which was approximately 
saturated at 50 %. Dissociation constants (KD) calculated from the fitted binding curves 
confirmed a strong, universal binding of TALE_SG*GG to the five cytosine 
nucleobases within one order of magnitude (Fig. 22c). 
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Figure 22: Binding curves of TALE_SG*GG with CDKN2A target DNA. a) EMSA for titration of 
150 nm TALE_SG*GG with target DNA bearing one of the five cytosine nucleobases opposite 
of repeat_SG*GG. b) Data points from a) with corresponding binding curves obtained from 
non-linear dose response fit. c) Calculated KD-values in nM for TALE binding. 
 
It would be of interest if the universal binding of TALE_SG*GG also applies to the other 
three canonical nucleobases A, G and T. This could be of use for targeting or 
bypassing variations in the consensus target DNA in the form of single nucleotide 
polymorphisms (SNPs) during epigenetic nucleobase analysis or in vivo (epi-)genome 
engineering and transcription control. EMSA data with TALE_SG*GG and target DNA 
bearing A, G or T opposite of repeat_SG*GG as well as a transcription activation assay 
with a luciferase reporter and TALE_SG*GG fused to the transcriptional activator VP64 
in HEK293T cells (credit to A. Witte) revealed similar binding to all four canonical 
nucleobases (Fig. 23a, b). However, the relative luciferase activity (RLA) triggered 
through expression of TALE_SG*GG-VP64 was only half as strong as for TALE_wt-
VP64 and the canonical target DNA. This suggests a difference in binding between the 
two proteins in live cell experiments. To analyze potential differences and affinity in 
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binding of TALEs in cellular systems, further in vivo studies with multiple cell lines are 
currently underway in the Summerer lab as of writing this thesis. 
 
 
Figure 23: Interaction of CDKN2A TALEs with target DNA bearing C, A, G or T opposite the 
variable repeat. a) EMSA of 1.5 pmol TALE_SG*GG and DNA. b) Luciferase transcription 
activation using TALE-VP64 constructs with indicated repeat opposite single C, A, G, or T in the 
target. Relative luciferase activity (RLA) normalized to TALE_wt binding to target site with C. 
Scrambled TALE control represents a binding of a TALE with a shuffled TALE_wt CRD sequence. 
 
Taken together, these results are in accordance with previous binding studies that 
reported similar binding profiles for TALEs with repeat_SG*GG for different target DNA 
sequences.324,325 This indicates that these selectivity profiles of TALE-DNA binding are 
not significantly influenced by the DNA context and/or protein sequence.  
Most importantly, these results revealed the first repeat design that enables universally 
binding to all eight human DNA nucleobases.  
It is likely, that negative discrimination of repeat_SG*GG applies to at least certain 
nucleobases. Unlike HD-repeats for C, the molecular structure of the loop does not 
provide chemical handles for positive recognition of nucleobases like C, 5caC, G or A. 
For the other bases however, repeat-SG*GG could provide the molecular scaffold for 
vdW interaction with 5-modification of 5mC, 5fC and T. This could explain the higher 
affinity of TALEs with engineered repeats with a deletion at aa position 13 for 5mC and 
5fC compared to 5hmC and 5caC.  
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3.1.2. Cytosine 5-modification-selective Blockage of TALE Binding  
Chemoselective conjugation of cytosine 5-modifications to block protein functions has 
been used to detect epigenetic 5-modified cytosines (cf. chapter 1.2.3.2.). To 
investigate the possibility of TALE binding reintroducing selectivity of for ox5mCs 
through this strategy, uridine diphosphate (UDP)-glucose (1)-dependent enzymatic 
glucosylation with T4 BGT was chosen (Fig. 24a). It is a well-established and facile 
5hmC-selective modification reaction (cf. chapter 1.2) which had been shown to 
obstruct protein function such as endonuclease activity of MspI for example.243 Multiple 
reaction times were tested (data not shown) and product formation was analyzed 
through electrospray ionization (ESI)-MS. The overnight reaction indicated efficient 
glucosylation with a high yield of 5ghmC (2) formation with a rest of 5hmC remaining 
detectable (Fig. 24b; Fig. SI3; Table SI1). 
TALE_SG*GG binding to oligonucleotides bearing 5ghmC opposite of repeat_SG*GG 
was evaluated in EMSA studies. In contrast to unmodified 5hmC, binding was strongly 
reduced for 5hmC-DNA subjected to enzymatic glucosylation. No blocking effects were 
observed for the other four cytosine nucleobases subjected to enzymatic glucosylation 
(Fig. 24c, d; Fig. SI4). Additionally, TALE binding in EMSA to different concentrations 
of 2-DNA did not exceed 10 %. No KD could be determined from TALE_SG*GG binding 
curves for 5ghmC-DNA, confirming the 5hmC-selective strong blocking effect 
(Fig. 24e, f). This indicates that the indicated conformational flexibility of 
repeat_SG*GG is limited and cannot evade steric clash with the large hydrophilic 
glucose moiety in 1. This suggests that labeling of 5fC and 5caC with similarly sterically 
challenging moieties can also obstruct TALE binding. 
Therefore, oxime formation with hydroxylamines varying in size, flexibility, branching 
degree and polarity was tested for 5fC-selective blockage. Oxime formation is a well-
established mild reaction. Moreover, oxime formation with supramolecular moieties 
have been used for 5fC-selective inhibition of protein function (cf. chapter 
1.2.3.2.).218,219  
Different reaction conditions and catalysts (data not shown) for DNA modification were 
tested with hydroxylamines including O-ethylhydroxylamine (3a to 4a), O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine (3b to 4b), O-ortho-benzylhydroxyl-amine (3c to 4c) and 
O-tert-butylhydroxylamine (3d to 4d) (Fig. 25a).  
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Figure 24: 5hmC-selective blockage of TALE binding. a) Glucosylation of 5hmC with UDP-Glc 
(1) to 5ghmC (2) by T4-β-glucosyltransferase (BGT). b) Extracted mass peaks from Fig. SI3 and 
Table SI1 indicating highly efficient glucosylation of 5hmC. c) Effect of 2 on TALE_SG*GG 
binding. d) Interaction of TALE_SG*GG with DNA containing nucleobase as indicated. EMSA 
data using each 150 nM TALE and reacted DNAs were subtracted from data of unreacted DNA 
and plotted as % difference (Δ). e) Binding curves of TALE_SG*GG with unreacted 5hmC-
containing DNA and reacted 5hmC (2)-containing DNA. f) KD values from binding curves in e). 
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Eventually, matrix-assisted laser desorption/ionization (MALDI) time of flight (TOF) MS 
indicated high oxime yields under mild acidic conditions in a phosphate buffer with 
para-phenylenediamine (pPDA) as catalyst (Fig. 25a, b; Fig. SI5; Table SI2).  
 
 
Figure 25: pPDA-catalzyed oxime formation of 5fC-DNA with hydroxylamines 3a-d. a) Oxime 
reaction scheme of 5fC to 4a-d with para-phenylenediamine (pPDA). b) Extracted mass peaks 
from Fig. SI5 and Table SI2 indicating highly efficient oxime formation. c) Effect of 3a-d 
opposite of repeat_SG*GG on TALE binding. 
 
EMSA for the evaluation of TALE_SG*GG binding to 5fC-DNA after oxime formation 
revealed that binding was strongly reduced to DNA with 4d but was still able to bind to 
DNA with 4a-c (Fig. 25c). A possible explanation of this binding profile could be a fixed 
orientation of oxime substituents due to the hydrogen bond of the oxime nitrogen with 
the 4-amino group similar to the orientation of the formyl group of 5fC in DNA.59 Crystal 
structures of TALE-DNA complexes indicate that TALE proteins do not completely 
occupy the major groove of the DNA.280,281 This might create a “blind spot” that can 
accommodate bulky substituents without interfering with TALE binding.372  
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Figure 26: 5fC-selective blockage of universal TALE binders. a) Interaction of TALE_SG*GG 
with DNA containing nucleobase as indicated. EMSA data using each 150 nM TALE and reacted 
DNAs with 3d were subtracted from data of unreacted DNA and plotted as % difference (Δ). 
b) Binding curves of TALE_SG*GG with unreacted 5hmC-containing DNA and reacted 5fC-
containing DNA (4d). c) KD values from binding curves in b). 
 
This leaves the possibility that structurally-related glucose groups like the 
tetrahydropyranyl group of 4b or aromatic residues like the rigid benzyl group of 4c 
and even bulkier substituents like an Alexa Fluor 488 probe (Fig. SI6) can be 
accommodated without interference. In contrast, the strong effect of 4d on TALE 
binding indicates, that the quaternary sp3-center of the tert-butyl residue was critical. 
Therefore, the orientation and conformational flexibility of the residue from the 5-
substituent after conjugation and not mere size of the conjugated residue appears to 
be an essential factor for effective blocking. Indeed, models (credit to J. Jasper and O. 
Koch) suggest that DNA with 4c for example can be favorably oriented to evade steric 
clash with the TALE_SG*GG repeat, whereas DNA with 4d cannot (Fig. SI7).  
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Similar to 5hmC-specific blocking, reaction of DNA with the five cytosine nucleobases 
and 3d only led to an effect for TALE binding in EMSA for 5fC-DNA (Fig. 26a, Fig. SI4). 
TALE binding to 4d-DNA was saturated <15 % in titration experiments with EMSA 
(Fig. 26b, c). Again, no KD-value could be determined for TALE_SG*GG with 4d-DNA 
(Fig. 26c, d).  
Carboxyl groups can form hydroxamates with hydroxylamines, but generally need to 
be activated to obtain good yields.373 Under the employed conditions, no blocking 
effect cannot be observed for 5caC. This indicates that either no hydroxamate between 
5caC and 3d is formed or that the formation does not significantly interfere with TALE 
binding. Also, no to very little differences in binding of TALE_SG*GG to unreacted and 
reacted DNA indicates that the DNA is not significantly denatured or otherwise affected 
in a way that could prevent TALE binding to the other nucleobases. Together, these 
results demonstrate a strong 5fC-selective blocking effect of TALE binding. 
Reactions with 5caC have only been reported in one instance for an EDC-catalyzed 
NHS ester formation and subsequent coupling with primary amines.158 Testing different 
reaction conditions and catalysts (data not shown), efficient amide bond formation of 
5caC with 7-azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium hexafluorophosphate 
(PyAOP) under mild basic conditions in MES buffer was identified (Fig. 27a). To the 
best knowledge, amide formation with PyAOP has not been previously reported for 
5caC. This can be an alternative to amide formation with EDC for other chemical 
modification-based approaches.  
MALDI-TOF MS of coupling reaction with different amines indicated good yields for 
ethylamine (5a to 6a), THP-methylamine (5b to 6b) and benzylamine (5c to 6c) (Fig. 
27b; Fig. SI5; Table SI2). In contrast, tert-butylamine (5d to 6d) reacted poorly (Fig. 
27b; Fig. SI5; Table SI2).  
Evaluation of TALE binding to target DNA bearing 5caC after amide coupling with 5a-
d in EMSA revealed that only formation of 6c led to effective blocking (Fig. 27c). Due 
to the orientation of the carboxyl group of 5caC with the carbonyl oxygen of 5caC 
making a hydrogen bond to the exocyclic C4-amino group,59 the substituents of 6a-d 
are likely differently positioned than substituents of 4a-d. This could explain the 
different structure-activity relationships compared to 5fC. Herein, the similar sized, but 
more flexible sp3-linked THP group of 6b but not the benzyl group of 6c could evade 
clash with the repeat backbone (Fig. SI8). Additionally, likely due to poor reactivity of 
5d no significant effect on TALE binding can be observed for 6d. 
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Figure 27: PyAOP-mediated amide formation with 5caC-DNA with amines 5a-d. a) Amide 
reaction scheme of 5caC to 6a-d with (7-azabenzotriazol-1-yloxy)tripyrrolidino-phosphonium 
hexafluorophosphate (PyAOP). b) Extracted mass peaks from Fig. SI5 and Table SI2 indicating 
highly efficient amide formation for 5a-c but not for 5d. c) Effect of 5a-d opposite of 
repeat_SG*GG on TALE binding. 
 
Similar to glucosylation for 5hmC and oxime formation for 5fC, the effect of amide 
coupling conditions with 5c was chemoselective for 5caC (Fig. 28a; Fig. SI4).  
Again, as DNA with other cytosines did not display strong differences in binding after 
the reaction, this indicates that the DNA is not significantly denatured or otherwise 
affected in a way that could prevent TALE binding to the other nucleobases. Under 
basic conditions, 5fC can participate in Schiff base formation.295 However, potentially 
due to the different position of the benzyl residue similar to 4c or low yield, no 
pronounced effect can be observed.  
TALE binding for DNA with 6c saturated <10 % in titration experiments with EMSA 
(Fig. 28b, c). As for DNA with 2 and 4d, no KD could be determined from fitted binding 
curves. (Fig. 28c, d). This demonstrates strong 5caC-selective blocking of TALE 
binding. 
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Figure 28: 5caC-selective blockage of universal TALE binders. a) Interaction of TALE_SG*GG 
with DNA containing nucleobase as indicated. EMSA data using each 150 nM TALE and reacted 
DNAs with 5c were subtracted from data of unreacted DNA and plotted as % difference (Δ). b) 
Binding curves of TALE_SG*GG with unreacted 5hmC-containing DNA and reacted 5caC-
containing DNA (6c). c) KD values from binding curves in b). 
 
Taken together, three facile non-denaturing chemical modification approaches were 
identified that obstruct binding of TALEs with an engineered universal repeat. This 
enable cytosine 5-modification-selective blockage of TALE binding for 5hmC, 5fC and 
5caC for the complete, programmable decoding of epigenetic 5-modified cytosines. 
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3.1.3. Complete decoding of oxidized 5mC nucleobases 
Finally, the approach was tested for detection of epigenetic nucleobases at single, 
user-defined positions of 5hmC, 5fC and 5caC in a TALE-based genomic enrichment 
assay324 with human genomic DNA background (Fig. 29a).   
 
 
Figure 29: Complete decoding of oxidized 5mC nucleobases in a genomic DNA background 
with a TALE-based enrichment assay. a) Affinity enrichment workflow. b) qPCR quantification 
of affinity enrichments with TALE_SG*GG and DNAs bearing single oxidized 5mC reacted as 
indicated. Copies of control enrichments without TALE were subtracted from enrichments 
with TALE. c) Enrichment of gDNA with 5mC, 5hmC or 1:1 mix as in b). ****: p ≤ 0.00001; n ≥ 5. 
 
To benchmark the chemoselective blocking strategy in the genomic enrichment assay, 
a defined modification status of target DNA is required. Therefore, 421 bp long 
sequences with the CDKN2A TALE target DNA and a single 5hmC, 5fC or 5caC 
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opposite repeat_SG*GG were generated (Fig. SI9a). Interestingly, efficient synthesis 
of spike-ins with 5caC in the target DNA was considerably more challenging with 
standard PCR protocols compared to spike-ins with 5hmC of 5fC in the target DNA. A 
plausible reason could be that G-5caC pairs have been reported to stimulate DNA 
polymerase exonuclease activity.374 This could apply to the 3′→5′ exonuclease activity 
of the utilized Q5 DNA polymerase. Therefore, the G-5caC pair could be detected as 
DNA lesion and affect polymerase activity. Accordingly, good processivity of 5caC in 
PCR with a polymerase without 3′→5′ exonuclease activity had been reported.375 
Additionally, Q5 polymerase is fused to the non-specific DNA-major groove binding 
protein Sso7d. It is used for better processivity, but can be sensitive to 5-modifications 
of a pyrimidine.376 5caC with the arguably sterically most challenging 5-modification 
could therefore have an impact on binding and hence Q5 polymerase processivity. 
Eventually, running a gradient PCR with low annealing temperatures resolved this 
issue. Still, understanding underlying mechanism could be an interesting topic for 
further studies. 
Synthesized amplicons were spiked into a fragmented (~300-700 bp) non-modified 
genome background (bg) DNA at a concentration of a single genome copy (Fig. SI9b). 
The bgDNA was generated through whole genome amplification (WGA) from gDNA of 
a human individual (ENCODE sample NA18507). To remove false-positive 
enrichment, bgDNA was digested within the corresponding spike-in sequence 
including the TALE target DNA (Fig. SI9c).  
Next, bgDNA with spike-ins bearing 5hmC, 5fC or 5caC were subjected to 
glucosylation, oxime formation or amide formation. Then, purified reacted and non-
reacted DNA samples were employed in TALE-based affinity enrichments324 with 
TALE_SG*GG.  
Non-reacted DNA and reacted DNA bearing off-target nucleobases were enriched at 
comparable levels from the genomic DNA background (Fig. 29b). In contrast, DNA 
with the target nucleobases were only enriched at background levels, confirming the 
previous results for cytosine 5-modification-selective blockage of TALE binding and 
advancing the approach from short oligonucleotides to a complex genomic DNA 
background (Fig. 29b). 
Next, the sensitivity of the approach was analyzed. Therefore, target sites with a 
heterogeneous modification status at a single CpG-site were spiked into bgDNA. 
 59 
 
Heterogeneity of naturally occurring 5-modifications at single CpGs in gDNA is an 
important aspect due to dynamic process of the iterative oxidation of 5mC.  
Enrichment of TALE targets with pure or equimolar mixed 5mC/5hmC-sites showed an 
inverse proportional TALE binding to 5hmC levels in reacted samples (Fig. 29c). This 
demonstrates differentiation between two epigenetic cytosine 5-modification based on 
chemoselective blockage in a complex genomic DNA background.  
Notably, the loss of DNA in both enrichment procedures were surprisingly high at 
~95 % and comparable to the denaturing conditions of bisulfite sequencing.137 It is 
possible that the genomic DNA behaves differently than short oligonucleotides under 
the different conjugation reaction conditions. Another option is the relatively short 
binding time of TALE to target DNA in the complex gDNA environment meaning that a 
high percentage of TALEs could be non-specifically bound to bgDNA searching for 
target DNA. During washing, this fraction of sample would then be lost. Additionally, 
the dense immobilization of TALEs on agarose beads could lead to restriction of their 
binding to DNA.  
In conclusion, these results demonstrate fully selective modification and sensitive 
detection of single 5hmC, 5fC and 5caC with TALEs in a genomic assay with high 
confidence which expands the toolbox of detection strategies for ox5mCs.  
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3.2. Programmable Protein-DNA Crosslinking for the Direct 
Capture and Quantification of 5-Formylcytosine 
3.2.1. Design of TALE Repeats bearing para-Acetylphenylalanine 
5fC is a highly dynamic, cell-type specific cytosine 5-modification. 5fC can be a stable 
modification but relatively little is known about the function of 5fC in gDNA.  
Several probes have been developed that enable enrichment and downstream 
analysis of genome wide 5fC-sites after chemical derivatization (cf. chapter 1.2.3.2). In 
one instance an oligonucleotide probe with a chemical handle for crosslinking of 5fC 
within the complementary sequence had been developed during the work of this 
thesis.75 A particular challenge for detection methods are the low genomic levels of 
5fC.  
No TALE repeats for positive selective recognition of 5fC are available. Oxime 
formation of 5fC with O-tert-butylhydroxylamine enables detection of target DNA 
bearing 5fC in gDNA background via chemoselective blockage of TALE 
repeat_SG*GG (Fig. 29b). However, this approach does not allow enrichment of 5fC.  
Based on the universal TALE repeat_SG*GG structure, novel TALE repeats were 
designed that bear the non-canonical amino acid pAcF (1) at aa position 11, 12 or 14 
(Fig. 30a-c). The ketone functionality enables crosslinking of TALE proteins to user-
defined 5fC-DNA sequences via oxime condensation with diaminooxy-linkers. 
First, the original and mutated module vectors were assembled via Golden Gate 
reaction into a set of TALE proteins (Fig. SI1a-c) targeting a 26 nt sequence of a 
promotor sequence associated with the DNA repair protein BRCA1 
(TCTTTCCTTTTACGTCATCCGGGGGC, human chr17: 43125551-43125576, 
BRCA1a) (Fig. 30d).  
Size-reduced repeats bearing 1 were positioned opposite the target C of the single 
CpG dinucleotide (underlined) (Fig. 30d). TALE proteins (TALEa_1G*GG, 
TALEa_S1*GG and TALEa_SG*1G) were expressed from a pET-vector. pAcF was 
incorporated into these TALEs via an orthogonal Methanocaldococcus jannaschii 
(M. jannaschii) tyrosyl-tRNA synthetase/tRNA pair365 in response to the amber codon 
in E. coli (Fig. 30e; Fig. SI10; Fig. SI11; Fig. SI12a, b). 
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Figure 30: Engineering size-reduced TALE repeats bearing the non-canonical amino acid 
(ncAA) para-acetylphenylalanine (pAcF, 1). a) Chemical structure of 1. b) Modelled TALE 
repeat_SG*GG with 5fC (design based on Fig. 21c). Positions for incorporation of 1 marked 
with red arrows. c) Design of TALEs for the d) BRCA1a target DNA with variable repeats 
opposite of the underlined CpG. The CpG contains one of the five cytosines as indicated. 
e) SDS-PAGE image of purified TALEa_1G*GG, TALEa_S1*GG, TALEa_SG*1G after expression 
either with or without pAcF (see Fig. SI12a for full gel). 
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Next, binding of the three TALE proteins to oligonucleotide duplexes containing the 
BRCA1a sequence with a single C, 5mC, 5hmC, 5fC or 5caC opposite the engineered 
repeat was evaluated in EMSA and compared to binding of TALEa_wt and 
TALEa_SG*GG (Fig. 31).  
 
  
Figure 31: Interaction of TALEs with BRCA1a target DNA bearing one of the five cytosines 
opposite of the variable repeat as indicated. a) Native PAGE gel images after EMSA of the five 
TALEs with the different target DNA as indicated. b) Binding profiles of the five TALEs with the 
different target DNA as indicated (0.75 pmol TALE to 7.5 pmol DNA). 
 
Expectedly, high binding of TALEa_wt to DNA was observed only to sequences with 
unmodified C, whereas TALE_SG*GG bound strongly to DNA with all five cytosine 
bases opposite the repeat_SG*GG.   
For TALEs with 1, binding of the three TALEs were observed to all five cytosines but 
compared to TALEa_SG*GG, the incorporation of the ncAA slightly reduced binding of 
TALEa_S1*GG and TALEa_1G*GG, whereas binding of TALEa_SG*1G was reduced 
by ~50 % compared to TALEa_SG*GG (Fig. 31). Reduced binding of TALEs with 
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repeat_1G*GG indicate a hindrance of TALE binding. This might be possible due to an 
unfavorable position of 1 towards the sterically challenging 5hmC and 5caC, as binding 
to 5mC and 5fC is comparable to TALEa_S1*GG. In contrast, the overall reduced 
binding of TALEa_SG*1G indicate a local impact on the repeat structure, rather than 
overall TALE folding or complex formation. Interestingly, the binding pattern of the 
TALE with repeat_S1*GG is significantly higher than of TALEs with the chemically 
similar aa F or Y in repeat_SF*GG or repeat_SY*GG,325 which suggests that 1 can 
either stabilize a more favorable loop structure for biding of 5-modified cytosines or the 
keto-group participates in TALE-DNA binding.  
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3.2.2. Programmable crosslinking of TALE repeats with pAcF and 5fC 
Next, the three TALEs were reacted with a set of diaminooxy-linkers with one to six 
ethylene glycol moieties that had been labeled to 5fC-DNA (Fig. 32a, L1-L5). The 
linkers had been synthesized (credit to G. Kubik) according to a previously published 
protocol via a Mitsunobu reaction with N-hydroxyphthalimide and subsequent 
hydrazinolysis (Fig. 32a).377 Both ESI-MS and NMR (1H and 13C) confirmed product 
formation (Fig. SI13; Fig. SI14).  
 
 
 
Figure 32: Crosslinking of 5fC with 1 via linker L1-L5 under mild acidic conditions. a) Synthesis 
scheme of linker L1-L5 with different number (n) of ethylene glycol moieties (see methods for 
full protocol). b) Crosslinking of 5fC in a pPDA-catalyzed two-step reaction to TALE proteins 
bearing 1. XL: Crosslink formation yields a 5fC-linker-1 adduct. 
 
For the crosslinking reaction, conditions for oxime formation compatible with DNA 
hybridization from chapter 3.1.2. were utilized. Interestingly, previous experiments 
under similar conditions were not able to provide TALE-DNA-crosslinks after TALE had 
been incubated with DNA (data not shown). In that instance, access of the reagents to 
5fC-sites and 1 could have been restricted after formation of the TALE-DNA complex.  
Therefore, a different approach of first reacting the DNA with the linker, then reacting 
TALE with DNA was employed. Briefly, 100 pmol DNA in 20 mM phosphate buffer at 
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pH = 6.0 was reacted with 2 µmol pPDA and 10 µmol linker L1-L5 (Fig. 32b). First, 
pPDA-catalyzed crosslink formation was analyzed by MS and gel electrophoresis 
(GE). MS data indicated high yields of 5fC-labeling with L1-L5, whereas DNA-DNA 
crosslinks of 5fC-containing 5’-FAM-labeled oligonucleotides could neither be detected 
with agarose GE nor with MALDI-TOF MS indicating that the linker excess under the 
reaction conditions led to quasi quantitative labeling of 5fC (Fig. SI15; Fig. SI16).  
In the next step, 100 pmol BRCA1a TALEs with 1 at aa position 11, 12 or 14 in repeat 
12 in 20 mM Tris-HCl buffer at pH = 6.0 was added to the DNA. Crosslink analysis via 
denaturing sodium dodecyl sulfate (SDS) PAGE revealed a series of new bands 
corresponding to increased weight compared to unreacted TALE proteins only for 
reactions with linker present (Fig. 33a). Interestingly, the position of 1 in the three 
TALEs apparently also influenced band formation and intensity for different linker.  
Especially strong bands were visible for the longest linker L4, L5 with 4 and 6 ethylene 
glycol moieties for all three TALEs (Fig. 33a). This suggests that during or after binding 
of TALE proteins the linker can be guided best to 1. However, these molecules need 
to be also accommodated within the TALE-DNA complex. In this regard, the chain 
could be positioned in a “blind spot”. This could be similar to linker of the Alexa Fluor 
488, which position at a 5fC-site in target DNA did not affect TALE binding (Fig. SI6).  
Notably, crosslinking of TALEa_SG*1G to 5fC-DNA via L2-L5 resulted in comparable 
strong bands. Following the orientation of aa side chains, 1 would face towards a 
similar direction as the second position of the RVD due to deletion of aa position 13. 
This would position the keto-group of 1 towards the modified 5fC and could explain 
why the crosslinking appears to be the most efficient for TALEa_SG*1G. Accordingly, 
from the orientation in the repeat_SHDGG (Fig. 12c) and modelled repeat_SG*GG 
(Fig. 30b) the position of 1 at aa position 11 or 12 would likely move the keto-group 
away from the labeled nucleobase and could explain why longer linker are required for 
crosslinking of TALEa_1G*GG and TALEa_S1*GG than for TALEa_SG*1G. 
Interestingly, no crosslinking could be observed for TALEs and L1 (Fig. 33a). It is 
unlikely that this is a result of poor reactivity in the labeling reaction of 5fC with L1. It 
could be a result of 1 not being proximal enough to the labeled 5fC-site, or in case of 
TALEa_SG*1G the modified 5fC cannot be efficiently and stably accommodated at the 
repeat for oxime formation between the hydroxylamine and 1. The consequence would 
be a dissociation of the TALE-DNA complex similar to the chemoselective blockage of 
4d or due to denaturation prior to the SDS-PAGE.  
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Figure 33: 5fC-specific DNA-TALE-crosslinking with TALE proteins bearing the ncAA pAcF. a) 
Denaturing SDS-PAGE image after crosslinking reaction with L1-L5, 5fC-DNA and TALEs as 
indicated. b) Denaturing SDS-PAGE image after crosslinking reaction with L1-L5, 5fC-DNA and 
TALEa_wt. c) Denaturing SDS-PAGE image after crosslinking reaction with L4, TALEa_S1*GG 
and DNA bearing either C, 5mC, 5hmC, 5fC or 5caC opposite the repeat with pAcF. 
 
As no or only background level bands could be observed for samples without linker or 
without DNA and linker, the band can be assigned to the formation of DNA-TALE-
crosslinks. Additionally, no crosslinking with TALEa_1G*GG and linker L4 could be 
observed for DNA containing C, 5mC, 5hmC or 5caC opposite the reactive repeat or 
of TALEa_wt with L1-L5 and 5fC-DNA (Fig. 33b, c). This confirms that the TALE-DNA 
crosslink is dependent on the presence of 5fC and 1. Furthermore, TALE-TALE-
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crosslinking (expected bands at ~260 kDa) could not be confidently detected for the 
three TALEs when DNA was present in the sample and might only be observed at 
background levels for reactions without DNA where free linker was still present in the 
sample (Fig. 34). Remarkably, no detectable crosslinking occurred between TALEs 
and an oligonucleotide duplex bearing a 5fC in the CDKN2A off-target sequence from 
chapter 3.1. (Fig. 34).  
 
 
Figure 34: Test for protein-protein crosslinking of BRCA1b_TALEs and off-target crosslinking 
to CDKN2A-DNA with 5fC as indicated. 
 
These results indicate that prior to the denaturation for SDS-PAGE the TALE was still 
able to bind its target DNA sequence despite the bulkier 5fC-linker adduct and acidic 
pH value. Indeed, TALE binding under reaction conditions still resulted in high 
percentage band shifts in EMSA (Fig. SI17).   
Most importantly, together these results demonstrate that the bands correspond to 5fC-
specific, programmable and pAcF-dependent TALE-DNA crosslinking without 
significant cross reactivity to other sequences. Furthermore, according to the several 
tested hydroxylamines in chapter 3.1.2, steric clash would not be expected between 
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the molecular structure of the linear linker and the size-reduced repeat. In the end, 
structural analysis of the covalently connected TALE-DNA complexes would be 
required to explain the different crosslinking profiles of the TALEs.  
To quantify the crosslinking yields for the different TALE-linker combinations, the 
previous experiment was repeated with 32P-labeled oligonucleotides.  
Denaturing SDS-PAGE revealed that crosslinking yields were overall slightly lower for 
TALEa_S1*GG except for L5, while TALEa_1G*GG and TALEa_SG*1G displayed 
similar crosslinking efficiency (Fig. 35). Expectedly, no adduct formation was visible 
for samples without linker or without DNA (Fig. 35; Fig. SI18).  
 
 
Figure 35: Quantification of crosslinking reactions with indicated TALE-linker combinations 
by SDS-PAGE analysis using 32P-labeled DNA. XL: Crosslink formation 
 
Readouts revealed a low amount (~7 %) crosslinking between L1 and TALEa_SG*1G 
whereas no crosslinking with L1 could be observed for TALE_1G*GG and 
TALEa_S1*GG (Fig. 35). Both TALEs required a linker with a minimal length of two 
ethylene glycol moieties (L2) (Fig. 35). From the heat maps it can be concluded that 
greater linker length yields higher crosslinking. While almost 40 % crosslinking could 
be observed for TALEa_SG*1G and L2, maximal crosslinking for the three different 
TALEs was observed for L3-L5 (Fig. 35). This supports the previous assumptions 
regarding positioning of 1 within the TALE repeat, linker length and flexibility. 
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To assess potential off-target crosslinking to 5fC-sites within the target DNA, TALEs 
targeting a triple-CpG sequence in the BRCA1 sequence context (BRCA1b, Fig. 36a) 
were constructed and expressed analog to BRCA1a_TALEs (Fig. SI11b; Fig. SI12c). 
Instead of the canonical C-selective repeat_SHDGG, universal repeat_SG*GG was 
positioned opposite the two Cs of the neighboring CpG-sites (TALEb_1G*GG, 
TALEb_S1*GG, TALEb_SG*1G) (Fig. 36a). TALE proteins were functional and 
displayed good and uniform binding to target DNA with 5fC at different positions 
(5fCpG1, 5fCpG2 or 5fCpG3) of the target strand or complementary strand 
(rev_5fCpG2) according to EMSA (Fig. 36b). The affinity of TALEb_1G*GG and 
TALEb_S1*GG with target DNA was comparable. Again, only TALEb_SG*1G bound 
weaker to the DNA (Fig. 36b). This result supports the hypothesis that the position of 
1 in TALEa_SG*1G and TALEb_SG*1G prevents effective binding to DNA. Moreover, 
these results are in good accordance to the EMSA of TALEs for the BRCA1a target 
DNA (Fig. 31).  
Additionally, no significant decrease in binding could be observed for incorporation of 
repeat_SG*GG modules. This indicates that incorporation of multiple size-reduced 
repeats with RVD G* does not significantly reduce TALE binding to the target DNA 
similar to TALE repeats with RVD N*.322  
SDS-PAGE analysis of crosslinking experiments with DNAs bearing a single 5fC in any 
of the two off-target CpGs on the target strand revealed a certain degree of positional 
off-target crosslinking for L3-L5 in all cases and for TALEb_SG*1G also with L2 
(Fig. 37). This shows that more flexible and longer linkers have a higher positional off-
target effect and that there is sufficient chemical space in the TALE-DNA complex for 
the linker to be guided to the 5-modification at other positions. For the on-target 
position, the crosslinking profile was similar to the BRCA1a-TALEs.  
Interestingly, L1 did not yield crosslinks to 5fCpG1 for all three TALEs but a strong 
band was only visible for TALEb_SG*1G and 5fCpG3. In fact, strong bands can be 
observed for this TALE and 5fC-position with all five linkers.  
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Figure 36: TALEs for positional resolution analysis of 5fC-crosslinking. a) TALE model showing 
the interaction of TALEs with repeats bearing 1 flanked by two universal repeat_SG*GG 
modules. BRCA1b target DNA bear a single 5fC at one of the indicated CpGs. b) EMSA for 
testing interaction of 0.75 pmol TALEs with 7.5 pmol BRCA1b target DNA as indicated. 
 
Another highly resolved position is the combination of L2 and TALEb_S1*GG for 
rev_5fCpG2, the 5fC opposite of the on-target position but on the complementary 
strand. 
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Figure 37: SDS-PAGE images of positional resolution of TALE-5fC-DNA crosslinking for 
BRCA1b. 
 
Again, the experiment was repeated with radiolabeled DNA to quantify the off-target 
crosslinking (Fig. 38, Fig. SI19). On- and off-target crosslinking for linker L4 and L5 
was equally high (between 40-70 %) for all positions and TALEs. This indicates that 
the free hydroxylamine group can be guided more freely from the DNA to different 
repeat positions through the TALE-DNA-complex. Selectivity for single CpG-sites 
could be observed for the target 5fCpG2 with the combination of TALEb_1G*GG and 
L2 but with a yield of only ~20 % (Fig. 38a, e). L3 was somewhat specific for CpG3 in 
combination with TALEb_S1*GG (Fig. 38b, f). Furthermore, the 5fCpG3-selective 
combination of TALEb_SG*1G and L1 produced crosslinks with excellent yield of 
~70 % (Fig. 38c, g). As L1 is the shortest of the linkers and does not make good 
crosslinks with 5fCpG2 this raises questions about how 1 or the TALE is positioned in  
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Figure 38: Quantification of positional resolution of TALE-5fC-DNA crosslinking for BRCA1b 
using 32P-labeled DNA. Crosslinking profiles for a), e) TALEb_1G*GG; b), f) TALEb_S1*GG; c), 
g) TALEb_SG*1G. d) Crosslinking profile for the three TALEs to 5fC opposite the variable repeat 
as indicated on the complementary DNA strand. 
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these cases and how changes of the TALE and DNA structure play into this 
observation. For the 5fCpG on the complementary strand opposite the central CpG, 
considerable to high off-target crosslinking could be observed for all three TALEs in 
combination with the L1-L5 (Fig. 38d). This gives more insight, how 1 could be 
positioned in the TALE repeat. Potentially, instead of facing away from 5fC it could 
rather extend past the nucleobase accommodated in the repeat and connect to the 5fC 
on the other strand.  
Considering all 4 possible combinations, TALEb_1G*GG and TALEb_S1*GG with L2 
yielded selective crosslinks with good yields of above 60 % and 40 %, respectively. 
Crosslinking of 1 to rev_5fCpG2 with L1 could be observed for TALE_1G*GG and 
TALE_SG*1G. These results indicate that there are several combinations of linker and 
TALE proteins, which enable resolved, position-specific crosslinking to 5fC-sites.  
They also show that limitations to the targeting of TALE-linker combinations for CpG-
rich target DNA exist. Currently it is unclear if the reactivity and selectivity profiles differ 
when multiple vicinal 5fC are present. In general, it needs to be considered as well that 
short synthetic oligonucleotides might react differently than natural, complex 
chromosomal DNA. Therefore, the observed effects, selectivities and crosslinking 
efficiencies might not apply to genomic DNA. 
Another approach for programmable 5fC-selective crosslinking could be the use of 
TALE proteins bearing pAcF outside the CRD in the LR (Fig. 39a). Therefore, the 
canonical TALE structure could be completely conserved. Additionally, due to the more 
flexible and less constraint LR and C-terminal structure this could provide a scaffold 
with novel positional resolution for targeting a 5fCpG in the 3’-region of a BRCA1 target 
DNA (BRCA1c). TALEs consisting of 20 or 21 modules including the last repeat with 1 
at aa position 12 were assembled and expressed analog to BRCA1a_TALEs 
(Fig. SI11c; Fig. SI12d). Like for the other TALEs in this study, EMSA revealed a 
strong, specific shift corresponding to TALE-DNA interaction only for the target site 
(Fig. 39b).  
SDS-PAGE analysis showed that L2-L5 was able to mediate crosslinks of LR_S1*GG 
opposite of the target nucleobase with 5fC (LR_S1*GG(20), Fig. 40). Interestingly, 
crosslinking of the five linker L1-L5 with 5fC could be observed with the LR_S1*GG 
targeting the nucleobase preceding 5fC (LR_S1*GG(19), Fig. 40).  
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Figure 39: Programmable TALE-DNA crosslinking with engineered last repeats. a) Schematic 
TALE with 18 or 19 RVDs and last repeats with 1 at aa position 12 targeting base 19 
(LR_S1*GG(19)) or 20 (LR_S1*GG(20)), respectively. The 5fC is opposite of position 20. b) 
Native PAGE image after EMSA of the 1.5 pmol TALEs with 7.5 pmol off-target CDKN2A DNA 
or 7.5 pmol target BRCA1c as indicated. c) Binding profiles of TALE-DNA interaction from b). 
Controls without DNA were subtracted from both samples. 
 
Again, no crosslinking could be observed with off-target 5fC-DNA. This indicates that 
even though polarity effects of TALE-DNA interactions have been reported,295 the 
binding is still specific between these sequences. However, bands corresponding to 
TALE-TALE (~220 kDa) crosslinking occurred in the absence of DNA (Fig. 40). 
The band formation gives an indication that there is a positional resolution to these 
TALEs. Quantifying the crosslink formation of TALEs with LR_S1*GG(19) and 
LR_S1*GG(20) with 32P-labeled DNA confirmed the high crosslinking yield with L3-L5 
for both TALEs comparable to the TALE_S1*GG for BRCA1a and BRCA1b target DNA 
(Fig. 41; Fig. SI18). Same goes for the combination of L2 and TALE_LR_S1*GG(20), 
while the combination of L2 and TALE_LR_S1*GG(19) shows approximately 60 % 
crosslinking. 
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Figure 40: Test for protein-protein crosslinking of BRCA1c_TALEs and off-target crosslinking 
to CDKN2A-DNA with 5fC as indicated. 
 
These results show that it is possible to design selective programmable probes for 
efficient crosslinking of target 5fC-DNA at different positions of the CRD. It is possible 
that the ncAA in the C-terminal domain is more accessible than in the CRD. If so, this 
could enable the crosslinking of 5fC-DNA with the TALE after formation of a non-
covalent TALE-DNA complex. This would allow for programmable TALE-DNA binding 
in vitro and in vivo, subsequent crosslinking and enrichment of 5fC-sites. However, it 
remains to be shown if the use of these constructs can match the selectivity and 
specificity of constructs allowing accommodation of labeled 5fC for crosslinking within 
the TALE structure. 
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Figure 41: Quantification of crosslinking reaction yields with indicated TALE-linker 
combinations by SDS-PAGE analysis using 32P-labeled DNA. 
 
 
  
 77 
 
3.2.3. Detection and quantification of single 5fC-sites in genomic DNA 
The next step was the detection and quantification of 5fC levels at single CpG in the 
background of mammalian genomic DNA. Considering both EMSA and SDS-PAGE 
analysis, TALEa_1G*GG was selected in combination with L4 due to good 5fC-binding 
and high yields in crosslinking reactions. Additionally, L2 was tested due to his 
selectivity in the context of the neighboring 5fCpG on the target DNA strand. 
The enrichment assay based on magnetic bead-immobilized TALEs established in 
chapter 3.1.3 was slightly modified with more stringent washing to separate non-
covalent bound target DNA from the crosslinked 5fC sequences (Fig. 42a). 
This was necessary because EMSA data had shown that TALEa_1G*GG has high 
universal affinity to DNA targets with cytosine 5-modifications. Different denaturing 
methods for example with SDS or other ionic detergents, heat or chemical additives 
were tried, but in the end a buffer containing 2 M NaCl proved best compatible with the 
enrichment process and most effective to disrupt non-covalent or off-target TALE-DNA 
binding.295 For enrichments, PCR targets with precisely defined 5fC levels at single 
positions were spiked into 5fC-free, fragmented and digested human gDNA (Encode 
NA18507) at a concentration of a single genome copy (cf. chapter 3.1.3 for details, 
Fig. SI20). Similarly, 5hmC as a structurally comparable off-target nucleobase was 
introduced at the BRCA1a target position via synthetic primers (Fig. SI20).  
For enrichments, 1 µg DNA with 10 µmol linker L2 or L4 and 2 µmol pPDA was reacted 
as previously described and purified. Then, samples were incubated with 10 pmol 
TALEa_1G*GG and fresh pPDA. After 6 h the reaction was quenched with 18.5 µl Tris 
buffer (pH = 9.0), purified it via gel filtration and incubated it with Ni-NTA magnetic 
beads in enrichment buffer. The beads were washed with buffer containing high 
amount of NaCl to disrupt non-covalent or off-target TALE-DNA binding.295 After 
another washing step with enrichment buffer, the beads were suspended in water and 
incubated at 95°C for 15 minutes. The beads were collected, and the supernatant was 
used for qPCRs, targeting a sequence adjacent to the BRCA1 TALE binding site.  
For both crosslinking reactions, 5fC-DNA was selectively enriched from human 
genomic background DNA in comparison to 5hmC-DNA (Fig. 42b). According to the 
previous experiments, higher crosslink efficiency could be expected for reaction with 
L4. Indeed, crosslinking with L4 led to approximately 3x fold higher enrichment of 5fC-
DNA compared to reaction with L2 (Fig. 42b,).  
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Figure 42: Covalent enrichment of 5fC-containing DNA sequences from mammalian genomic 
DNA backgrounds. a) Assay workflow. b) qPCR quantification of enrichments with 
TALE_S1*GG and DNA with 100 % 5fC or 5hmC levels in the BRCA1 target CpG, including basic 
controls as indicated. A background control without TALE was subtracted from other 
enrichments. Enrichments were conducted in triplicates, each quantified with triplicate 
qPCRs. c) qPCR quantification of enrichments with TALE_S1*GG performed as in b), but with 
background of mESC gDNA. A background control without linker was subtracted from other 
samples d) Enrichments as in b) with different 5fC levels. * = p < 0.005. ** = p < 0.0005. *** = 
p < 0.00005 from student-t-test. R2 from linear regression = 0.99. 
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Enriched copy numbers of 5hmC-containing DNA and 5fC-target in absence of linker 
were negligible in the experiments, confirming covalent enrichment as a robust and 
reliable method for 5fC detection in gDNA (Fig. 42b).  
An experiment with non-amplified mESC gDNA extracted from J1 cells containing 
background off-target 5fC did not decrease enrichment of target sites from background 
gDNA after crosslinking with L4 (Fig. 42c). This confirms the selectivity of user-defined 
TALE-DNA crosslinking from the previous experiments and demonstrate, that no 
significant amount of the enriched 5fC-target DNA is lost due to off-target 5fC.    
Regarding the sensitivity and potential for quantification of 5fC in target DNA, the 
experiment was repeated with different 5fC levels obtained from a mixture of 5fC- and 
5hmC-target DNA. Copy numbers of enriched 5fC-DNA for single levels differed 
significantly from each other (Fig. 42d). Moreover, an increase in 5fC-levels correlated 
proportionally with enriched copy numbers (Fig. 42d).  
Taken together, this shows that the approach allows selective quantification of 5fC 
levels at a single, user-defined CpG in a human genome background by TALE 
crosslinking.  
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4. Summary and Outlook 
Utilizing TALE proteins as programmable probes enabled sequence-specific targeting 
of single nucleobase positions. However, previous efforts to engineer new TALE 
selectivities did either not provide full selectivity for the target epigenetic 5-modified 
cytosine nucleobases or displayed decreased overall affinity. In this work, TALE-based 
approaches utilizing cytosine 5-modification-selective chemical conjugation reactions 
enabled complete, programmable decoding of ox5mCs in DNA and the direct capture 
and quantification of 5fC.  
In the first project, size-reduced TALE repeats were designed. TALE repeat_SG*GG 
was found to universally bind to all eight human DNA nucleobases. Chemoselective 
modifications of 5hmC, 5fC and 5caC with substituents with distinct chemical 
properties via enzymatic glucosylation, oxime condensation or amide formation, 
respectively, was found to effectively block TALE binding and induce full selectivity for 
the modified nucleobase in the universal repeat_SG*GG. This enabled complete, 
programmable decoding of each ox5mC in target DNA at single user-defined positions 
with oligonucleotides as well as with a complex human gDNA background.  
Additionally, PyAOP-catalyzed amide formation provides a new conjugation strategy 
for 5caC. This could be of use for other chemical modification-based approaches.  
In the next project, the direct, programmable targeting of TALEs was advanced to 
covalent capture of user-defined target 5fC-DNA. First, size-reduced TALE repeats 
bearing the ncAA pAcF were engineered. These repeats were still able to bind to the 
five human cytosine nucleobases. Second, chemoselective crosslinking of repeats 
bearing pAcF to 5fC with different hydroxylamine-functionalized linker through oxime 
condensation was demonstrated. Positional resolution analysis revealed TALE repeat-
linker combinations with single CpG resolution for target DNA-stands. However 
positional off-target crosslinking to the complementary DNA-strand was observed for 
all cases. Notably, the combination TALEb_1G*GG and L2 was selective for the off-
target 5fC on the complementary DNA strand. Third, covalent enrichment of target 5fC-
DNA withTALEa_1G*GG and L2 and L4 demonstrate that the method can be used for 
robust and sensitive detection and quantification of 5fC-levels in gDNA. 
For future applications, the design of TALEs for different target DNA and comparison 
with data from other highly sensitive and established approaches will help to develop 
both chemoselective blockage or crosslinking for the detection of naturally occurring 
 81 
 
epigenetic nucleobases. Additionally, programmable covalent enrichment of DNA 
could enable to detect associated proteins.  
However, pPDA-catalyzed oxime formation is incompatible with pH-sensitive proteins 
and live cells. Schiff base formation between 5fC and lysine residues of protein has 
been reported in vitro and in vivo. Encoding lysine or photocaged derivatives might be 
an approach for a biocompatible 5fC-selective crosslinking in live cells that could be 
spatially and temporally controlled.  
Additionally, TALE repeats bearing amino acids with distinct chemical handles could 
extend covalent enrichment to the other ox5mCs. 
Alternatively, the possibility to encode ncAA at the RVD of TALE repeats could add a 
new layer of functionality to TALEs as DNA-binding scaffolds. The introduction of 
residues with distinct chemical properties could provide new selectivity profiles of TALE 
repeats for epigenetic 5-modified cytosines.  
Taken together, the two methods extend the application scope of TALEs as versatile 
probes for the programmable targeting of nucleobases beyond A, G, T and C. In 
comparison with non-programmable DNA-binding probes and tagging strategies alone, 
the use of TALEs in combination with chemoselective modification provides a user-
defined sequence specificity and nucleotide resolution which overcomes previous 
limits of TALE-based approaches for the selective detection and analysis of the 
epigenetic cytosine nucleobases 5hmC, 5fC and 5caC in DNA in vitro.  
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5. Materials and Methods 
5.1. Materials 
5.1.1. Table 1: List of Services 
Service Product Company 
Synthesis Oligonucleotides Sigma Aldrich 
Synthesis 
Oligonucleotides bearing 5mC 
or ox5mCs  
Metabion 
Analysis ESI-TOF mass spectrometry Metabion 
Analysis Sanger Sequencing 
GATC (now Eurofins 
Genomics) 
Cell line HEK293T ATCC 
Cell line J1 mESC ATCC 
Plasmids TALE toolbox Addgene 
Human 
genomic DNA 
Male Yoruban individual, 
Encode sample NA18507 
Coriell Institute 
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5.1.2. Table 2: List of Software and Tools 
Name Purpose Developer/Distributor 
BioDoc 
Analyze 2.1 
Imaging of Agarose gels Jena Biosciences 
CFX Manager 
Analysis and presentation of 
data from qPCR 
Bio-Rad 
Chemdraw 
18.0 
Chemical structure and reaction 
scheme design 
PerkinElmer 
Citavi 6 Citation Swiss Academic Software 
Excel Data analysis and presentation Microsoft 
ExPASy 
Bioinformatic tools (UniProt KB, 
BLAST, Compute pI/MW) 
Swiss Institute of Bioinformatics 
flexAnalysis 
3.0 
Analysis and presentation of 
data from mass spectrometry 
Bruker 
ImageJ 
Picture editing and data 
analysis 
National Institutes of Health 
ImageQuant 
TL ver. 8.1.0.0 
Analysis of data from EMSA 
and phosphor screens 
GE-Healthcare 
InDesign CC 
2017 
Figure design and formatting Adobe 
mMass 
Analysis and presentation of 
data from mass spectrometry 
Martin Strohalm 
NanoDrop2000 
Software 
1.6.198 
Data analysis of DNA 
concentration measurements 
Thermo Fisher Scientific 
OligoCalc 
Oligonucleotide Properties 
Calculator 
Northwestern University 
Origin 2018 Data analysis and presentation OriginLab 
Pymol Protein structure design Schroedinger 
Quantity One 
Analysis of data from gel 
images and phosphor screens 
Bio-Rad 
Research 
MestReNova 
Lite CDE 
Analysis and presentation of 
data from NMR spectrometry 
Mestrelab 
 84 
 
Spectra 
Manager Suite 
Analysis of CD spectroscopy Jasco 
SnapGene 
Analysis of data from Sanger 
sequencing, design of plasmid 
maps 
GSL Biotech 
Word 
Data presentation and writing of 
manuscript 
Microsoft 
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5.1.3. Table 3: List of Lab Equipment 
Modell Purpose Manufacturer/Distributor 
102-C 
Converter for Digital 
Sonifiers 
Branson 
300TH Ultrasonic cleaner vwr 
5810R/5424/5415R/5427R Centrifuges Eppendorf 
Avance III 400 NMR spectrometry Bruker 
AX224 Analytical scale Satorius 
BAS-Cassette 2025 
Phosphor screen 
cassettes 
FUJIFILM Life Science 
BAS-IP MS 2025 E Storage phosphor screen GE Healthcare 
BIOER Thermocell 
Cooling and heating 
block 
biozym 
Biophotometer Plus Cuvette photometer eppendorf 
CanoScan 9000F Scanner Canon 
CB 161 Magnetic stirrer Stuart 
CFX384 Touch Real-Time 
PCR Detection System 
qPCR Bio-Rad 
Concentrator plus 
Centrifugal vacuum 
concentrator 
Eppendorf 
Digital Sonifier 450 
Power and control unit for 
sonification 
Branson 
Easypet Pipettor eppendorf 
ED8525.3J Microwave exquisit 
Eporator Electric transformation eppendorf 
EV233 
Electrophoresis power 
supply 
Consort 
FiveEasy Standard pH meter Mettler Toledo 
GFX 460 Contact thermometer ebro 
Ground steel MTP 384 
target 
Plate for spotting MALDI-
TOF samples 
Bruker 
I26 Incubator shaker New Brunswick Scientific 
Infinite M1000 Plate reader Tecan 
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J-715 CD spectropolarimeter Jasco 
JB Aqua 12 PW Water bath Grant 
kuroGEL MiniPlus 10 
Agarose gel 
electrophoresis system 
vwr 
Laborota 4000-efficient Rotary evaporator Heidolph 
LA-DC58K Conversion lens adapter Canon 
LE410 3-in-1 pH glass electrode Mettler Toledo 
LQT Orbitrap Fournier 
Transformation mass 
spectrometer 
High resolution mass 
spectrometry 
Thermo Fisher Scientific 
MagRack 6 Magnetic stand GE Healthcare 
MGD-4534 Gel dryer vwr 
Mini-Protean Tetra System 
Gel electrophoresis 
system 
Bio-Rad 
Modell 100-800 Incubator memmert 
MR Hei Standard 
Magnetic stirrer and 
heater 
Heidolph 
MyCycler Thermocycler Bio-Rad 
MZ 2 NT Membrane pump vacubrand 
MZ2C NT+AK+EK Vacuum system vacubrand 
Nanodrop 2000 
Spectrometer for 
concentration 
determination of DNA 
Thermo Fisher Scientific 
PCR workstation pro PCR workstation peqlab/vwr 
PM400 Scale Mettler 
PowerPac basic Power supply for PAGE Bio-Rad 
PowerShot G10 
Camera for agarose gel 
documentation 
Canon 
Premium GGU 1500 Freezer Liebherr 
ProfiLine GG 4010 Freezer Liebherr 
ProfiLine FKU 1800 Fridge Liebherr 
RCT classic 
Magnetic stirrer and 
heater 
IKA 
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Research plus 
1000/100/10/2.5 µl 
Pipettes eppendorf 
RZ-6 Rotary vane pump vacubrand 
SimpliAmp Thermocycler applied biosystems 
Sorvall Lynx 6000 Ultracentrifuge Thermo Scientific 
SSE-1 Sonifier sound enclosure Branson 
Steel chamber 18/10 Agarose gel staining bath Bochem 
Thermomixer 
compact/comfort 
Thermomixer eppendorf 
Thermostat plus Heating block eppendorf 
TPersonal Thermocycler Biometra 
Tube Revolver Tube Revolver Thermo Scientific 
Typhon FLA 9500 
Imaging of native gels 
and radioactive screens 
GE Healthcare 
U725-G 
Ultra-low temperature 
freezer 
New Brunswick Scientific 
ultrafleXtreme MALDI 
TOF/TOF instrument 
MALDI-TOF mass 
spectrometry 
Bruker 
Unimax 1010 Plate shaker Heidolph 
UV star 
UV Chamber for agarose 
gel documentation 
Biometra 
VL-6.LC 365 nm/254 nm UV lamp Vilber Lourmat 
VortexGenie2 Vortexer Scientific Industries 
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5.1.4. Table 4: List of Disposables and Glass Ware 
Product  Manufacturer/Distributor 
384 well Lightcycler plate PP Sarstedt 
96 deep well plates Sarstedt 
96 fritted deep well plates Thermo Fisher Scientific 
96 well plates transparent Carl Roth 
Adhesive clear qPCR seals Biozym 
Amicon Ultra MWCO 3 kDa Millipore 
Amicon Ultra-0.5 ml Centrifugal Filters Merck Millipore 
Amicon Ultra-15, PLQK Ultracel-PL 
Membrane, 50 kDa 
Merck Millipore 
C18 Ziptips Millipore 
Cap, snap ring, 11 mm, blue, soft vwr 
Cuvettes Sarstedt 
Disposable glass Pasteur pipettes, 
sealed point, pre-marked, 230 mm 
vwr 
Electroporation cuvettes 1 mm Carl Roth 
epT.I.P.S. LoRetention 0.1 -10 µl eppendorf 
Erlenmayer flasks (2 l, 1 l, 500 ml, 
100 ml, 25 ml) 
vwr 
Conical plastic tubes, 15 ml Sarstedt 
Conical plastic tubes, 50 ml Sarstedt 
Filter discs, grade 3hw, 125 mm Sartorius 
Filter discs, grade 3hw, 45 mm Sartorius 
Filter tips, low retention (2-100µl) vwr 
Folded qualitative filter paper, 301 vwr 
Folded qualitative filter paper, 305 vwr 
Glass beads VWR 
Glass test tubes, boro 5.1 vwr 
Glass vial, snap ring, 1.5 vwr 
Gloves Nitrile VWR 
illustra MicroSpin G-25 columns GE Healthcare 
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MµLTIGUARD 100-1000 µl low retention 
filter tips 
Sorenson 
Microplate 384 well, PS, F-Bottom, 
small volume, black 
Greiner 
Multiply Pro 0.2 mL reaction tube Sarstedt 
NORM-JECT single-use syringes 
(20 ml, 5 ml) 
Henke-Sass, Wolf 
Nunc sealing tape, breathable, sterile Thermo Fisher Scientific 
Omnifix single-use syringes (50 ml, 
20 ml, 10 ml) 
B.Braun 
Omnifix-F single-use syringes (1 ml) B.Braun 
Parafilm PM-996 Bemis 
Pierce C18 tips, 10 µl Thermo Fisher Scientific 
Pierce centrifuge columns, 0.8 ml Thermo Fisher Scientific 
Pipette tips (10 μL, 200 μL, 1000 μL) 
Sarstedt 
Sarstedt 
Polypropylene columns, 1 ml Qiagen 
Polypropylene columns, 5 ml Qiagen 
Protein LoBind Tubes eppendorf 
Reaction tubes 1.5 mL  Sarstedt 
Reaction tubes 2.0 mL  Sarstedt 
Round bottom flask 
with standard ground joint (250 ml, 
100 ml) 
Duran 
Scalpel  B.Braun 
Schott flasks (1000 ml, 500 ml, 250 ml, 
100 ml, 50 ml) 
Duran 
Schott flasks (1000 ml, 500 ml, 250 ml, 
100 ml, 50 ml) 
vwr 
Serological pipette 10 mL  Sarstedt 
Serological pipette 25 mL  Sarstedt 
Slide-A-Lyzer Dialysis Cassette MWCO 
10 kDa  
Thermo Fisher Scientific 
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Slide-A-Lyzer MINI Dialysis Unit MWCO 
10 kDa  
Thermo Fisher Scientific 
Sterican single-use needles 0.80 x 120 
mm, 21 G x 4 ¾’’ 
B.Braun 
Sterican single-use needles 0.90 x 
40 mm, 20 G x 1 ½’’ 
B.Braun 
Sterican single-use needles 0.90 x 
70 mm, 20 G x 2 ¾’’ 
B.Braun 
Sterican single-use needles 1.20 x 
40 mm, 18 G x 1 ½’’ 
B.Braun 
Syringe filter 0.2 μM  Sarstedt 
UV cuvettes  Sarstedt 
ZelluTrans dialysis membrane T1 
MWCO 3.5 kDa  
Carl Roth 
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5.1.5. Table 5 List of Consumables 
Name Use Manufacturer/Distributor 
10 % FBS Supplement for DMEM PAN Biotech 
2-Log DNA Ladder (0.1-
10 kb) 
Standard DNA ladder for 
agarose gels 
NEB 
Bright-Glo 
Luciferase assay master 
mix 
Promega 
DMEM 
Medium for HEK293T 
cells 
PAN Biotech 
DPBS 
Wash buffer for 
Luciferase assay 
Pan Biotech 
Dynabeads His-Tag 
Isolation and Pulldown 
Magnetic Ni-NTA beads Invitrogen 
EmbryoMAX ES cell 
qualified FBS 
Supplement for stem cell 
culture 
Merck Milipore 
Gelatine solution 
Coating of cell culture 
dishes 
Pan Biotech 
GlutaMAX 
Supplement for stem cell 
culture 
Thermo Fisher Scientific 
HisPur Ni-NTA Resin 
High-capacity, high-
performance Ni-IMAC 
resin 
Thermo Fisher Scientific 
KnockOut DMEM 
Medium for Medium for 
culturing J1 mESC 
Thermo Fisher Scientific 
LB agar (Lennox) Solid medium for E.coli Carl Roth 
LB-medium (Lennox) Liquid medium for E.coli Carl Roth 
Lipofectamin 2000 Transfection reagent Thermo Fisher Scientific 
Low Molecular Weight 
DNA Ladder (25 bp to 766 
bp) 
DNA ladder for high 
percentage agarose gels 
NEB 
Mouse recombinant LIF 
Supplement for stem cell 
culture 
StemCell Technologies 
Ni-NTA Magnetic Agarose 
Beads 
Nickel-charged magnetic 
agarose beads 
Qiagen 
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Non-essential amino 
acids 
Supplement for stem cell 
culture 
Thermo Fisher Scientific 
Opti MEM 
Medium for HEK293T 
cells 
Gibco 
PageRuler Plus 
Prestained Protein Ladder 
(10 to 250 kDa) 
Protein ladder for SDS-
PAGE  
Thermo Fisher Scientific 
Penicillin/Streptavidin 
solution 
Antibiotics for stem cell 
culture 
Pan Biotech 
Unstained Protein Ladder, 
Broad Range (2-212 kDa) 
Protein ladder for SDS-
PAGE 
NEB 
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5.1.6. Table 6: List of Commercial Kits and Master Mixes 
Name Type Manufacturer/Distributor  
GeneJET Gel extraction 
Purification of PCR 
products and DNA from 
agarose gels 
Thermo Fisher Scientific 
GeneJET PCR 
purification 
Purification of PCR 
products and DNA from 
reaction mixes 
Thermo Fisher Scientific 
GeneJET Plasmid 
Miniprep Kit 
Plasmid DNA purification Thermo Fisher Scientific 
GoTaq qPCR Master Mix qPCR Master Mix Promega 
illustra Ready-To-Go 
GenomiPhi V3  
Whole genome 
amplification kit 
GE Healthcare 
Monarch PCR & DNA 
Cleanup Kit 
Purification of PCR 
products and DNA from 
reaction mixes 
NEB 
NucleoSpin Plasmid Easy 
Pure 
Plasmid DNA purification Macherey Nagel 
NucleoSpin Gel and PCR 
Clean-up 
Purification of PCR 
products and DNA from 
reaction mixes and 
agarose gels 
Macherey Nagel 
Nucleotide Removal Kit 
Clean-up of DNA labeling 
reactions 
Qiagen 
Pierce BCA Protein Assay 
Kit 
Protein concentration 
determination 
Thermo Fisher Scientific 
QIAamp DNA Mini Kit 
Purification of WGA DNA 
or gDNA 
Qiagen 
REPLI-g Mini Kit 
Whole genome 
amplification kit 
Qiagen 
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5.1.7. Table 7: List of Enzymes 
Name Distributor 
AbaSI NEB 
BanII NEB 
BsaI NEB 
BsmBI NEB 
EarI NEB 
FatI NEB 
FokI NEB 
PlasmidSafe nuclease Biozym 
Proteinase K Roche 
KF(exo)- NEB 
Q5 polymerase NEB 
RNase A Thermo Fisher Scientific 
Lysozyme Sigma Aldrich 
XhoI NEB 
NcoI NEB 
SacI NEB 
T4 ligase Thermo Fisher Scientific 
Pfu DNA Polymerase Promega 
T4 Phage β-glucosyltransferase (T4 
BGT) 
NEB 
T4 Polynucleotide kinase (T4 PNK) Thermo Fisher Scientific 
Taq polymerase NEB 
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5.1.8. Table 8: List of Chemicals 
Name CAS Distributor 
(7-Azabenzotriazol-1-yloxy)tri-
pyrrolidinophosphonium hexa-
fluorophosphate (PyAOP) 
156311-83-0 Acros Organics 
[ɣ-32P]-ATP (370MBq) in 50 mM Tricine-
buffer (pH 7.6) 
- 
Hartmann 
Analytic 
1,4-Dithiothreitol (DTT) 3483-12-3 Carl Roth 
2-(N-morpholino)ethanesulfonic acid (MES) 145224-94-8 Fisher Scientific 
2-Mercaptoethanol 60-24-2 Merck 
2-Propanol 67-63-0 Fisher Scientific 
3-Hydroxypicolinic acid 874-24-8 Sigma Aldrich 
5-Brom-4-chlor-3-indoxyl-β-D-
galactopyranosid (X-Gal) 
7240-90-6 
Thermo Fisher 
Scientific 
Acetic Acid 64-19-7 Carl Roth 
Acetonitrile 75-05-8 Sigma Aldrich 
Adenosintriphosphat, 10 mM solution 56-65-5 NEB 
Agarose 9012-36-6 Biozym 
Albumin, Bovine Serum (BSA) 9048-46-8 
Cell Signaling 
Technology 
Alexa Fluor 488 - 
Thermo Fisher 
Scientific 
Ammonium acetate 631-61-8 Sigma Aldrich 
Ammonium peroxodisulfate 7727-54-0 Carl Roth 
Benzylamine 100-46-9 Sigma Aldrich 
Boric acid 10043-35-3 Carl Roth 
Bromophenol blue 115-39-9 Sigma Aldrich 
Calcium chloride 10043-52-4 Fisher Scientific 
Carbenicillin disodium salt 4800-94-6 Carl Roth 
Chloramphenicol 56-75-7 Carl Roth 
Chloroform-d 865-49-6 Sigma Aldrich 
Coomassie Brilliant Blue G250 6104-58-1 Carl Roth 
Diammonium hydrogen citrate 3012-65-5 Sigma Aldrich 
 96 
 
Dichlormethan  75-09-2  Acros Organics 
Diethyl ether 60-29-7 Sigma Aldrich 
Diethylene glycol 111-46-6 abcr 
Diisopropyl azodicarboxylate (DIAD) 2446-83-5 abcr 
Dimethyl sulfoxide (DMSO) 67-68-5 Carl Roth 
dNTP solution mix, 10 mM - NEB 
Ethanol 96 % 64-17-5 Fisher Scientific 
Ethanol, absolute 64-17-5 Sigma Aldrich 
Ethidium bromide 1239-45-8 Sigma Aldrich 
Ethylamin 75-04-7 Alfa Aesar 
Ethylene glycol 107-21-1 abcr 
Ethylenediaminetetraacetate (EDTA) 60-00-4 Carl Roth 
Formamide 75-12-7 Acros Organics 
Glycerole  56-81-5 Carl Roth 
Glycine 56-40-6 Carl Roth 
HEPES 7365-45-9 Carl Roth 
Hexaethylene glycol 2615-15-8 abcr 
Hydrazine hydrate 7803-57-8 Fisher Chemical 
Hydrochloric acid (1 M) 7647-01-0 vwr 
Hydrochloric acid (37 %) 7647-01-0 vwr 
Imidazole 288-32-4 abcr 
Isopropyl-β-D-thiogalactopyranosid 367-93-1 Roth 
Kanamycinsulfate 25389-94-0 Carl Roth 
L(+)-Arabinose 5328-37-0 Carl Roth 
Magnesium chloride hexadydrate 7791-18-6 Acros Organics 
Magnesium sulfate heptahydrate 10034-99-8 Merck 
MES sodium salt 71119-23-8 Acros Organics 
Methanol 67-56-1 Sigma Aldrich 
N-(3-Dimethylaminopropyl)-N'-
ethylcarbodiimidhydrochlorid (EDC) 
25952-53-8  Sigma Aldrich 
N,N,N',N’-Tetramethylene-ethylenediamine 
(TEMED) 
110-18-9 Carl Roth 
N-Hydroxyphtalimide 524-38-9 Acros Organics 
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O-(tert-Butyl)hydroxylamine 39684-28-1 Acros Organics 
 O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine 6723-30-4 Acros Organics 
O-Benzylhydroxylamin hydrochloride 2687-43-6 Alfa Aesar 
O-Ethylhydroxylamine hydrochloride 3332-29-4 Sigma Aldrich 
para-Acetylphenylalanine (pAcF) 122555-04-8 Chem Impex 
para-Phenylenediamine (pPDA) 7447-40-7 Acros Organics 
Phenylmethylsulfonyl fluoride 329-98-6 Carl Roth 
Phenylmethylsulfonylfluorid (PMSF) 329-98-6 Carl Roth 
Potassium chloride 7447-40-7 Carl Roth 
Roti-Phenol/Chloroform/Isoamylalkohol - Carl Roth 
Rotiphorese Gel 40 (37.5:1) - Carl Roth 
Rotiphorese sequencing gel concentrate - Carl Roth 
Silica gel 60M 0.04-0.063 nm 112926-00-8 Macherey Nagel 
Sodium acetate 127-09-3 Merck 
Sodium chloride 7647-14-5 Carl Roth 
Sodium dihydrogen phosphate monohydrate 10049-21-5 Merck 
Sodium dodecyl sulfate (SDS) 151-21-3 Carl Roth 
Sodium hydroxide 1310-73-2 Fisher Scientific 
Sodium lauroyl sarcosinate 137-16-6 AppliChem 
Sodium phosphate dibasic dihydrate 10028-24-7 Sigma Aldrich 
Spermine tetrahydrochloride 306-67-2 Alfa Aesar 
tert-Butylamin 75-64-9 Acros Organics 
Tetracycline hydrochloride 64-75-5 Carl Roth 
Tetraethylene glycol 112-60-7 abcr 
Tetrahydropyran-2-ylmethylamine 6628-83-7 Maybridge 
Triethylene glycol 112-27-6 abcr 
Trifluoroacetic acid (TFA) 76-05-1 Sigma Aldrich 
Triphenylphosphine 603-35-0 Alfa Aesar 
Tris(hydroxymethyl)aminomethane 77-86-1 Sigma Aldrich 
Triton-X 9002-93-1 Fluka 
Trizma base (Tris) 77-86-1 Carl Roth 
Tween20 9005-64-5 Fisher Scientific 
Urea 57-13-6 Carl Roth 
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Uridine Diphosphate Glucose solution, 2 
mM 
133-89-1 NEB 
Water, nuclease-free 7732-18-5 Qiagen 
Xylencyanol 2650-17-1 Carl Roth 
Yeast extract 8013-01-2 Carl Roth 
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5.1.9. Table 9: List of Buffers and Stock Solutions 
Name Components 
4xPBS 
548 mM NaCl, 43 mM KCl, 69 mM Na2HPO4, 3.2 g/l KH2PO4, 
pH = 8 
Amide reaction 
buffer 
50 mM MES, pH = 8 
Cam stock 34 mg/ml chloramphenicol in ethanol 
Carb stock 50 mg/ml carbenicillin disodium salt in 1:1 ethanol:water 
CD spectroscopy 
buffer 
20 mM Tris-HCl, 50 mM NaCl, pH = 7.5 
CutSmart buffer 
50 mM KOAc, 20 mM Tris-acetate, 10 mM Mg(OAc)2, 
100 μg/ml BSA, pH = 7.9 
Enrichment buffer 
(EB) 1 
150 mM NaCl, 30 mM Tris-HCl, 5 mM MgCl2, 0.05 % 
Tween20, 0.5 mg/ml BSA, pH = 7.9 
Enrichment buffer 
(EB) 2 
500 mM NaCl, 30 mM Tris-HCl, 5 mM MgCl2, 100 µM 
spermine, 0,005 % Tween20, 0.5 mg/ml BSA, pH = 7.9 
Enrichment high-
salt wash buffer 
(EWB) 
2 M NaCl, 30 mM Tris-HCl, 5 mM MgCl2, 10 µM spermine, 
0,005 % Tween20, 0.5 mg/ml BSA, pH = 7.9 
HEK293T lysis 
buffer 
100 mM NaH2PO4, 0.2 % Triton X-100 
Kan stock 50 mg/ml kanamycin sulfate in water 
KF (exo-) storage 
buffer 
25 mM Tris-HCl, 1 mM DTT, 0.1 mM EDTA, 50 % glycerol, 
pH = 7.4  
LB Medium  10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, pH = 7 
mESC lysis buffer 
100 mM Tris, 5 mM EDTA, 200 mM NaCl, 0.2 % SDS, 
400 µg/ml proteinase K, 200 µg/ml RNase A, pH = 5.5 
NEB1 
10 mM bis-Tris-propane-HCl, 10 mM MgCl2, 1 mM DTT, 
pH = 7 
NEB2 
50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, 
pH = 7.9 
NEB3 
100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, 
pH = 7.9 
 100 
 
NEB4 
50 mM KOAc, 20 mM Tris-acetate, 10 mM Mg(OAc)2, 1 mM 
DTT, pH = 7.9 
Oxime reaction 
buffer 
50 mM NaHPO4/Na2PO4, pH = 6.0 
Purple loading dye 
2.5 % Ficoll-400, 10 mM EDTA, 3.33 mM Tris-HCl, 0.08 % 
SDS, 0.02 % Dye 1, 0.001 % Dye 2, pH = 8 
Qiagen lysis buffer 50 mM NaH2PO4 monohydrate, 300 mM NaCl, pH = 8 
Qiagen lysis buffer 
20 
Qiagen Lysis buffer + 20 mM imidazole  
Qiagen lysis buffer 
50 
Qiagen Lysis buffer + 50 mM imidazole 
Qiagen lysis buffer 
500 
Qiagen Lysis buffer + 500 mM imidazole 
SDS-PAGE 
running buffer 
3.03 g/l Tris base, 14.40 g/l glycine, 1.00 g/l SDS 
SDS-PAGE 
sample buffer 
50 mM Tris-HCl (pH = 6.8), 2 % SDS, 10 % glycerol, 
0.02 % bromophenol blue, 1 % β-mercaptoethanol 
SDS-PAGE 
staining solution 
10 % v/v acetic acid, 50 % v/v methanol, 40 % v/v water, 
0.1 % w/v Comassie brilliant blue 
SDS-PAGE 
destaining solution 
10 % v/v acetic acid, 20 % v/v ethanol, 70 % v/v water 
SOB++ 
20 g/l tryptone, 5 g/l yeast extract, 0.5 g/l NaCl, 0.186 g/l KCl, 
10 mM MgCl2, 10 mM MgSO4 
SOC medium  
0.58 g/l NaCl, 2.03 g/l MgCl2 hexahydrate, 2.46 g/l MgSO4 
heptahydrate, 5 g/l yeast extract, 20 g/l tryptone, 1 M glucose, 
pH = 7.5 
Spec stock 100 mg/ml spectinomycin in water 
T4 DNA ligase 
buffer 
50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, 
pH = 7.5 
T4 PNK buffer A 
350 mM Tris-HCl (pH = 7.6), 50 mM MgCl2, 500 mM KCl, 
5 mM 2-mercaptoethanol 
TAE buffer 40 mM Tris-acetate, 2.5 EDTA, pH = 7.8 
TAL storage buffer 200 M NaCl, 20 mM Tris, 5 % glycerol, pH = 7.5 
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TALE Binding 
Buffer (TBB) 1 
20 mM Tris-HCl (pH = 8.0), 50 mM NaCl, 5 mM MgCl2, 5 % 
Glycerol 
TALE-DNA-
Crosslinking (TDC) 
Buffer  
20 mM Tris-HCl, 10 mM NaCl, 1.25 mM MgCl2, 5 % glycerol, 
pH = 6 
Taq lysis buffer 
10 mM Tris-HCl, 300 mM NaCl, 2.5 mM MgCl2, 0.1 % Triton 
X-100, pH = 9  
TBE Buffer 
10.78 g/l Tris base, 5.50 g/l boric acid, 0.585 g/l EDTA, 
pH = 8.3 
TE buffer 100 mM Tris-HCl, 10 mM EDTA, pH = 7.4 
Tet stock 12.5 mg/ml tetracycline in ethanol 
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5.1.10. Table 10: List of Oligonucleotides 
Name Sequence Description 
o7 CTGCAGTTTCAAACGCTAAATTGCCTGAT
G 
Sequencing primer 
pEVOL pAcF 
o41 AGTTTAAACGGTCTCCAGC Sequencing primer 
pEVOL pAcF 
o42 ATTGCAGAGATCATGTAGG Sequencing primer 
pEVOL pAcF 
o83 AGTTCCCTACTCTCGCATG Sequencing primer 
pEVOL pAcF 
o247 GGGTTATGCTAGTTATTGCTCAG Sequencing primer pET 
TALE expression vector 
o315 CGTAGAGGATCGAGATC Sequencing primer pET 
TALE expression vector 
o410 GAGTAACAGCGGTAGAG Sequencing primer pET 
TALE expression vector 
o734 TTGATGCCTGGCAGTTCCCT Sequencing primer pFUS 
vector 
o735 CGAACCGAACAGGCTTATGT Sequencing primer pFUS 
vector 
o814 AATGCGCAAACCAACCC Sequencing primer pMV 
vector 
o890 AGATATGATTGCGGCCCTG Sequencing primer pET 
TALE expression vector 
o1152 GGATGTGGAAACGGAAGAGCTCACGGTG
GAAGAAGCCACTGAAGATGCTGTAACGC
TGGGGCTGAAGAGTGGGAATCCA 
Reference 
sequence_1297_rev 
o1408 AGAAGCGCGATCACATG Sequencing primer pET 
TALE expression vector 
o1411 TCAATATCACTGTGTGGC Sequencing primer pLR 
vector 
o1422 TGGATTCCCACTCTTCAGCCCCAGCGTTA
CAGCATCTTCAGTGGCTTCTTCCACCGTG
AGCTCTTCXGTTTCCACATCC (X = 5caC) 
Reference 
sequence_1297_C → 
5caC 
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o1423 TGGATTCCCACTCTTCAGCCCCAGCGTTA
CAGCATCTTCAGTGGCTTCTTCCACCGTG
AGCTCTTCXGTTTCCACATCC (X = 5fC) 
Reference 
sequence_1297_C → 5fC 
o1494  TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCGGCGGCAA
GCAAGCGCTCGAAACGGTGCAGCGG 
pHD2_SHDGG → 
pG*2_SG*GG 
o1495 TTTTCTCGAGGGTCTCGGTCCTGGCACA
GCACCGGCAACAGCCGCTGCACCGTTTC
GAGCGCTTGCTTGCCGCCGCCGCT 
pHD2_SHDGG → 
pG*2_SG*GG 
o1496 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCGGCAAGCA
AGCGCTCGAAACGGTGCAGCGGCTG 
pHD2_SHDGG → 
pG**2_S***G 
o1497 TTTTCTCGAGGGTCTCGGTCCTGGCACA
GCACCGGCAACAGCCGCTGCACCGTTTC
GAGCGCTTGCTTGCCGCCGCTGGC 
pHD2_SHDGG → 
pG**2_S***G 
o1498 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCAAGCAAGC
GCTCGAAACGGTGCAGCGGCTGTTG 
pHD2_SHDGG → 
pG***2_S***G 
o1499 TTTTCTCGAGGGTCTCGGTCCTGGCACA
GCACCGGCAACAGCCGCTGCACCGTTTC
GAGCGCTTGCTTGCCGCTGGCGAT 
pHD2_SHDGG → 
pG***2_S***G 
o1500 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCAAGCAAGCGCTC
GAAACGGTGCAGCGGCTGTTGCCG 
pHD2_SHDGG → 
pS****2_ S**** 
o1501 TTTTCTCGAGGGTCTCGGTCCTGGCACA
GCACCGGCAACAGCCGCTGCACCGTTTC
GAGCGCTTGCTTGCTGGCGATAGC 
pHD2_SHDGG → 
pS****2_ S**** 
o1502 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAATAAGCAAGCGCTC
GAAACGGTGCAGCGGCTGTTGCCG 
pHD2_SHDGG → 
pN****2_ N**** 
o1503 TTTTCTCGAGGGTCTCGGTCCTGGCACA
GCACCGGCAACAGCCGCTGCACCGTTTC
GAGCGCTTGCTTATTGGCGATAGC 
pHD2_SHDGG → 
pN****2_ N**** 
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o1504 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCGGCGGCAA
GCAAG 
pHD5_SHDGG → 
pG*5_SG*GG 
o1505 TTTTCTCGAGGGTCTCCTGCACCGTTTCG
AGCGCTTGCTTGCCGCCGCCGCTGGCGA
TAG 
pHD5_SHDGG → 
pG*5_SG*GG 
o1506 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCGGCAAGCA
AGCGC 
pHD5_SHDGG → 
pG**5_S***G 
o1507 TTTTCTCGAGGGTCTCCTGCACCGTTTCG
AGCGCTTGCTTGCCGCCGCTGGCGATAG
CCA 
pHD5_SHDGG → 
pG**5_S***G 
o1508 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCAAGCAAGC
GCTCG 
pHD5_SHDGG → 
pG***5_S***G 
o1509 TTTTCTCGAGGGTCTCCTGCACCGTTTCG
AGCGCTTGCTTGCCGCTGGCGATAGCCA
CCA 
pHD5_SHDGG → 
pG***5_S***G 
o1510 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCAAGCAAGCGCTC
GAAA 
pHD5_SHDGG → 
pS****5_ S**** 
o1511 TTTTCTCGAGGGTCTCCTGCACCGTTTCG
AGCGCTTGCTTGCTGGCGATAGCCACCA
CTT 
pHD5_SHDGG → 
pS****5_ S**** 
o1512 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAATAAGCAAGCGCTC
GAAA 
pHD5_SHDGG → 
pN****5_ N**** 
o1513 TTTTCTCGAGGGTCTCCTGCACCGTTTCG
AGCGCTTGCTTATTGGCGATAGCCACCA
CTT 
pHD5_SHDGG → 
pN****5_ N**** 
o1516 CTTCCTCTTCCGTCTCTTTCCTTTTACGTC
ATCCGGGGGCAGACT 
BRCA1a 
o1518 CTTCCTCTTCCGTCTCTTTCCTTTTAXGTC
ATCCGGGGGCAGACT (X = 5mC) 
BRCA1a_C13 → 5mC 
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o1520  CTTCCTCTTCXGTCTCTTTCCTTTTACGTC
ATCCGGGGGCAGACT (X = 5hmC) 
Reference 
sequence_BRCA1_C → 
5hmC 
o1521 CTTCCTCTTCCGTCTCTTTCCTTTTAXGTC
ATCCGGGGGCAGACT (X = 5hmC) 
BRCA1a_C13 → 5hmC 
o1524 CTTCCTCTTCCGTCTCTTTCCTTTTAXGTC
ATCCGGGGGCAGACT (X = 5fC) 
BRCA1a_C13 → 5fC 
o1525 CTTCCTCTTCCGTCTCTTTCCTTTTACGTC
ATCXGGGGGCAGACT (X = 5fC) 
BRCA1c_C13 → 5fC 
o1527 CTTCCTCTTCCGTCTCTTTCCTTTTAXGTC
ATCCGGGGGCAGACT (X = 5caC) 
BRCA1a_C13 → 5caC 
o1529 AGTCTGCCCCCGGATGACGTAAAAGGAA
AGAGACGGAAGAGGAAG 
BRCA1a_C13_rev 
o1570 CAATCCAGAGCCCCG Sequencing primer 
BRCA1a spike-in  
o1577 GGACTCTACTACCTTTACC Sequencing primer 
BRCA1a spike-in 
o1591 GGCCAGCCAGTCAGCCGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC 
CDKN2A  
o1592 GGCCAGCCAGTCAGCXGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC (X = 5mC) 
CDKN2A _C5 → 5mC 
o1593 GGCCAGCCAGTCAGCXGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC (X = 5hmC) 
CDKN2A _C5 → 5hmC 
o1594 GGCCAGCCAGTCAGCXGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC (X = 5fC) 
CDKN2A _C5 → 5fC 
o1595 GGCCAGCCAGTCAGCXGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC (X = 5caC) 
CDKN2A _C5 → 5caC 
o1596 AGGGCGGTGTGGGGGGCAGG
TGGGGAGGAGCCCAGTCCTC
CTTCCT 
CDKN2A_PCR primer for 
spike-in amplicons 
o1601 GTCAAAGAATACCCATCTGTCAGCTTCGG
AAATCCACTCTCCCAC 
BRCA1a_PCR primer for 
spike-in amplicons 
o1607 AGGAGCCCAGTCCTC CDKN2A_qPCR primer 
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o1617 GCCGGCGGCGGGGAGCAGCATGGAGCC
TTCGGCTGACTGGCTGGCC 
CDKN2A_rev 
o1750 TTTTCCATGGCCTGACTCCGGACCAAGT
GGTGGCTATCGCCAGCGGCGGCGGCAA
GCAAGCGCTCGAAACGGTGCAGCGG 
pHD4_SHDGG → 
pG*4_SG*GG 
o1751 TTTTCTCGAGGGTCTCCAACAGCCGCTG
CACCGTTTCGAGCGCTTGCTT 
pHD4_SHDGG → 
pG*4_SG*GG 
o1902 GGCCAGCCAGTCAGCAGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC 
CDKN2A _C5 → A 
o1903 GGCCAGCCAGTCAGCTGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC 
CDKN2A _C5 → T 
o1904 GGCCAGCCAGTCAGCGGAAGGCTCCATG
CTGCTCCCCGCCGCCGGC 
CDKN2A _C5 → G 
o2016 TTTTGTCGACTCAGCCGAAGGCTCCATG
CTGCTCCCACTAGTTTTT 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 
o2017 AAAAACTAGTGGGAGCAGCATGGAGCCT
TCGGCTGAGTCGACAAAA 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 
o2018 TTTTGTCGACTCAGCAGAAGGCTCCATGC
TGCTCCCACTAGTTTTT 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 → 
A6 
o2019 AAAAACTAGTGGGAGCAGCATGGAGCCT
TCTGCTGAGTCGACAAAA 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 → 
A6 
o2020 TTTTGTCGACTCAGCGGAAGGCTCCATG
CTGCTCCCACTAGTTTTT 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 → 
G6 
o2021 AAAAACTAGTGGGAGCAGCATGGAGCCT
TCCGCTGAGTCGACAAAA 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
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oN2A_TALE binding_C6 
→ G6 
o2022 TTTTGTCGACTCAGCTGAAGGCTCCATGC
TGCTCCCACTAGTTTTT 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 → 
T6 
o2023 AAAAACTAGTGGGAGCAGCATGGAGCCT
TCAGCTGAGTCGACAAAA 
pSF_MinCMV_Fluc → 
pSF_MinCMV_Fluc_CDK
N2A_TALE binding_C6 → 
T6 
o2087 GCCGGCGGCGGGGAGCAGCATGGAGCC
TTCTGCTGACTGGCTGGCC 
CDKN2A _C5 → A_rev 
o2088 GCCGGCGGCGGGGAGCAGCATGGAGCC
TTCAGCTGACTGGCTGGCC 
CDKN2A _C5 → T_rev 
o2089 GCCGGCGGCGGGGAGCAGCATGGAGCC
TTCCGCTGACTGGCTGGCC 
CDKN2A _C5 → G_rev 
o2129 TGAGTCGGAGTCTCATTCTGTC CDKN2A_PCR primer for 
spike-in amplicons 
o2130 CTCACAAAACAGGAGTAGGGAG Sequencing primer 
CDKN2A spike-in  
o2131 CCTCTTCTTTGCAGGATTCCTC BRCA1a_PCR primer for 
spike-in amplicons  
o2132 CACTCTTGTGCTGACTTACCAG BRCA1a_PCR primer for 
spike-in amplicons 
o2135 GAAGCCATACTTTCCCTATG CDKN2A_PCR primer for 
spike-in amplicons 
o2136 CCTTTCATTCCGCAACGC BRCA1a_PCR primer for 
spike-in amplicons 
o2165 XGCCGGCGGCGGGGAGCAGCATGGAGC
CTTCGGCTGACTGGCTGGCC (X = 5’-Cy5) 
CDKN2A_rev_Cy5 
o2313 CTCTTTCTTCCTCCGGTGCTG CDKN2A_qPCR primer 
o2485 CAAGTGGTGGCTATCGCCAGCGGCTAGG
GCAAGCAAGCG 
pG*2_SG*GG → 
pG*12_SG*1G 
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o2486 CCGTTTCGAGCGCTTGCTTGCCCTAGCC
GCTGGCGATAG 
pG*2_SG*GG → 
pG*12_SG*1G 
o2487 CGGACCAAGTGGTGGCTATCGCCTAGGG
CGGCGGCAAGC 
pG*2_SG*GG → 
p1G*2_1G*GG 
o2488 TCGAGCGCTTGCTTGCCGCCGCCCTAGG
CGATAGCCACC 
pG*2_SG*GG → 
p1G*2_1G*GG 
o2489 CAAGTGGTGGCTATCGCCAGCTAGGGCG
GCAAGCAAGCG 
pG*2_SG*GG → 
p1*2_S1*GG 
o2490 CCGTTTCGAGCGCTTGCTTGCCGCCCTA
GCTGGCGATAG 
p1*2_SG*GG → 
p1*2_S1*GG 
o2551 AGTCTGCCCCCGGATCGCGCGAAAGGAA
AGAGACGGAAGAGGAAG 
BRCA1b_rev 
o2552 CTTCCTCTTCCGTCTCTTTCCTTTXGCGC
GATCCGGGGGCAGACT (X = 5fC) 
BRCA1b_C11 → 5fC 
o2553 CTTCCTCTTCCGTCTCTTTCCTTTCGXGC
GATCCGGGGGCAGACT (X = 5fC) 
BRCA1b_C13 → 5fC  
o2554 CTTCCTCTTCCGTCTCTTTCCTTTCGCGX
GATCCGGGGGCAGACT (X = 5fC) 
BRCA1b_C15 → 5fC 
o2555 AGTCTGCCCCCGGATCGXGCGAAAGGAA
AGAGACGGAAGAGGAAG (X = 5fC) 
BRCA1b_C13 → 5fC_rev 
o2556 CTTCCTCTTCCGTCTCTTTCCTTTCGCGC
GATCCGGGGGCAGACT 
BRCA1b 
o2901 TTTTTTTTTTTCGTTTTTTTTTTT Reference 
sequence_RefSeq_rev 
o2910 XAGTCTGCCCCCGGATGACGTAAAAGGA
AAGAGACGGAAGAGGAAG (X = 5’-Cy5) 
BRCA1a_rev_Cy5 
o2939 TCTGAGAGGCTGCTGCTTAG BRCA1a _qPCR primer  
o2943 GGAAGTCTCAGCGAGCTCAC BRCA1a _qPCR primer 
o2963 CGGACCAAGTGGTGGCTATCGCCAGCGG
CGGCGGGAGAC 
pHD10_SHDGG → 
pG*10_SG*GG 
o2964 GTGGCTCGAGGGTCTCCCGCCGCCGCT
GGCGATAGCCAC 
pHD10_SHDGG → 
pG*10_SG*GG 
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o3116 YAAAAAAAAAAAXGAAAAAAAAAAA (Y = 
5’-FAM; X = 5fC) 
Reference 
sequence_RefSeq_5fC12 
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5.1.11. Table 11: List of Plasmids 
Name Description 
Antibiotic 
Resistance 
pDaS71 
pEVOL vector for expression of M. jannaschii 
tyrosyl-tRNA synthetase/tRNA pair for 
incorporation of pAcF via amber suppression 
Cam 
pAnI521 
pET TALE expression vector with N-terminal 
GFP-domain, shortened AvrBs3-type TALE N-
terminus and C-terminal His-tag 
Carb 
pMaG635 pHD2_SHDGG → SG*GG module vector with 
H12G and D13* 
Tet 
pMaG636 pHD2_SHDGG → SG**G module vector with 
H12G, D13* and G14* 
Tet 
pMaG637 pHD2_SHDGG → SG*** module vector with 
H12G, D13*, G14* and G15* 
Tet 
pMaG638 pHD2_SHDGG → S**** module vector with 
H12*, D13*, G14* and G15* 
Tet 
pMaG639 pHD2_SHDGG → N**** module vector with 
S11N, H12*, D13*, G14* and G15* 
Tet 
pMaG640 pHD5_SHDGG → SG*GG module vector with 
H12G and D13* 
Tet 
pMaG641 pHD5_SHDGG → SG**G module vector with 
H12G, D13* and G14* 
Tet 
pMaG642 pHD5_SHDGG → SG*** module vector with 
H12G, D13*, G14* and G15* 
Tet 
pMaG643 pHD5_SHDGG → S**** module vector with 
H12*, D13*, G14* and G15* 
Tet 
pMaG644 pHD5_SHDGG → N**** module vector with 
S11N, H12*, D13*, G14* and G15* 
Tet 
pMaG659 pET_GFP_BRCA1a_TALE_wt_6His Carb 
pMaG660 pET_GFP_BRCA1a_TALE_SG*GG_6His Carb 
pMaG661 pET_GFP_BRCA1a_TALE_SG**G_6His Carb 
pMaG662 pET_GFP_BRCA1a_TALE_SG***_6His Carb 
pMaG663 pET_GFP_BRCA1a_TALE_S****_6His Carb 
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pMaG664 pET_GFP_BRCA1a_TALE_N****_6His Carb 
pMaG665 pET_GFP_CDKN2A_TALE_wt_6His Carb 
pMaG666 pET_GFP_CDKN2A_TALE_SG*GG_6His Carb 
pMaG667 pET_GFP_CDKN2A_TALE_SG**G_6His Carb 
pMaG668 pET_GFP_CDKN2A_TALE_SG***_6His Carb 
pMaG669 pET_GFP_CDKN2A_TALE_S****_6His Carb 
pMaG670 pET_GFP_CDKN2A_TALE_N****_6His Carb 
pMaG1017 pHD4 → SG*GG module vector with H12G and 
D13* 
Tet 
pMaG1184 pMaG635_SG*GG → SG*1G with G14pAcF Tet 
pMaG1185 pMaG635_SG*GG → 1G*GG with S11pAcF Tet 
pMaG1186 pMaG635_SG*GG → S1*GG with G12pAcF Tet 
pMaG1187 pMaG640_SG*GG → SG*1G with G14pAcF Tet 
pMaG1188 pMaG640_SG*GG → 1G*GG with S11pAcF Tet 
pMaG1189 pMaG640_SG*GG → S1*GG with G12pAcF Tet 
pMaG1190 pLR_NG_SNGGG→S1*GG with N12pAcF and 
G13* 
Tet 
pMaG1201 pET_GFP_BRCA1a_TALE_1G*GG_6His Carb 
pMaG1202 pET_GFP_BRCA1a_TALE_S1*GG_6His Carb 
pMaG1203 pET_GFP_BRCA1a_TALE_SG*1G_6His Carb 
pMaG1208 pET_GFP_BRCA1c_TALE_LR_S1*GG(20)_6His Carb 
pMaG1209 pET_GFP_BRCA1c_TALE_LR_S1*GG(19)_6His Carb 
pMaG1269 pET_GFP_BRCA1b_TALE_1G*GG_6His Carb 
pMaG1270 pET_GFP_BRCA1b_TALE_S1*GG_6His Carb 
pMaG1271 pET_GFP_BRCA1b_TALE_SG*1G_6His Carb 
pMaG1535 pHD10_SHDGG → SG*GG module vector with 
H12G and D13* 
Tet 
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5.1.11. Table 12: List of TALE Proteins 
Name RVD Sequence (non-canonical repeats in brackets) 
CDKN2A_TALE_wt HD NI NN HD HD NN NI NI NN NN HD NG HD HD NI 
NG NN HD NG NN HD NG HD HD HD 
CDKN2A_TALE_SG*GG HD NI NN HD (SG*GG) NN NI NI NN NN HD NG HD 
HD NI NG NN HD NG NN HD NG HD HD HD 
CDKN2A_TALE_SG**G HD NI NN HD (SG**G)NN NI NI NN NN HD NG HD HD 
NI NG NN HD NG NN HD NG HD HD HD 
CDKN2A_TALE_SG*** HD NI NN HD (SG***) NN NI NI NN NN HD NG HD HD 
NI NG NN HD NG NN HD NG HD HD HD 
CDKN2A_TALE_S**** HD NI NN HD (S****) NN NI NI NN NN HD NG HD HD 
NI NG NN HD NG NN HD NG HD HD HD 
CDKN2A_TALE_N**** HD NI NN HD (N****) NN NI NI NN NN HD NG HD HD 
NI NG NN HD NG NN HD NG HD HD HD 
BRCA1a_TALE_wt HD NG NG NG HD HD NG NG NG NG NI HD NN NG 
HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_SG*GG HD NG NG NG HD HD NG NG NG NG NI (SG*GG) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_SG**G HD NG NG NG HD HD NG NG NG NG NI (SG**G) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_SG*** HD NG NG NG HD HD NG NG NG NG NI (SG***) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_S**** HD NG NG NG HD HD NG NG NG NG NI (S****) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_N**** HD NG NG NG HD HD NG NG NG NG NI (N****) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_1G*GG HD NG NG NG HD HD NG NG NG NG NI (1G*GG) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_S1*GG HD NG NG NG HD HD NG NG NG NG NI (S1*GG) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
BRCA1a_TALE_SG*1G HD NG NG NG HD HD NG NG NG NG NI (SG*1G) NN 
NG HD NI NG HD HD NN NN NN NN NN LR_HD 
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BRCA1b_TALE_1G*GG HD NG NG NG HD HD NG NG NG (SG*GG) NN 
(1G*GG) NN (SG*GG) NN NI NG HD HD NN NN NN 
NN NN LR_HD 
BRCA1b_TALE_S1*GG HD NG NG NG HD HD NG NG NG (SG*GG) NN 
(S1*GG) NN (SG*GG) NN NI NG HD HD NN NN NN 
NN NN LR_HD 
BRCA1b_TALE_SG*1G HD NG NG NG HD HD NG NG NG (SG*GG) NN 
(SG*1G) NN (SG*GG) NN NI NG HD HD NN NN NN 
NN NN LR_HD 
BRCA1c_ 
TALE_LR_S1*GG(20) 
HD NG NG NG HD HD NG NG NG NG NI HD NN NG 
HD NI NG HD LR_S1*GG 
BRCA1c_ 
TALE_LR_S1*GG(19) 
HD NG NG NG HD HD NG NG NG NG NI HD NN NG 
HD NI NG LR_S1*GG 
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5.1.12. Table 13: List of Strains/Cell Lines 
Type Host 
GH371 E. coli 
BL21 DE3 Gold E. coli 
HEK293T H. sapiens 
J1 mESC M. musculus 
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5.2. Methodse 
5.2.1. Biological/Biochemical Methods 
5.2.1.1. Plate Culture 
Bacterial swabs were streaked onto LB-Agar supplemented with antibiotic in plastic 
petri dish, if necessary. Alternatively, bacterial suspension (either water or SOC 
medium) were pipetted onto LB-Agar supplemented with antibiotic in plastic petri 
dishes and spread out using glass beads close to the flame. Plates were incubated at 
37°C and grown overnight in an incubator. 
5.2.1.2. Liquid Overnight Culture  
Single bacterial colonies were transferred to LB medium supplemented with antibiotics 
and incubated at 37 °C whilst shaking at 180 rpm overnight in glass Erlenmeyer flasks 
or conical plastic tubes.  
5.2.1.3. Preparation of Chemical-competent GH317 E.coli bacteria 
From the strain stock, bacteria were streaked onto LB-Agar plates and incubated at 
37°C overnight. A single colony of E. coli GH317 strain was transferred to 15 ml LB 
medium and incubated overnight at 37 °C shaking at 180 rpm (rounds per minute). 
8 ml of bacterial overnight culture were added to 800 ml of LB medium and incubated 
at 37 °C whilst shaking at 180 rpm until an OD600 of 0.5 was reached. The culture was 
first cooled on ice and subsequently centrifuged at 4 °C for 10 minutes at 4000 rpm. 
The supernatant was promptly discarded. The pellet was resuspended in 80 ml of 
precooled, sterile 100 mM MgCl2 on ice. The suspension was again centrifuged (4 °C, 
15 min, 4000 rpm), the pellet recovered, kept on ice and resuspended in 80 ml of ice-
cold, sterile 50 mM CaCl2. After another round of centrifugation, the pellet was again 
resuspended in 4 ml ice-cold, sterile 50 mM CaCl2 supplemented with 15 % glycerol. 
Finally, the suspension was aliquoted into fractions of 50 µl on ice and immediately 
frozen in liquid nitrogen. Frozen cells were stored at -80 °C. 
5.2.1.4. Preparation of Chemical-competent BL21 E.coli bacteria 
From the strain stock, bacteria were streaked onto LB-Agar plates and incubated at 
37°C overnight. A single colony of E. coli BL21 strain was transferred to 15 ml LB 
                                            
e The protocols of this section have been (partly) published in Gieß et al. (2018) and Gieß et al. (2019).369,370 
Reprinted (adapted) with permission from ref.369 and ref.370 Copyright 2019 American Chemical Society 
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medium and incubated overnight at 37 °C shaking at 180 rpm. 800 ml of SOB++ 
medium was inoculated with 5 ml of bacterial BL21 overnight culture and incubated at 
room temperature (~25-30 °C) whilst shaking till an OD600 = 0.5 was reached. The 
culture was chilled on ice for 10 min. and then kept on ice as much as possible during 
the procedure. The culture was centrifuged at 4 °C for 10 minutes at 4000 rpm. Then, 
the supernatant was discarded, and the pellet was resuspended in 200 ml cold TB-
Buffer and incubated on ice for 10 min. After 10 minutes of centrifugation at 4 °C for 
and 4000 rpm the supernatant was discarded, and the pellet was resuspended in 30 ml 
of cold TB-Buffer. Next, 2 ml DMSO was added, and the suspension incubated for 
10 minutes on ice. Aliquots of 200 µl were prepared on ice and immediately frozen in 
liquid nitrogen. Frozen cells were stored at -80 °C. 
5.2.1.5. Preparation of Electro-competent GH371 or BL21 E.coli 
From LB-Agar plates single colonies of an E. coli strain were inoculated into 25 ml LB-
overnight culture, if necessary supplied with appropriate antibiotics. The suspension 
was incubated at 37 °C and shaking at 180 rpm. Next, 5 ml of overnight culture was 
transferred to 500 ml of LB medium and incubated at 37 °C whilst shaking at 200 rpm 
until an OD600 = 0.4 was reached. The culture was chilled on ice and kept cool as much 
as possible during the procedure. The culture was centrifuged at 4 °C for 15 minutes 
at 3500 g. The supernatant was discarded, and the pellet resuspended in 20 ml ice 
cold sterile MilliQ-Water. The suspension was centrifuged again at 4 °C for 15 minutes 
at 3500 g. This was repeated once with 10 ml ice cold sterile MilliQ-Water. The 
supernatant was discarded, and the pellet resuspended in 7 ml ice cold sterile 10 % 
glyceroleaq. The suspension was centrifuged again at 4 °C for 20 minutes at 4000 rpm. 
The supernatant was discarded, and the pellet resuspended in 2.5 ml ice cold sterile 
10 % glyceroleaq. Finally, the suspension was aliquoted in volumes of 25 µl, frozen in 
liquid nitrogen and stored at -80 °C. 
5.2.1.6. Transformation by Heat Shock 
Depending on purity and concentration of the plasmid solution up to 5 µl (usually 0.1 µl 
if purified and concentrated plasmid at >100 ng/µl had been used and 2.5 µl if crude 
plasmid solutions were used) were very carefully mixed with 25-50 µl bacterial 
suspension (GH317 E.coli for plasmid amplification) or (BL21 E.coli for protein 
expression) in a 1.5 ml micro centrifuge tube and cooled on ice for 30 minutes.  
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After a heat shock at 42 °C for maximal 45 s, the tube was immediately mixed with 
1 ml tempered SOC medium (37 °C). Afterwards the suspension was incubated for 1 h 
at 37 °C whilst shaking at 600 rpm. Finally, up to 500 µl of the suspension (usually 
below 50 µl if purified and concentrated plasmid had been used and 100 µl if crude 
plasmid solutions were used) was plated onto LB-Agar supplemented with antibiotics 
in plastic petri dishes using glass beads and incubated at 37 °C overnight. 
5.2.1.7. Transformation by Electroporation 
Depending on purity and concentration of the plasmid solution, 1µl of 10 – 100 ng of 
DNA plasmids were resuspended in a 25 μl cell aliquot on ice. The cell suspension 
was transferred to a pre-cooled electroporation cuvette and transformed with 1800 V 
in an electroporator. Cells were resuspended with 1 ml pre-warmed SOC medium (37 
°C) and incubated in a Thermomixer at 37 °C, 1400 rpm shaking for 1 h. 10-500 µl of 
the suspension was plated on LB-agar supplemented with the appropriate antibiotics 
in plastic petri dishes and incubated overnight at 37 °C. 
5.2.1.8. Cassette Mutagenesis 
4 µM complementary oligonucleotide pairs bearing the mutation were hybridized in 
100 µl 1x NEB2 at 95 °C for 10 minutes. If necessary, the oligonucleotides were 
extended with 5 Units (Un) Klenow fragment (3'→5' exo-) and 3 µl of 10 mM dNTPs 
for 2 h at 37 °C and purified with the PCR purification kit according to the 
manufacturer’s protocol.  
Then, 60 µl of paired oligonucleotides (>150 ng/µl) were digested in 1x CutSmart buffer 
with 15 Un of NcoI and XhoI. The reaction was incubated for 1 h at 37 °C before 
stopping the reaction at 80 °C for 20 minutes. The reaction was purified with the PCR 
purification kit. Similarly, 60 µl of pMV (>100 ng/µl) were digested and purified. 
Digested vectors and paired oligonucleotides were ligated in 10 µl 1x T4 DNA ligase 
reaction buffer using 400 U T4 DNA ligase for 4 hours at 16 °C. The reaction was 
stopped by heating the mixture to 65 °C for 10 minutes. 
5 µl of the crude reaction mixture was transformed into GH317 and plated onto LB-
Agar supplemented with tetracycline and incubated overnight. Single colonies were 
picked, inoculated in 5 ml LB-Medium supplemented with tetracycline and grown 
overnight. Plasmids were isolated, purified, checked for correct sequence and stored 
at -20 °C. 
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5.2.1.9. Site-directed Mutagenesis (SDM) by PCR 
Primer containing the amber stop codon targeting the site of mutation were designed 
according to the guidelines of standard QuickChange protocols with a short overlap, 
moderate melting temperature (Tm) and GC content, if possible.  
The PCR reactions were performed as indicated below. Next, samples were digested 
without any further purification with 10 Un DpnI at 37 °C for 1 h. 10 μl of this reaction 
mixture were transformed into 50 μl chemically competent E.coli GH371 cells. After 
growing single colonies in liquid overnight cultures, plasmids were isolated, purified, 
checked for correct sequence and stored at -20 °C. 
 
Table 14: SDM-PCR reagent concentrations in 25 µl 
Reagent Volume 
Template (100 ng/µl) 1 μl 
Primer, forward (10 µM) 0.5 μl 
Primer, reverse(10 µM) 0.5 μl 
Pfu buffer (10x) 2.5 μl 
dNTPs (10mM each) 0.5 μl 
Sterile water 19.5 μl 
Pfu polymerase (2.5 Un/μl) 0.5 μl 
 
Table 15: SDM-PCR reaction times and temperatures 
T t Cycles 
95 °C  60 s 1 
95 °C  30 s 
18 55 °C  30 s 
68 °C 600 s 
68 °C  600 s 1 
 
5.2.1.10. Agarose Gel Electrophoresis 
First, Agarose was dissolved in 0.5x TBE Buffer. The solution was heated until boiling, 
then kept at room temperature whilst stirring. When the solution had cooled down but 
was still liquid, it was poured into the gel casting chamber and a comb was added for 
sample well creation. After solidification, the gel was transferred to the running 
chamber filled with 0.5x TBE buffer. Then, 12 µl of samples with loading dye were 
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pipetted into the sample wells and the electrophoresis was performed at 5 V/cm for 90 
minutes. Afterwards the gel was stained with ethidium bromide and DNA bands were 
visualized by UV light. 
5.2.1.11. Colony PCR 
Single colonies were inoculated in 20 µl of sterile water and kept on ice. The PCR 
reaction was pipetted on ice, with the polymerase being added last. Colony PCR was 
performed as indicated below. Product formation was analyzed via agarose gel 
electrophoresis with a DNA ladder as a reference. 
 
Table 16: Colony PCR reagent concentrations in 25 µl 
Reagent Volume 
Bacterial colony suspension 1 μl 
Primer, forward (10 µM) 0.25 μl 
Primer, reverse(10 µM) 0.25 μl 
Thermo Pol buffer (10x) 2.5 μl 
dNTPs (10mM each) 0.625 μl 
Sterile water 20.2 μl 
Taq polymerase (5 Un/μl) 0.2 μl 
 
Table 17: Colony PCR reaction times and temperatures 
T t Cycles 
95 °C  120 s 1 
95 °C  30 s 
35 55 °C  30 s 
68 °C 180 s 
68 °C  300 s 1 
 
5.2.1.12. TALE Assembly via Golden Gate Reaction 
pFUS vectors were assembled according to the target sequence for CDKN2A, 
BRCA1a, BRCA1b and BRCA1c as indicated below. 
Canonical and mutated pMV for the respective CDKN2A, BRCA1a and BRCA1b 
sequence position 1-10 were assembled into pFUSA30A whereas pMV for BRCA1c 
sequence position 1-10 were assembled into pFUSA. CDKN2A, BRCA1a and BRCA1b 
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sequence position 11-20 were assembled into pFUSA30B. CDKN2A, BRCA1a and 
BRCA1b sequence position 21-24 were assembled into pFUSB4 whereas pMV for 
BRCA1c sequence position 11-17 or sequence position 11-18 into pFUSB7 and 
pFUSB8, respectively. 
After Golden Gate 1 reaction, all non-circular plasmid DNA was removed by adding 
5 nmol ATP and 5 Un Plasmid-safe Nuclease and incubating the mixture for 1h at 
37°C.  
10 µl of Golden Gate reaction mixes were directly transformed into GH317 E.coli and 
plated onto LB-Agar plates supplemented with spectinomycine and 50 µg/ml x-Gal for 
blue-white screening. 
Four white colonies from the previous step were used to perform a colony PCR to 
check for correct insertion of pMV fragments into pFUS vectors with agarose gel 
electrophoresis. 
One correct colony per pFUS vector was used for overnight culture. Plasmid were 
isolated, purified and sequenced. 
 
 Table 18: Golden Gate 1 reagent concentrations in 25 µl 
Reagent Volume 
Each pMV (150 ng/µl) 1 μl 
pFUS vector (75 ng/µl) 1 µl 
T4 ligase buffer (10x) 2.5 µl 
BsaI (10 Un/µl) 1 μl 
T4 DNA ligase (400 Un/µl) 1 μl 
Sterile water to 25 μl 
 
Table 19: Golden Gate 1 reaction times and temperatures 
T t Cycles 
37 °C  300 s 
15 
16 °C  600 s 
50 °C  300 s 1 
80 °C  300 s 1 
 
Next, pFUS vector for CDKN2A, BRCA1a, BRCA1b and BRCA1c were assembled with 
their specific original or mutated pLR vectors into pAnI521. 
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After Golden Gate 2 reaction, 10 µl of reaction mixes were directly transformed into 
GH317 E.coli and plated onto LB-Agar plates supplemented with carbenicillin and 
50 µg/ml x-Gal for blue-white screening. 
Six white colonies were picked for colony PCR to check for correct insertion of pFUS 
and pLR fragments into the pET TEV with agarose gel electrophoresis. 
Two colonies with the correct insert length were inoculated in 5 ml LB-Medium 
supplemented with carbenicillin and incubated at 37 °C overnight. Plasmids were 
isolated, purified and sequenced. 
 
 
Table 20: Golden Gate 2 reagent concentrations in 25 µl 
Reagent Volume 
Each assembled pFUS vector (150 ng/µl) 1 μl 
pLR vector (150 ng/µl) 1 µl 
T4 ligase buffer (10x) 2.5 µl 
BsmBI (10 Un/µl) 1 μl 
T4 DNA ligase (400 Un/µl) 1 μl 
Sterile water to 25 μl 
 
Table 21: Golden Gate 2 reaction times and temperatures 
T t Cycles 
37 °C  600 s 
10 
16 °C  900 s 
37 °C  900 s 1 
80 °C  300 s 1 
 
5.2.1.13. SDS-PAGE 
Protein samples were mixed with SDS loading buffer and were denatured for 5 minutes 
at 95 °C. The samples were allowed to cool to room temperature and were loaded on 
an SDS polyacrylamide gel with protein marker as a reference. SDS gels were run for 
1 h 15 minutes at 120 V. After electrophoresis, the gels were washed with water and 
stained in Comassie solution for 1 h on a shaker. The gels were developed first in 
destaining solution for 2 h, then in a diluted aqueous destaining solution overnight. Gel 
images were scanned on the CanoScan 9000F. 
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5.2.1.14. TALE Expression 
For expression of standard TALE proteins, single clones of E. coli BL21(DE3) Gold 
transformed with a TALE expression plasmid were grown in LB media supplemented 
with 50 µg/ml carbenicillin at 37 °C overnight. These cultures were diluted 50-fold into 
LB medium supplemented with the same antibiotic and incubated at 37 °C and 200 rpm 
shaking until an OD600 of 0.4 was reached. IPTG was added to a final concentration of 
0.2 mM and the cultures were further incubated under the same conditions. Then, cells 
were pelleted at 4 °C for 20 minutes at 4000 rpm, the supernatant discarded and if 
necessary frozen overnight.  
The pellets were lysed in lysis-buffer (10 mM Tris-HCl, 300 mM NaCl, 2.5 mM MgCl2, 
0.1 % Triton X-100, pH = 9) containing 1 mM PMSF and 50 µg/ml by shaking at room 
temperature at 1400 rpm for 30 minutes. The suspension was pelleted by 
centrifugation and the supernatant was collected and extracted with Ni-NTA. Ni-NTA 
beads were washed two times with 4x PBS-buffer (0.55 M NaCl, 43 mM KCl, 69 mM 
Na2HPO4·2 H2O, 24 mM KH2PO4, pH = 8), four times with wash buffer (50 mM 
NaH2PO4·H2O, 300 mM NaCl, pH = 8) containing 20 mM imidazole and once with 
wash buffer containing 50 mM imidazole. The protein was eluted three times or until 
all protein was visibly eluted from the Ni-NTA with wash buffer containing 500 mM 
imidazole. Pooled elution fractions were added to a dialysis tube and dialyzed against 
TALE storage buffer (20 mM Tris-HCl, 200 mM NaCl, 10 % glycerol, 1 mM DTT, 
pH = 7.5). For CD-spectroscopy, TALEs were dialyzed against a different TALE 
storage buffer (20 mM Tris-HCl, 50 mM NaCl, pH = 7.5). Purity of the TALE protein 
was analyzed with SDS-PAGE. Concentrations were quantified with a BCA assay 
according to the manufacturer’s protocol. The proteins were snap-frozen and stored in 
aliquots at −80 °C. 
For Expression of TALEs bearing pAcF, TALE plasmids were co-transformed with 
plasmid pDaS71 (encoding for pAcF tRNA/RS; under control of araBAD promotor) into 
E. coli BL21 DE3 gold cells and grown at 37 °C on carbenicillin/chloramphenicol LB 
agar plates. Single colonies were inoculated into 5 ml LB medium with 
carbenicillin/chloramphenicol and grown at 37 °C overnight. Overnight culture was 
added to 250 mL LB medium with carbenicillin/chloramphenicol containing 1 mM of 
pAcF. Cultures were grown at 37°C whilst shaking at 180 rpm and until an OD600 of 0.4 
was reached. Then, expression of the tRNA synthetase/tRNA pair was induced by 
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adding arabinose to a final concentration of 0.02 %. After an hour, TALE expression 
was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.2 mM. The expression was continued overnight. Then, cells were 
pelleted at 4 °C for 20 minutes at 4000 rpm and the supernatant discarded.  
The pellet was re-suspended in lysis-buffer (10 mM Tris-HCl, 300 mM NaCl, 2,5 mM 
MgCl2, 5 % DMSO, 0.2 % sodium lauroyl sarcosinate, 0.1 % Triton X-100, pH = 9) 
containing 1 mM PMSF and 50 µg/mL lysozyme. The suspension was lysed by 
repeated sonication on ice (2 runs of 3 minutes; 20 % amplitude; 4s on, 2s off), letting 
samples cool on ice for 1 minute between runs. Cell debris was pelleted by 
ultracentrifugation and the supernatant was collected and extracted with Ni-NTA. Ni-
NTA beads were washed in 4 steps with 25 times the bead volume with wash buffer 
(50 mM NaH2PO4·H2O, 300 mM NaCl, pH = 8) containing 5 mM, 10 mM, 20 mM 
imidazole and 50 mM imidazole. The protein was eluted three times or until all protein 
was visibly eluted from the Ni-NTA with wash buffer containing 500 mM imidazole. 
Pooled elution fractions were added to a dialysis tube and dialyzed against TALE 
storage buffer (20 mM Tris-HCl, 200 mM NaCl, 10 % glycerol, 1 mM DTT, pH = 7,5). 
Purity of the TALE protein was analyzed with SDS-PAGE. Concentrations were 
determined with a BCA assay according to manufacturer’s instructions. The proteins 
were snap-frozen and stored in aliquots at −80 °C. 
5.2.1.15. Circular Dichroism Spectroscopy 
Circular Dichroism (CD) spectra were recorded on a J-715 spectropolarimeter between 
190 nm and 260 nm with a scanning speed of 50 nm/min and a band-width of 1 nm in 
a cylindrical quartz cell with a path length of 0.01 cm. The spectra represent the 
average of ten scans for 350 µl of samples with a concentration of 1 mg/ml, which were 
corrected for the baseline of a buffer control and normalized for the molecular 
concentration of the sample in the Spectra Manager Suite. Obtained values were 
plotted in OriginPro. 
5.2.1.16. Electromobility Shift Assay 
Oligonucleotide pairs for TALE binding (see SI) were hybridized in TALE binding buffer 
(20 mM Tris, 50 mM NaCl, 5 mM MgCl2 and 5 % v/v glycerol, pH = 8) by incubating at 
95 °C for 5 minutes, followed by 30 minutes at room temperature. Then, defined 
amounts of DNA duplex were incubated with the respective TALE protein in TALE 
binding buffer with a final volume of 10 µl. The reaction was kept at room temperature 
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for 60 minutes and then at 4 °C for 30 minutes. The native polyacrylamide gel (0.5 x 
TAE buffer, 8 % Rotiphorese gel 40, 0.1 % APS and 0.01 % TEMED) was pre-run at 
4 °C for 30 minutes in a Mini Protean vertical electrophoresis cell at 70 V. The gel was 
loaded with 7,5 µl sample and then run for 90 minutes at 4 °C and 70 V. GFP 
fluorescence of the gels was recorded with a Typhoon FLA-9500 laser scanner and 
analyzed using the software ImageJ or ImageQuant TL 8.1.  
5.2.1.17. Structure Modelling 
The modelling workflow was performed using MOE 2016.08378 and Chimera.379 As 
starting point, the crystal structure PDB 4GJR (chains A, I and J) was used. The base 
pairs of the DNA strand were mutated to the corresponding base pairs of the used DNA 
sequence using Chimera. After that, the respective cytosine modifications were added 
to the DNA in MOE, resulting in five different DNA models (C, 5mC, 5hmC, 5fC, 5caC). 
After that, one homology model was created for each combination of protein variant 
and C modification using the homology modelling module of MOE. Here, the option 
“include selected atoms as environment for induced fit option” was enabled to transfer 
the modified DNA to the homology model and to consider it in the modelling process. 
25 main chain models with 3 sidechain samples each were created and refined using 
the “Fine” setting with an RMS gradient of 0.1. Apart from that, standard settings were 
used with the default force field Amber10:EHT.380,381 
For analyzing the impact of further modifications at the 5fC and 5caC base, the 
respective modifications were introduced using the “Build Molecule” functionality in 
MOE. To get reasonable structures of these modifications that do not affect binding, 
the modified base and residues within a 4.5 Å radius were minimized using MOE 
default settings. 
5.2.1.18. Luciferase Assay 
HEK293T cells were maintained in DMEM media supplemented with 1 % 
penicillin/streptomycin, 10 % FBS and 1 % L-glutamine. 1.6 x 104 cells were cultured 
in a 96 well plate overnight prior transfection. Opti MEM and Lipofectamin 2000 were 
mixed according to the manufacturer’s protocol. 25 ng of the luciferase reporter 
plasmid (encoding the TALE binding site and a minCMV promoter upstream of a firefly 
luciferase gene) and 175 ng of the TALE plasmid (encoding the TALE-VP64 fusion 
constructs; for plasmid maps, see the SI Fig. 13). Transfection mix was added to each 
plasmid pair and incubated for 20 minutes at RT. The solution was added to wells of 
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the 96 well plate and incubated at 37 °C and 5 % CO2 for 48 hr. Each well was then 
washed with 20 µl of DPBS. 40 µl of lysis buffer (100 mM NaH2PO4 and 0.2 % Triton 
X-100) was added to each well and mixed vigorously. The plate was then incubated 
on ice for 20 min. After incubation, 20 µL of the lysis solution from each well was 
combined with each 90 µL of Bright-Glo in a second 96 well plate. The plate was quickly 
spun down and the luminescence was immediately measured on a TECAN M1000 
plate reader (wavelength 380-600 nM). Ratio of luminescence from each sample to 
that of a sample transfected with TALE-VP64 and the luciferase reporter plasmid 
bearing the CDKN2A_TALE binding_C6 was plotted as relative luminescence. The 
error bars represent standard errors from duplicate experiments. 
5.2.1.19. Phenol/Chloroform Extraction and Ethanol Precipitation of DNA 
An equal volume of a 25:24:1 mixture of phenol/chloroform/isoamylalcohol (pH = 7.5-
8.0) was added to at least 100 µl of sample. The mixture was vortexed vigorously for 
15 s at max speed. Then, the dispersion was shortly spun down. The upper aqueous 
phase was transferred to a fresh microcentrifuge tube. The extraction was repeated 
once. The extracted aqueous phase without any organic phase or precipitate from the 
interphase was mixed thoroughly with 0.1x fold of the sample volume 3M sodium 
acetate (pH = 5.2). Then, 3x fold of ice-cold absolute ethanol was added to the sample. 
The solution was mixed by inverting and kept at -20 °C overnight. The next day, the 
solution was centrifuged at full speed for 30 minutes at 4 °C to pellet the precipitated 
nucleic acid. The solution was carefully removed to not disturb the pellet. Next, the 
pellet was washed with 100 µl of ice-cold 70 % ethanolaq and the sample centrifuged 
for 5 minutes at full speed at 4 °C. The supernatant was carefully removed and the 
washing step repeated again. Finally, the pellet was dried in a vacuum concentrator 
and then taken up in nuclease-free water or sterile TE-buffer. 
5.2.1.20. Enzymatic Glucosylation 
500 pmol of dsDNA containing 5hmC was incubated for 18 h at 37 °C with 30 units T4 
BGT and 800 nmol UDP-glucose in 50 µl of NEB4 (50 mM KOAc, 20 mM Tris-HOAc, 
10 mM Mg(OAc)2, 1 mM DTT, pH = 7.9). The reaction was stopped by incubation at 
65 °C for 10 minutes. The DNA was purified using standard phenol-chloroform-
extraction and ethanol precipitation. Remaining contaminants were removed by using 
the Nucleotide Removal Kit according to the manufacturer’s protocol. The 
concentration and purity of the DNA solution was determined with the Nanodrop 2000. 
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5.2.1.21. Preparation of Oligonucleotides for MALDI-TOF MS 
Oligonucleotides were hybridized in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH = 7.4) 
by incubating at 95 °C for 5 minutes, followed by 30 minutes at room temperature. The 
dsDNA was then digested for 1 h with SacI in order to improve the resolution of the 
DNA fragments in mass spectrometry. After phenol-chloroform-extraction and ethanol 
precipitation, the DNA was dissolved in nuclease-free water and used for subsequent 
treatment. After the reaction, the sample was again purified as described and dried. 
The pellet was dissolved in 10 µl of an aqueous solution of 0.1 % TFA and 1 % 
Acetonitrile. The sample was aspirated into an equilibrated C18 tip and rinsed with 10 
µl of an aqueous solution with 0.1 % TFA and 5 % acetonitrile according to the 
manufacturer’s instructions. The sample was eluted by slowly aspirating 2 µl of a 
solution of 50 mg/mL 3-hydroxypicolinic acid in 50 % acetonitrileaq / 0.1 % TFAaq and 
10 mg/mL diammonium hydrogen citrate and slowly dispensing the complete volume 
onto a position on the ground steel MTP 384 target. Spectra were recorded in linear 
positive mode on a Bruker ultrafleXtreme MALDI.TOF/TOF system and analyzed using 
flexControl and mMass. 
5.2.1.22. Crosslinking Efficiency Analysis 
Oligonucleotides were 5´-32P-end labeled using γ-32P-ATP and T4 polynucleotide 
kinase and purified using a G-25 gel filtration column as per manufacturer’s 
instructions. 0.5 pmol of the labeled oligonucleotide was diluted into 100 pmol of the 
same, but unlabeled oligonucleotide. The mix was hybridized with 125 pmol of a fully 
reverse, complementary oligonucleotide in 1 x TE buffer at 95 °C for 5 minutes. After 
30 minutes at room temperature, the DNA was cross-linked to 100 pmol of TALE 
protein as described above. After the second reaction step, 15 µl of 4x SDS-PAGE 
buffer were added to the sample and the mixture was incubated at 95 °C for 
15 minutes. After letting the sample cool to ambient temperature, they were loaded on 
a denaturing 12 % SDS-polyacrylamide gel and run in 1 x running buffer (250 mM Tris-
HCl (pH = 8.3), 1.918 M glycine, 1 w/v % SDS) at 120 V until the loading dye front had 
migrated to the bottom. Gels were carefully dried and incubated on a storage phosphor 
screen. Data on the screen was read out using the Typhoon FLA-9500 laser scanner 
and analyzed using the software ImageQuant TL 8.1.  
 127 
 
5.2.1.23. Preparation of Spike-In DNA 
To introduce single site cytosine modifications in the CDKN2A-TALE binding site, 421 
bp long spike-ins containing either 5hmC, 5fC or 5caC at position 5 of the TALE binding 
site were obtained by PCR on amplicons derived from HeLa cell gDNA. First, 
amplicons from original HeLa cell gDNA were produced with primer pair o2129/o2130 
via Template PCR. This fragment was used without further purification as template for 
Pre-Spike-In PCR with primer pair o2129/o2135. The resulting PCR product was 
purified using the GeneJet PCR Purification Kit according to manufacturer’s 
instructions and subsequently used as template for introducing a single 5hmC, 5fC, or 
5caC at position 6 within the target TALE binding sequence through primer pair o1593 
(for 5hmC), o1594 (for 5fC) or o1595 (for 5caC) and o1596 for the Spike-in PCR. 
To introduce single site cytosine modifications in the BRCA1-TALE binding site, 421 
bp long spike-ins containing either 5hmC, 5fC or 5-caC at position 5 of the TALE 
binding site were obtained by PCR on amplicons derived from HeLa cell DNA. First, 
amplicons from original HeLa cell gDNA were produced with primer pair o2131/o2132 
via template PCR. This fragment was used for Pre-Spike-In PCR without further 
purification as template for primer pair o2132/o2136. The resulting PCR product was 
purified using the Monarch PCR & DNA Cleanup kit according to manufacturer’s 
instructions and subsequently used as template for introducing a single 5hmC or 5fC 
at position 13 within the target TALE binding sequence through primer pair o1521 (for 
5hmC) or o1524 (for 5fC) and o1529for the Spike-in PCR. All amplicons were purified 
by agarose gel electrophoresis and the sequence was verified by Sanger sequencing.  
 
Table 22: PCR reagent concentrations for the preparation of spike-in DNA in 50 µl 
 Template PCR Pre-Spike-In PCR Spike-In PCR 
Reagent Volume Volume Volume 
Template  1 µl (~100 ng/µl) 1 µl (<10 ng/µl) 
Primer, forward (10 µM) 2.5 µl 5 µl 
Primer, reverse (10 µM) 2.5 µl 5 µl 
Q5 buffer (5x) 10 µl 10 µl 
dNTPs (10 mM) 1 µl 1 µl 
DMSO 1.5 µl 1.5 µl 
Water, nuclease-free 31 µl 26 µl 
Q5 polymerase (2 Un/µl) 0.5 µl 0.5 µl 
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Table 23: PCR settings for the preparation of spike-in DNA 
Template PCR Pre-Spike-In PCR Spike-In PCR 
T t Cycles T t Cycles T t Cycles 
98 °C 30 s 1 98 °C 120 s 1 98 °C 120 s 1 
98 °C 30 s 
35 
98 °C 30 s 
35 
98 °C 20 s 
20 66 °C 30 s 66 °C 60 s 68 °C 30 s 
72 °C 300 s 72 °C 600 s 72 °C 120 s 
72 °C 600 s 1 72 °C 120 s  1 98 °C 20 s 
40 
      72 °C 180 s 
      72 °C 600 s 1 
 
5.2.1.24. Purification of DNA via Agarose Gel Electrophoresis 
3 % agarose gels were prepared as described above, but with big sample wells. The 
full sample was loaded, run and stained as described above. The gel was illuminated 
with UV light as shortly as possible and position of single bands corresponding to the 
PCR amplicon were marked. Gel fragments were cut out, dissolved and the DNA 
recovered via commercial kits as per manufacturer’s instructions. The concentration 
and purify was determined on a Nanodrop 2000. Low purity could be improved via 
standard phenol/chloroform extraction and ethanol precipitation. A higher amount of 
DNA could be obtained by using the purified sample in another round of PCR with the 
respective primer and purifying the amplicons with a PCR purification kit as per 
manufacturer’s instruction. 
5.2.1.25. Preparation of Genomic DNA (for chapter 3.1.3) 
Human gDNA (male Yoruban individual, Encode sample NA18507) was obtained from 
the Coriell Institute. For erasing epigenetic cytosine modifications, gDNA samples were 
whole genome amplified and purified using the QIAamp DNA mini kit according to 
manufacturer’s instructions. gDNA samples were sheared by sonication (20 % power, 
8 cycles of 30 s on / 30 s off), resulting in a broad fragment size distribution around 
500 bp.  
Respective amount of amplicon were spiked into non-methylated WGA gDNA that had 
been digested with FatI, BanII and EarI, all cutting within the binding sites of qPCR 
primers, and purified by the Monarch PCR & DNA cleanup kit according to the 
manufacturer’s instructions. 
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5.2.1.26. Quantitative PCR (qPCR) 
Quantitative PCR on the CFX384 Touch real-time PCR detection system was 
performed with the 2x GoTaq master mix. First, 4µl of (diluted) sample was pipetted in 
a PCR workstation into a 384 well plate. Then, 5 µl of master mix was added to 0.5 µl 
of each primer and mixed carefully. This mixture was pipetted to the sample into the 
384 well plate without mixing. The plate was tightly sealed with clear qPCR seals. The 
plate was centrifuged at room temperature for 1 minute at 2500 rpm and transferred to 
the qPCR cycler. 
 
Table 24: qPCR reaction times and temperatures 
T t Cycles 
95 °C  180 s 1 
95 °C  15 s 
45 
65 °C  60 s 
95 °C 30 s 1 
65 °C (0.5°/cycle) 5 s 60 
 
5.2.1.27. Enrichment (for chapter 3.1.3) 
Before each enrichment, Ni-NTA magnetic agarose beads were freshly 
washed/equilibrated with enrichment buffer (150 mM NaCl, 30 mM Tris-HCl, 5 mM 
MgCl2, 0.05 % Tween20, 0.5 mg/ml BSA, pH = 7.9) at room temperature using a 
magnetic stand with keeping the overall volume constant. To prepare the beads for 
enrichment, 5 µl of the bead suspension were added to 25 µl of 200 nM TALE protein. 
After addition of 20 µl enrichment buffer, the suspension was incubated in a 
thermomixer at room temperature for 30 minutes whilst shaking at 600 rpm.  
Then, 500 ng of sheared gDNA (with the respective amount of spike-in) were added 
and the volume of the mixture was adjusted to 500 µl with enrichment buffer. The 
samples were first incubated in a thermo-mixer at room temperature, and then cooled 
to 4 °C for 30 minutes while shaking at 600 rpm, each. The tubes were placed on the 
magnetic stand for 2 minutes and the liquid was carefully removed without disturbing 
the beads. The beads were washed once with 500 µl of pre-chilled enrichment buffer 
by slowly pipetting up and down once. The liquid was completely removed and 500 µl 
of nuclease-free water was added. The tube was shaken at 1400 rpm at 95 °C for 15 
minutes. The tubes were cooled down to room temperature, spun shortly (2-3 s) and 
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placed on the stand. The supernatant was collected in a fresh tube, dried in a vacuum 
concentrator and re-suspended with 20 µl of DNA-, nuclease-free water. qPCRs were 
conducted with 5 µl GoTaq qPCR Master Mix, 0.5 µl of each 10 µM primer and 4 µl of 
the sample as template in the CFX384 Touch real-time PCR detection system. Copy 
number quantification for enriched gDNA was done by linear regression from serial 
dilutions of the respective gDNA with each spike-in DNA. 
5.2.1.28. Preparation of Genomic DNA (for chapter 3.2.3) 
Human gDNA (male Yoruban individual, Encode entry NA18507) was purchased from 
the Coriell Institute. For erasing epigenetic cytosine modifications, gDNA samples were 
whole genome amplified using the illustra Ready-To-Go GenomiPhi V3 DNA 
Amplification kit and purified using the Monarch PCR & DNA Cleanup kit according to 
the manufacturer’s instructions.  
Genomic DNA from mouse embryonic stem cells (mESC) was isolated from J1 mESC 
(ATCC SCRC-1010). J1 cells were cultured on gelatin-coated plates using KnockOut 
DMEM supplemented with 10 % of EmbryoMAX ES cell qualified FBS, 103 U/ml of 
mouse recombinant LIF, 2 mM of GlutaMAX, 50 µM 2-mercaptoethanol, 1x Pen/Strep 
and 1x non-essential amino acids. Cells were split every 2-3 days using 0.25 % 
Trypsin/EDTA. Samples were collected by trypsinization, washed with DPBS once and 
harvested by centrifugation for 10 minutes at 400x g. Isolation of genomic DNA from 
mESC was adapted from Booth et al..78 J1 cells were lysed overnight at 55 °C in 200 
µl lysis buffer (100 mM Tris, pH 5.5, 5 mM EDTA, 200 mM NaCl, 0.2 % SDS, 400 µg/ml 
proteinase K, 200 µg/ml RNase A). After standard phenol-chloroform extraction, the 
DNA was precipitated in ice-cold 70 % ethanol and washed two times using ice-cold 
70 % ethanol. The DNA was dried for 15 minutes in a vacuum concentrator and 
dissolved in nuclease free water by incubating the solution for 2 h at 65 °C and 
overnight at 4 °C. 
gDNA samples were sheared by sonication (8 cycles of 30 s on / 30 s off), resulting in 
a broad fragment size distribution.  
Respective amount of amplicon was spiked into original, non-methylated WGA DNA 
that was previously digested with FokI and SacI and purified by the Monarch PCR & 
DNA Cleanup kit according to the manufacturer’s instructions. 
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5.2.1.29. Enrichment (for chapter 3.2.3) 
Per sample, 10 µl Dynabeads His-Tag Isolation and Pulldown were equilibrated in 
buffer EB2 at room temperature using the MagRack 6 magnetic stand with keeping the 
overall volume constant and added to the sample. The suspension was rotated at 15 
rpm for 30 minutes at 4°C in a tube revolver/rotator. 
The tubes were placed on the magnetic stand for 2 minutes and the liquid was carefully 
removed without disturbing the beads. The beads were then incubated for 5 minutes 
with 500 µl of pre-chilled buffer EWB (2 M NaCl, 30 mM Tris-HCl, 5 mM MgCl2, 10 µM 
Spermine, 0,005 % Tween20, 0.5 mg/mL BSA, pH 7.9). After removing the 
supernatant, the beads were washed twice with 500 µl of pre-chilled buffer EB1 
(150 mM NaCl, 30 mM Tris-HCl, 5 mM MgCl2, 0,005 % Tween20, 0.5 mg/ml BSA, 
pH = 7.9) by slowly pipetting up and down twice while keeping the tubes in the 
magnetic stand the whole time. Between each washing step the beads were let to rest 
for 2 minutes on the stand. After taking off the supernatant in the last washing step, 
the beads were shortly spun down (1000x g, 5 s), collected again at the magnet and 
any remaining buffer was completely removed.  
The beads were taken up in 50 µl DNA-, nuclease-free water and the suspension in 
the tube was shaken at 1400 rpm at 95 °C for 13 minutes, then shortly spun down 
(1000x g, 5 s) and incubated for 2 minutes at 95°C. The tubes were then immediately 
placed on the stand, the beads collected on the magnet and the supernatant was 
transferred to a fresh tube. qPCRs were conducted with 5 µl GoTaq qPCR Master Mix, 
0.5 µl of primer pair o2139/o2143 (10 µM each) and 4 µl of the sample as template in 
the CFX384 Touch real-time PCR detection system. Copy number quantification for 
enriched gDNA was done by linear regression from serial dilutions of the respective 
gDNA with each spike-in DNA. 
5.2.2. Chemical Methods 
5.2.2.1. Oxime Formation 
In 20 µl of reaction buffer (50 mM NaHPO4/Na2HPO4, pH = 6.0), 200 pmol DNA 
containing 5fC, 2 µmol 1,4-benzenediamine (pPDA) and 2 µmol of the hydroxylamine 
were combined and mixed thoroughly. The sample was shaken and incubated in the 
dark at room temperature overnight. To remove excessive reagents, the DNA was 
precipitated through standard ethanol precipitation, pelleted, dried and taken up in 
water. Remaining contaminants were removed by using the Nucleotide Removal Kit 
according to the manufacturer’s protocol. The concentration of the DNA solution was 
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determined with the Nanodrop 2000. The resulting UV spectrum, 260/280 nm and 
260/230 nm ratio values confirmed the purity of the sample. 
For oxime ligation of the amplicons spiked into bgDNA, the protocol was carried out as 
described above but with 0.2 µmol pPDA. Furthermore, the DNA was purified with the 
Monarch PCR & DNA cleanup kit (NEB). The concentration of the gDNA samples was 
quantified by qPCR and interpolation on a calibration curve of the untreated gDNA with 
spike-in DNA. The concentration was adjusted to 200 ng/µl. 
 
5.2.2.2. Amide Formation 
200 pmol dsDNA containing 5caC in 72 µl of 50 mM MES buffer (pH = 8.0) was treated 
with 5 µl of 0.6 M EDC-HClaq and incubated for 15 minutes at room temperature and 
shaking at 800 rpm. Then, 16 µl of a 1 M NaClaq solution were added and the solution 
was adjusted to 120 µl with nuclease-free water. 
The aqueous mixture was added carefully to a 30 µl solution containing 3 µmol PyAOP 
and 2.75 µmol of amine in DMSO. The mixture was shaken at 800 rpm and incubated 
for 24 h at room temperature. The reaction was quenched by addition of 20 µl of 3 M 
NH4OAc (pH = 5.2) and incubation at room temperature for 30 minutes. The DNA was 
subsequently precipitated overnight by addition of 620 µl ice-cold absolute ethanol. 
The DNA was pelleted, dried and taken up in water. Remaining contaminants were 
removed by using the Nucleotide Removal Kit according to the manufacturer’s 
protocol. The concentration of the DNA solution was determined with the Nanodrop 
2000. The resulting UV spectrum, 260/280 nm and 260/230 nm ratio values confirmed 
the purity of the sample. 
For 5caC-bearing amplicons spiked into bgDNA, 96 µl of a pre-activated solution 
containing 3 µmol EDC-HCl and 1.2 µg of gDNA in 50 mM MES, 125 mM NaCl (pH = 8) 
was added carefully to 4 µl of 0.3 µmol PyAOP and 0.275 µmol benzylamine in DMSO. 
The reaction mixture was incubated in a thermomixer for 24 h at room temperature and 
shaking 800 rpm. After 24 h, the reaction was quenched by adding 15 µl of 0.5 M 
ammonium acetate, purified with the Monarch PCR & DNA cleanup kit. The 
concentration of the gDNA samples was quantified by qPCR and interpolation on a 
calibration curve of the untreated gDNA with spike-in DNA. The concentration was 
adjusted to 200 ng/µl. 
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5.2.2.3. Linker Synthesis (modified from Holder, Francis 2007377) 
HO R
OH
O R
O
N
N
O
O
O
O
N-hydroxyphtalimide, 
PPh3, DIAD
Ra
 = CH2
Rb
 = CH2OCH2CH2
Rc
 = CH2(OCH2CH2)2
Rd
 = CH2(OCH2CH2)3
Re
 = CH2(OCH2CH2)5
rt, 12 h
1a-e 2a-e  
 
A flame-dried, argon purged 100 mL round-bottom flask equipped with a magnetic stir 
bar was charged with N-hydroxyphthalimide (2.2 equiv.), triphenylphosphine (2.1 
equiv.) and 1a-e (1.1g, 1 equiv.). The flask was evacuated and purged with argon. The 
solids where dissolved in anhydrous dichloromethane (25 mL). After 15 minutes, the 
mixture was treated in small portions (~0.25 mL) with DIAD (2.2 equiv.), allowing the 
orange color to fade between each addition. After 12 h of stirring, the mixture was 
concentrated in vacuo and diluted with 100 mL of diethyl ether and stirred vigorously 
at 4 °C for 30 minutes. The white precipitate was collected via filtration and was 
recrystallized two times from diethyl ether and dried in vacuo to give 2a-e used for 
hydrazinolysis without further purification. 
 
2,2'-(ethane-1,2-diylbis(oxy))bis(isoindoline-1,3-dione) (2a): The product was 
obtained as an off-white solid (3.91 g, 10.97 mmol, 62 %).  
2,2'-((oxybis(ethane-2,1-diyl))bis(oxy))bis(isoindoline-1,3-dione) (2b): The 
product was obtained as an off-white solid (2.7 g, 6.82 mmol, 65 %). 
2,2'-(((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(isoindoline-1,3-
dione) (2c): The product was obtained as an off-white solid (2.6 g, 5.9 mmol, 79 %). 
2,2'-((((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-
diyl))bis(oxy))bis(isoindoline-1,3-dione): The product was obtained as an off-white 
solid (2d): (1.54 g, 3.22 mmol, 62.5 %).  
2,2'-((3,6,9,12,15-pentaoxaheptadecane-1,17-diyl)bis(oxy))bis(isoindoline-1,3-
dione) (2e): The product was obtained as an off-white solid (1.81 g, 3.16 mmol, 89 %). 
 
Synthesis of linkers L1-5 (3a-e) (modified procedure from Holder & Francis1) 
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O R
O
N
N
O
O
O
O
Ra
 = CH2
Rb
 = CH2OCH2CH2
Rc
 = CH2(OCH2CH2)2
Rd
 = CH2(OCH2CH2)3
Re
 = CH2(OCH2CH2)5
rt, 12 h
2a-e
O R
O
3a-e
H2N
NH2
H2NNH2
 
 
A 100 mL round-bottom flask was charged with a solution of 2a-e in anhydrous 
dichloromethane. The solution was treated in one portion with 2.2 eqv. of hydrazine 
hydrate and stirred vigorously at room temperature for 12 h. The resulting pasty off-
white solid was removed by filtration. The clear eluent was diluted into diethyl ether 
and stirred vigorously for 1 h at 4°C.The resulting solid was removed by filtration. The 
filtrate was dried in vacuo and the resulting residue was taken up in chloroform. The 
solution was filtered again, and the filtrate was dried in vacuo yielding the desired 
product 3a-e as clear oil. 
 
L1: O, O'-(ethane-1,2-diyl)bis(hydroxylamine) (3a): The product was obtained as 
colorless oil (0.82 g, 8.9 mmol, 96 %).  
1H-NMR (400 MHz, CDCl3): δ 5.51 (4H, s), 3.85 (4H, m),  
13C-NMR (101 MHz, CDCl3): δ 73.88 
LCMS (m/z): [M+H] + (calculated for C2H8N2O2) = 93.06585 u; [M+H] + (observed) 
= 93.06535. 
L2: O, O'-(oxybis(ethane-2,1-diyl))bis(hydroxylamine) (3b): The product was 
obtained as yellowish oil (0.81 g, 5.95 mmol, 60 %).  
1H-NMR (400 MHz, CDCl3): δ 5.47 (4H, br s), 3.85-3.82 (4H, m), 3.68-3.65 (4H, m) 
13C-NMR (101 MHz, CDCl3): δ 74.87, 69.88 
LCMS (m/z): [M+H] + (calculated for C4H12N2O3) = 137.09207 u; [M+H] + (observed) 
= 137.09184 u. 
L3: O,O'-((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(hydroxylamine) (3c): 
The product was obtained as colorless oil (0.6 g, 3.33 mmol, 56 %).  
1H-NMR (400 MHz, CDCl3): δ 5.50 (4H, br s), 3.84-3.82 (4H, m), 3.69-3.66 (8H, m) 
13C-NMR (101 MHz, CDCl3): δ 74.95, 70.66, 69.75 
LCMS (m/z): [M+H] + (calculated for C6H16N2O4) = 181.11828 u; [M+H] + (observed) 
= 181.11807 u. 
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L4: O,O'-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-
diyl))bis(hydroxylamine) (3d): The product was obtained as colorless oil (0.58 g, 
2.59 mmol, 81 %).  
1H-NMR (400 MHz, CDCl3): δ 5.52 (4H, br s), 3.84-3.82 (4H, m), 3.69-3.64 (12H, m) 
13C-NMR (101 MHz, CDCl3): δ 74.94, 70.73, 70.69, 69.77 
LCMS (m/z): [M+H] + (calculated for C8H20N2O5) = 225.14450 u; [M+H] + (observed) 
= 225.14451 u.  
L5: O,O'-(3,6,9,12,15-pentaoxaheptadecane-1,17-diyl)bis(hydroxylamine) (3e): 
The product was obtained as colorless oil (1.58 g, 5.06 mmol, 80 %).  
1H-NMR (400 MHz, CDCl3): δ 5.51 (4H, br s), 3.84-3.82 (4H, m), 3.72-3.65 (20H, m) 
13C-NMR (101 MHz, CDCl3): δ 74.94, 70.76, 70.75, 70.72, 70.70, 69.77 
LCMS (m/z): [M+H] + (calculated for C12H28N2O7) = 313.19693 u; [M+H] + (observed) 
= 313.19700 u. 
5.2.2.4. Crosslinking Reaction 
In 20 µl of sodium phosphate buffer (20 mM, pH = 6.0) 100 pmol DNA containing 5fC, 
2 µmol para-phenylenediamine (pPDA) (dissolved in 5 µl of 0.5 % acetic acid) and 
10 µmol of Linker L1-5 were combined and mixed thoroughly. The sample was shaken 
at 550 rpm and incubated at room temperature overnight. The next day, 100 pmol of 
TALE protein in 10 µl of TALE storage buffer was added to the reaction mix together 
with 5µl of freshly prepared pPDA-solution and 10 µl of 5x TDC buffer (20 mM Tris-
HCl, 10 mM NaCl, 1.25 mM MgCl2, 5 % glycerol, pH = 6). The reaction mix was filled 
up to 50 µl with nuclease-free water and the reaction was kept at room temperature for 
6 h whilst shaking at 550 rpm. The reaction was stopped by quenching with 4x SDS-
PAGE loading buffer (200 mM Tris-HCl (pH = 6.8), 8 w/v % SDS, 0.08 w/v % 
bromophenol blue, 40 v/v % glycerol, 1 v/v % 2-mercaptoethanol) or 100 mM Tris-HCl 
(pH = 9). 
For 5fC-DNA spiked into a gDNA background, 1 µg of sheared, digested gDNA (either 
whole genome amplified from human gDNA or directly isolated from J1 mESC) with 
the respective amount of intact spike-in DNA was incubated in 20 µl of 20 mM 
phosphate buffer (pH = 6) overnight with 2 µmol of pPDA (dissolved in 5 µl 0.5 % acetic 
acid) and 10 µmol of linker at room temperature whilst shaking at 550 rpm. To remove 
excess of linker and oxidized catalyst, the reaction mix was purified using the Monarch 
PCR purification kit. The purified DNA was taken up in 50 µl of 1x TDC buffer (20 mM 
Tris-HCl, 10 mM NaCl, 1.25 mM MgCl2, 5 % glycerol, pH = 6) and treated with 5 pmol 
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pPDA (dissolved in 5 µl 0.5 % acetic acid) and 10 pmol of TALE protein and incubated 
for 6 h at room temperature and shaking at 550 rpm.  
To terminate the reaction, the sample was quenched with 18.5 µl of 100 mM Tris-HCl 
(pH 9) and purified via a G25-Sephadex column according to the manufacturer’s 
instructions. The filtrate was buffered into 90 µl 1x EB2 (500 mM NaCl, 30 mM Tris-
HCl, 5 mM MgCl2, 100 µM Spermine, 0,005 % Tween20, 0.5 mg/mL BSA, pH = 7.9). 
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6. Supplementary Dataf 
 
Figure SI1a: Module, array and backbone vectors for TALE assembly. a) Module vectors 
(MV) for single TALE repeats. b) pFUS (A, A30A, A30B and B1-B10) vectors for assembly of 
arrays of 10 (for A, A30A, A30B) or up to 10 repeat modules (for B) in the Golden Gate 1 
reaction. c) Last repeat (LR) vector containing also part of the TALE C-terminal domain. d) 
TALE expression vector (TEV) with N-terminal GFP domain and C-terminal His-tag. Assembled 
array plasmids can be cloned into the expression vector in the Golden Gate 2 reaction. 
 
 
                                            
f The contents of this section have been (partly) published in Gieß et al. (2018) and Gieß et al. (2019).369,370 
Reprinted (adapted) with permission from ref.369 and ref.370 Copyright 2019 American Chemical Society 
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Figure SI1b: TALE assembly via two-step Golden Gate reaction. 
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Figure SI1c: Exemplary pET vector for TALE expression.     
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CDKN2A_TALEs 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQH
PAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQL
DTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQ
RLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASN
NGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDH
GLTPDQVVAIAXXXXXKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETV
QRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDH
GLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALET
VQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAI
ASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQ
DHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQAL
ETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVV
AIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVL
CQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGK
QALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPD
QVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLL
PVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLLEHHHHH
H 
 
 XXXXX MW(calc.) [Da] 
TALE_SHDGG SHDGG 131660.95 
TALE_SG*GG SG*GG 131465.78 
TALE_SG**G SG**G 131408.72 
TALESG*** SG*** 131351.67 
TALE_S**** S**** 131294.62 
TALE_N**** N**** 131321.64 
 
Figure SI2a: Protein sequence and molecular mass of CDKN2A_TALEs. Sequence colored 
green marks the GFP domain; orange marks the N-terminal domain; Black marks the central 
repeat domain; Red marks the variable repeat (XXXXX marks the variable positions); Yellow 
marks the last repeat; Purple marks the C-terminal domain with His-tag. * represents the of 
the amino acid deletion. 
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BRCA1_TALEs 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQH
PAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQL
DTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQ
RLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALE
TVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVA
IASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLC
QDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIAXXXXXKQALETVQRLLPVLCQDHGLTPDQV
VAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPV
LCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGK
QALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPD
QVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLL
PVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNG
GKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLT
PDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQR
LLPVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLLEHHHH
HH 
 
 XXXXX MW(calc.) [Da] 
TALE_SHDGG SHDGG 131305.52 
TALE_SG*GG SG*GG 131110.34 
TALE_SG**G SG**G 131053.29 
TALESG*** SG*** 130996.23 
TALE_S**** S**** 130939.18 
TALE_N**** N**** 130966.21 
 
Figure SI2b: Protein sequence and molecular mass of BRCA1_TALEs. Color code as in Fig. SI2a 
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Figure SI3: ESI-MS spectra of dsDNA before and after glycosylation. a) ESI-TOF mass spectrum 
of oligonucleotide pair o1520/o1529 before glycosylation. b) ESI-TOF mass spectrum of 
oligonucleotide pair o1520/o1529 after glycosylation. 
 
Table SI1: Theoretical and observed peak list of BRCA1_5hmC before and after glycosylation 
by ESI-TOF mass spectrometry. 
 Theoretical Mass Δmcalc Observed Mass Δmobs 
 starting + CPD converted  starting + CPD converted  
ODN-5hmC 13652.8 
- - - 13652.82 - - - 
+ 1 13815.0 162.2 13562.38 + 1 13814.90 162.52 
 
 
13652.82 
13652.38 
13814.90 
14060.11 
14060.24 
b)    
a)    
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Figure SI4: Representative EMSA data for differential TALE interaction with their cognate 
targets before and after treatment as shown in Fig. 24d, Fig. 26a, and Fig. 28a. Treatment 
refers to the different reaction types of I: Glycosylation, II: Oxime formation, III: Amide 
formation. 
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Figure SI5: MALDI-TOF MS spectra of dsDNAs used for 5fC conversion with hydroxylamines 
and 5caC conversion with amines. a) 5fC-ODN untreated. b) 5fC-ODN after reaction with O-
ethylhydroxylamine (3a). c) 5fC-ODN after reaction with O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine (3b). d) 5fC-ODN after reaction with O-(benzyl)hydroxylamine (3c). e) 5fC-
ODN after reaction with O-(tert.-butyl)hydroxylamine (3d). f) 5caC-ODN untreated. g) 5caC-
ODN after reaction with ethylamine (5a). h) 5caC-ODN after reaction with (tetrahydro-2H-
pyran-2-yl)methylamine (5b). i) 5caC-ODN after reaction with benzylamine (5c). j) 5caC-ODN 
after reaction with tert.-butylamine (5d). 
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Table SI2: Observed and calculated masses for 5fC- and 5caC-ODN from data of Fig. SI5. 
Asterisks indicate oligonucleotides with a mass difference of 79.9 compared to standard 
calculated mass, matching the weight of an additional phosphate group. These were observed 
in MS analyses of digested dsDNA oligonucleotides for both non-reacted and reacted DNA. 
Δmcalc and Δmobs correspond to masses of introduced oxime and amide substituents. 
 Theoretical Mass Δmcalc Observed Mass Δmobs 
 starting + CPD converted  starting + CPD converted  
ODN-5fC 
5060.3 
5140.3)* 
- - - 
5065.6 
5145.7)* 
- - - 
+ 2a 
5103.4 
5183.4)* 
43.1 
5065.4 
5145.8)* 
+ 2a 
5110.9 
5191.1)* 
45.5 
45.3)* 
+ 2b 
5159.4 
5139.4)* 
99.1 
5064.8 
5145.3)* 
+ 2b 
5164.9 
5244.5)* 
100.1 
99.2)* 
+ 2c 
5165.4 
5245.3)* 
105.1 
5064.7 
5145.3)* 
+ 2c 
5170.6 
5250.2)* 
105.9 
104.9)* 
+ 2d 
5131.4 
5212.4)* 
71.1 
5068.3 
5151.2)* 
+ 2d 
5143.1 
5222.7)* 
74.8 
71.5)* 
ODN-5caC 
5077.3 
5157.3)* 
 
- - 
5083.3 
5163.4)* 
- - - 
+ 4e 
5094.4 
5284.4)* 
27.1 
5084.5 
5165.5)* 
+ 4e 
5112.2 
5193.9 
27.7 
28.4)* 
+ 4f 
5159.4 
5139.4)* 
97.2 
5082.1 
5164.1)* 
+ 4f 
5180.8 
5262.5)* 
98.6 
98.3)* 
+ 4g 
5165.4 
5245.3)* 
89.1 
5082.7 
5160.1)* 
+ 4g 
5171.4 
5250.6) 
88.7 
90.5)* 
+ 4h 
5131.4 
5212.4)* 
55.1 
5083.1 
5166.1)* 
+ 4h 
5135.8 
5219.5)* 
52.7 
53.4)* 
 
 
 146 
 
 
Figure SI6: Oxime formation of 5fC-DNA with Alexa Fluor 488 hydroxylamine. a) Chemical 
structure of Alexa Fluor 488 hydroxylamine. b) MALDI-TOF MS of reacted 5fC shows correct 
product formation of 6e. c) Native PAGE image. Increasing fluorescent bands of the 
fluorescent probe shows presence of 5fC DNA at bands for unbound and excessive DNA. d) 
Comparison of shifted bands for unreacted and reacted 5fC. 
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Figure SI7: Superimposed models of DNA containing benzyloxime (4c) or tert-butyloxime 
(4d) bound by TALE_SG*GG. a) Positioning of benzyl substituent of 4c (red sticks) to evade 
steric clash with a minimized TALE repeat structure. (DNA surface grey, TALE surface light 
brown). b) Hypothesis for a steric clash of 4d as a result of different orientation of benzyl 
substituent of 4c (grey sticks) and tert-butyl substituent of 4d (pale red sticks).  
 
 
Figure SI8: Model of DNA containing benzylamide (6c) (grey sticks) clashing with non-
minimized structure of repeat_SG*GG. 
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Figure SI9: Spike-ins and genomic DNA for enrichment. a) Agarose gel of 421bp_C6 → X spike-
in PCR products. Lane 1: 2-log DNA-ladder, Lane 2: CDKN2A_421bp_TALE binding_C6 → 
5hmC6, Lane 3: CDKN2A_421bp_TALE binding_C6 → 5fC6, Lane 4: CDKN2A_421bp_TALE 
binding_C6 → 5caC6. b) Agarose gel analysis of human whole genome amplified DNA 
randomly sheared by sonication. Lane 1: 2-log DNA Ladder, Lane 2: Whole genome amplified 
human DNA (100ng), Lane 3: Fragmented whole genome amplified human DNA (100ng). c) 
qPCR on human genomic DNA samples with and without spike-in DNA. red: 500 ng sheared, 
digested gDNA, green: 500 ng sheared, digested gDNA with 421 bp-spike-in 
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Figure SI10: Plasmid maps for vectors containing genes for a) pAcF tRNA/aaRS, for b) BRCA1a 
and BRCA1b or c) BRCA1c genes. TAG denotes the codon for the position of pAcF in the 
protein. 
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BRCA1a_TALEs 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQH
PAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQL
DTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQ
RLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALE
TVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVA
IASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLC
QDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIAXX*XGKQALETVQRLLPVLCQDHGLTPDQVV
AIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVL
CQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQ
ALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQ
VVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLP
VLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGG
KQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTP
DQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRL
LPVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLLEHHHHH
H 
 
 XX*X MW(calc.) [Da] 
TALE_1G*GG 1G*GG 131305.52 
TALE_S1*GG S1*GG 131110.34 
TALE_SG*1G SG*1G 131053.29 
 
Figure SI11a: Protein sequence and molecular mass of BRCA1a_TALEs. Color code as in 
Fig. SI2a. * represents the of the amino acid deletion. 1 represents the para-
acetylphenylalanine (pAcF). 
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BRCA1b_TALEs 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQH
PAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQL
DTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQ
RLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALE
TVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVA
IASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLC
QDHGLTPDQVVAIASG*GGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIAXX*XGKQALETVQRLLPVLCQDHGLTPDQVV
AIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASG*GGKQALETVQRLLPVLC
QDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQV
VAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPV
LCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGK
QALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPD
QVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLL
PVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLLEHHHHH
H 
 
 XX*X MW(calc.) [Da] 
TALE_1G*GG 1G*GG 130961.19 
TALE_S1*GG S1*GG 130991.22 
TALE_SG*1G SG*1G 130991.22 
 
Figure SI11b: Protein sequence and molecular mass of BRCA1b_TALEs. Color code as in 
Fig. SI2a. * represents the of the amino acid deletion. 1 represents the para-
acetylphenylalanine (pAcF). 
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BRCA1c_TALEs 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAE
VKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKANFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQH
PAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQL
DTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASHDGGKQALETVQ
RLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALE
TVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVA
IASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLC
QDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQV
VAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPV
LCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGK
QALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHG(LTP
DQVVAIASHDGGKQALETVQRLLPVLCQDHG)LTPDQVVAIAS1*GGKQALESIVAQL
SRPDPALAALTNDHLLEHHHHHH 
 
 MW(calc.) [Da] 
TALE_LR_S1*GG(20) 109810.09 
TALE_LR_S1*GG(19) 106199.00 
 
Figure SI11c: Protein sequence and molecular mass of BRCA1c_TALEs. Color code as in 
Fig. SI2a. * represents the of the amino acid deletion. 1 represents the para-
acetylphenylalanine (pAcF). The full sequence represents TALE_LR_S1*GG(20). For 
TALE_LR_S1*GG(19) only the sequence outside of round brackets (…) need to be considered.  
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Figure SI12: SDS-PAGE images of TALE proteins. a) Full image of Fig. 30d). Lane 1: Protein 
ladder (bands correspond to MW in kDa). Lane 2: Isolated protein fraction from expression 
with pAcF of pET_BRCA1a_TALE_1G*GG and pEVOL_pAcF with IPTG and Arabinose. Lane 3: 
Isolated protein fraction from expression without pAcF of pET_BRCA1a_TALE_1G*GG and 
pEVOL_pAcF with IPTG and Arabinose. Lanes 4-7: As lane 2 and lane 3 but for TALE_S1*GG 
(lanes 4-5) and for TALE_SG*1G (lanes 6-7). b) SDS-PAGE image of the expression and 
purification of pET_BRCA1b_TALEs. Lane 1: Protein ladder (bands correspond to MW in kDa). 
Lane 2: Cell lysate after pET_BRCA1a_TALE_1G*GG expression. Lanes 3-5: Washing fractions 
of TALE_1G*GG purification with PBS (Lane 3), wash buffer with 20 mM imidazole (Lane 4), 
wash buffer with 50 mM imidazole (Lane 5). Lane 6: Isolated TALE_1G*GG protein. Lanes 7-
18: As lanes 1-6 but for TALE_S1*GG (lanes 7-12) and TALE_SG*1G (lanes 13-18). c) SDS-PAGE 
image of the expression and purification of pET_BRCA1b_TALEs. Lane 1: Protein ladder (bands 
correspond to MW in kDa). Lane 2: Flowthrough after Ni-NTA purification of BRCA1b 
TALE_1G*GG. Lane 3: Purified TALE_1G*GG. Lanes 4-7: As lane 2 and lane 3 but for 
TALE_S1*GG (lanes 4-5) and for TALE_SG*1G (lanes 6-7). d) SDS-PAGE image of the expression 
of TALE_LR_S1*GG(20) and TALE_LR_S1*GG(19). Lanes 1-12: As lanes 1-6 in b) but for 
TALE_LR_S1*GG(20) (lanes 2-6) and TALE_LR_S1*GG(19) (lanes 8-12).   
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Figure SI13: 1H and 13C NMR spectra of L1-5 
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Figure SI14: High resolution mass spectra of L1-5 
  
 160 
 
 161 
 
 162 
 
 163 
 
 
 
 164 
 
 
 
Figure SI15: 5 % agarose gels of 5’-FAM labeled RefSeq_5fC12 oligonucleotide after 
incubation under crosslinking conditions do not show crosslinking between 5fC-bearing 
oligonucleotides. 
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Figure SI16: MALDI-TOF mass spectrometry analysis of reference oligonucleotides with 5fC 
after incubation under crosslinking conditions without or with linkers L1-5. Mass peaks of 
oligonucleotides with 5fC treated with linker L1-5 shift from the mass observed for the 
oligonucleotide missing a linker in the reaction to values corresponding with expected masses 
after oxime ligation (see table). Mass peaks of the complementary reverse strand appear at 
~6600 u and do not shift in the presence of linker L1-5. Crosslinking between two 
oligonucleotides could not be observed for linker L1-5.   
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Figure SI17: EMSA assays of BRCA1a TALEs with pAcF and its target DNA under crosslinking 
reaction conditions. 100 pmol of oligonucleotides were buffered into phosphate buffer (pH = 
6) and added to 100 pmol of TALE protein in a final volume of 50 µl of 1x TALE binding buffer 
BMaG1 (pH = 6). After incubation at room temperature and at 4 °C at 30 minutes each, 1 µl (2 
pmol TALE/DNA complex) of the solution was buffered into 10 µl of TALE binding buffer (pH = 
8) and subjected to native PAGE.  
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Figure SI18: SDS-PAGE gel image for TALE-DNA crosslinking as indicated from Fig. 35. 
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Figure SI19: SDS-PAGE gel images for positional resolutions of TALE-DNA crosslinking as 
indicated from Fig. 38. 
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Figure SI20: Spike-ins and genomic DNA for enrichment. a) Agarose gel of 421bp_C13 → X 
spike-in PCR products. Lane 1: DNA-ladder, Lane 2: BRCA1a_421bp_TALE binding_C13 → 
5hmC13, Lane 3: BRCA1a _421bp_TALE binding_C13 → 5fC13. b) Agarose gel analysis of 
human whole genome amplified DNA randomly sheared by sonication. Lane 1: DNA Ladder, 
Lane 2: Fragmented whole genome amplified human DNA (100ng). c) qPCR activity of 100 ng 
sheared WGA DNA (blue), 100ng background (bg) DNA (WGA DNA, sheared/digested) without 
(gray) and with BRCA1a_5fC13 spike-in (green). 
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